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Abstract 
Statins, competitive inhibitors of the rate limiting cholesterol/ergosterol enzymes 
HMG-CoA reductase (HMG1 and HMG2), are the most widely prescribed human 
therapeutic drugs. They are effective in lowering cholesterol levels in atherosclerosis 
and related syndromes. However, statins exhibit a range of pleiotropic side effects 
whose mechanisms are poorly understood.  
 
This study investigates statin pleiotropy by analysis of genetic interaction networks 
in yeast, Saccharomyces cerevisiae, which shows high homology to mammalian 
pathways affected by statins. Synthetic genetic array (SGA) analysis allows 
elucidation of functional genetic networks of genes of interest (“query genes”) by 
measurement of genetic epistasis in double mutants of the query gene with the 
genome - wide deletion mutant array of ~4800 non-essential strains. Chemical-
genetic profiling is similar where a SMP may effectively replace the query gene in 
genome wide epistatic analysis.  
 
The genetic interaction networks resulting from use of HMG1 and HMG2 as query 
genes for SGA analysis were compared to the chemical-genetic profiles of 
atorvastatin, cerivastatin and lovastatin. The genes ARV1, BTS1, OPI3 displaying 
phenotypic enhancements (i.e. their deletion caused major growth inhibition) with 
statins became essential in the presence of all the statins. Two mitochondrial genes, 
COX17 and MMM1, showed phenotypic suppressions (i.e. their deletion allowed 
better growth) in common to all three statin drugs. An attractive hypothesis is that 
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major pleiotropic effects of statins could be due to variation in function or expression 
of these enhancing or suppressing genes.  
 
Other processes compensating statin use were also elucidated.  For example, when 
HMG1 and its epistatically interacting genes are shut down by deletion coupled with 
inhibition of HMG2 with statin, there is strong evidence that the cell attempts to 
maintain membrane/lipid homeostasis via anterograde and retrograde transport 
mechanisms, including the mobilisation of lipid storage droplets.   
 
To aid refinement of genetic analysis in this and future studies, a more direct 
phenotypic assay was developed for quantifying ergosterol. Such an assay may be 
used as a phenotype to map the effect of up - and downstream - genes, or network 
genes affecting ergosterol levels. This assay was used to quantify ergosterol in a drug 
- resistant mutant developed by others aiding confirmation of the drug target.  
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Chapter 1. Introduction 
 
1.1. Cardiovascular disease  
 
This study focuses on key enzymes of sterol synthesis and statin inhibitors, in 
light of the importance of sterol metabolism in diseases. Cardiovascular disease 
(CVD), for example, accounted for 41% of all deaths in New Zealand in 2000 
(MOH, 2003). CVD is now recognised as a global epidemic, equalling infectious 
disease as the leading cause of death and disability worldwide (Fig.1.1, 
reproduced from WHO 2001) and is expected to surpass infectious diseases in the 
next 15 years (WHO, 2001). High levels of total cholesterol 
(hypercholesterolemia) and low-density lipoprotein cholesterol (LDL-C) with low 
levels of high-density lipoprotein cholesterol (HDL-C) are important risk factors 
for coronary heart disease (Yusuf, et al., 2001). 
 
 
Figure 1.1 World Health Organisation human disease mortality. 
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Hypercholesterolemia is characterised by an increase in low density lipoprotein 
(LDL) and a decrease in high density lipoprotein (HDL) caused by a combination 
of genetic and environmental factors that disturb the transport of apolipoprotein 
B-100 in plasma (Austin, et al., 2004). Familial hypercholesterolemia is an 
autosomal dominant disorder of lipoprotein metabolism characterised by 
mutations of the LDL receptor resulting in an accumulation of LDL cholesterol in 
the plasma. It has been estimated that familial hypercholesterolemia affects 
approximately one in 500 of the British population and carries with it an increased 
risk of CVD (Broome, 1991). It is the aim of this dissertation to assemble genetic 
interaction networks around the genes of the mevalonate pathway and of their 
statin inhibitors in order to better understand the mechanism of the drugs. 
 
1.2. Statin drugs 
 
Mammalian and yeast 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) 
reductase is an integral membrane glycoprotein of the endoplasmic reticulum 
(ER) which catalyses the rate determining reaction in cholesterol biosynthesis 
namely the conversion of HMG-CoA to mevalonate (Fig.1.4). Statin drugs are 
HMG-CoA reductase inhibitors that are effective and reasonably safe drugs used 
for the prevention and treatment of atherosclerosis. Statins inhibit cholesterol 
synthesis, increase LDL uptake, improve endothelial function and prevent 
thrombus formation. They are currently the most widely prescribed class of all 
therapeutic drugs with sales (of atorvastatin) in the order of $US12b pa. 
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However, it is unsurprising given the central role sterol metabolism in cell 
processes and physiology that statins display side-effects. In addition to their 
cholesterol lowering effects, statins also exhibit a range of pleiotropic effects 
including nitric oxide mediated promotion of blood vessel growth, stimulation of 
bone formation, protection against oxidative modification of LDL and anti - 
inflammatory effects (Liao and Laufs, 2005). It is an aim of this study to 
understand the network effects of statins in genetic interaction networks. As an 
example as to what is meant by ‘network effects’ the effects of aspirin (Fig.1.2, 
reproduced from Huang 2002) are a good illustration (Huang, 2002). Salicylate 
has network effects across a number basic pathways of importance in cell 
physiology as can be seen in the figure. However, even salicylate is not without 
side - effects. 
 
Figure 1.2 Salicylate example of drug target networks (Huang, 2002). 
 
 
An example is Reyes syndrome that may appear in children suffering from acute 
viral infections. Reyes syndrome results from damage to cellular mitochondria 
(Gosalakkal and Kamoji, 2008) – a side-effect that might not be immediately 
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evident in the main (anti - inflammatory) mechanism of aspirin action. Statins 
may also have pleiotropic effects across pathways (this thesis), including 
mitochondrial effects and given the therapeutic value of statins such network 
effects should be studied. 
 
Statins are competitive inhibitors of HMG-CoA reductase (Fig. 1.4) possessing an 
HMG-like moiety (Schachter, 2005) inhibiting the deacylation of HMG-CoA to 
form CoA and mevalonate (Istvan and Deisenhofer, 2001):  
 
(S)-HMG-CoA + 2NADPH + 2H+                 (R)-mevalonate + 2NADP+ + CoASH 
 
Type one fungal derived statins contain rigid hydrophobic groups that are 
covalently linked to the HMG-like moiety (Fig. 1.3A, adapted from Istvan, 2001 
and Schachter, 2005). In contrast type two statins are fully synthetic with larger 
groups linked to the HMG-like moiety (Fig. 1.3B). The additional groups range 
from very hydrophobic (cerivastatin) to partially hydrophobic (rosuvastatin). 
Type 1 and type 2 statins inhibit binding of the substrate HMG-CoA, but not co-
enzyme NADPH to the enzyme. Statins can also exist as ‘pro drugs’ (lovastatin) 
in their inactive lactone form which is hydrolysed in vivo (in mammals) to the 
active hydroxy acid form, whereas the other statins exist freely in the active 
hydroxy acid form (Istvan and Deisenhofer, 2001; Schachter, 2005).  
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Figure 1.3 Structural formulae of statin drugs. A. Type one statins Lovastatin, 
Simvastatin and Pravastatin. B. Type Two Statins, Fluvastatin, Atorvastatin 
Cerivastatin, Pitavastatin and Rosuvastatin. C. Structure of HMG-CoA.                 
(Istvan and Deisenhofer, 2001; Schachter, 2005) 
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1.3. Mevalonate pathway 
 
In addition to cholesterol synthesis, mevalonate is the precursor of multiple 
isoprenoid compounds that become incorporated into many end products (Fig.1.4, 
reproduced from Goldstein, 1990) including haem A and ubiquinone (electron 
transport), polyisoprenoid biosynthesis (Basson, et al., 1988), dolichol 
(glycoprotein synthesis), isopentyladenine (tRNA) and intracellular messengers 
such as cytokines in plants, farnesylated mating factors in fungi, hormones in 
insects and steroid hormones in mammals (Brown and Goldstein, 1980; Goldstein 
and Brown, 1990). Cellular cholesterol is also derived from plasma LDL in 
mammals and to maintain sterol homeostasis, cells must balance and maintain 
equilibrium between sterol biosynthesis, uptake, transport, utilisation, efflux and 
storage of the sterol products. Aberrations in any of these processes may lead to 
multiple human disease pathologies including atherosclerosis and 
neurodegeneration (Sturley, 2000). The balance within the pathway is coordinated 
mainly through feedback regulation from HMG-CoA reductase (Goldstein and 
Brown, 1990; White, 1972). 
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Figure 1.4 The mevalonate pathway in mammalian cells (Goldstein and Brown, 
1990). 
 
 
 Mevalonate synthesis is predominately regulated by feedback inhibition from the 
sequential enzymes HMG-CoA synthase and HMG-CoA reductase but is also 
regulated by LDL receptors (Brown and Goldstein, 1980). In the presence of 
exogenous LDL and/or mevalonate, HMG-CoA synthase and HMG-CoA 
reductase activities can decrease to under 10% with the cells producing only the 
minuscule amounts of mevalonate needed for non sterol products. Conversely, 
when exogenous LDL is absent, animal cells maintain high activities of the two 
enzymes (Fig. 1.5) and the ER degradation is decreased (Goldstein and Brown, 
1990; Hampton and Rine, 1994). 
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Figure 1.5 Bi-modal feedback regulation of HMG-CoA reductase 
(Brown and Goldstein, 1980). 
 
 
Figure 1.5 (reproduced from Brown, 1980) shows that cells require mevalonate 
and cholesterol for HMG-CoA reductase to be suppressed. Because cholesterol 
may be supplied exogenously from LDL or endogenously from mevalonate, high 
levels of mevalonate alone are required to completely suppress the enzyme 
(Brown and Goldstein, 1980). This bimodal feedback regulation of HMG-CoA 
reductase is an important mechanism for therapeutic intervention to inhibit 
cholesterol production and also plasma LDL levels. In addition to regulation of 
mevalonate synthesis, cells also regulate mevalonate use between sterol and non-
sterol pathways. The enzymes of the non – sterol pathways (Figs.1.4 and 1.6) 
have much higher affinities for mevalonate than those of the sterol derived 
substrates. Thus, when mevalonate is sparse, it is preferentially shunted into the 
higher affinity non sterol pathways (Goldstein and Brown, 1990).  
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1.4. HMG-CoA reductase in yeast and 
humans 
 
The mammalian genome contains a single gene encoding HMG-CoA reductase 
(Basson, et al., 1988). In contrast, yeast (Saccharomyces cerevisiae) has two 
genes, designated HMG1 and HMG2 (Fig.1.6). Cells containing an inoperative 
mutant allele of HMG1 or HMG2 show only a subtle growth defect, whereas cells 
containing null mutant alleles for both HMG1 and HMG2 show a synthetic lethal 
phenotype (Basson, et al., 1986). This phenotype can be rescued with the 
insertion of the human HMG gene demonstrating the aptness of the yeast model. 
The functional conservation (in the catalytic domain) between yeast and human 
HMG-CoA reductase allows the use of yeast cells in the identification of drugs 
with therapeutic value in the treatment of diseases such as hypercholesterolemia 
(Basson, et al., 1988).  
 
Figure 1.6 Details of the mevalonate pathway. The bulk product of mevalonate 
synthesis in mammals is cholesterol, whereas the end product in yeast is 
ergosterol. Adapted from (Brown and Goldstein 1980; Goldstein and Brown 
1990; Bammert and Fostel 2000). 
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Ergosterol differs from cholesterol in that it contains two extra double bonds and 
a methyl group (Fig. 1.7). However, ergosterol is synthesised, regulated and 
esterified in very similar processes as mammalian cells. Mevalonate biosynthesis 
and signalling pathways are also highly conserved between yeast and humans 
(Smith, et al., 1996; Veen and Lang, 2005).  
 
 
Figure 1.7 Structural difference of ergosterol and cholesterol with double  
bonds at C7 and C22 and an additional methyl group at C28  
(Smith, Crowley et al. 1996; Veen and Lang 2005). 
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1.5. Pleiotropic effects of statins 
 
Though statins are structurally different, they all possess the HMG-CoA-like 
domain (Fig.1.3), these various statins differ in their tissue permeability and 
metabolism and entail different potencies for HMG-CoA reductase inhibition. 
However, it was thought that the pleiotropic effects of statins were primarily 
mediated by the inhibition of mevalonate synthesis, with other unidentified 
mechanisms playing an important role (Laufs, et al., 1998; Liao and Laufs, 2005). 
By inhibiting mevalonate synthesis statins also prevent de novo synthesis of 
isoprenoid intermediates (see Mevalonate Pathway) as shown in Figures 1.4 and 
1.6.  
 
These intermediates provide lipid moieties in the post-translational modification 
of a variety of proteins affecting intracellular trafficking, such as found in the 
gamma subunit of heterotrimeric G-proteins, Heme-a, nuclear lamins, the small 
guanosine triphosphate (GTP)-binding protein RAS, and the RAS like proteins 
Rho, Rab, Rac, Ral and Rap (Van Aelst and Dae Souza-Schorey, 1997). In 
endothelial cells Ras translocation from the cytoplasm to the plasma membrane is 
dependent on farnesylation, whereas Rho translocation is dependent of 
geranylgeranylation. Thus statins inhibit both Ras and Rho isoprenylation which 
leads to the accumulation of inactive Ras and Rho in the cytoplasm (Liao and 
Laufs, 2005).  
 
Rho inhibition by statins also leads to inhibition of the downstream target Rho-
kinase. Members of the Rho GTPase family play important roles in cell shape, 
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motility, secretion and proliferation. The distinct functions of Rho proteins also 
exhibit cell signalling effects. When cells reorganise their cytoskeleton in 
response to extracellular signals, they alter the co-localisation of intracellular 
proteins (Van Aelst and Dae Souza-Schorey, 1997). Therefore, these changes can 
also affect intracellular transport, membrane trafficking, mRNA stability and gene 
transcription. This suggests that some of the non-sterol associated effects caused 
by statin drugs could be due to the inhibition of isoprenylation of Rho and Ras 
proteins (Liao and Laufs, 2005; Van Aelst and Dae Souza-Schorey, 1997), 
however,  the mechanisms are not well understood (Liao and Laufs, 2005). 
Another example of non-sterol effects is statin binding to an allosteric site within 
the β2 integrin function associated antigen-1, which appears to occur 
independently of mevalonate synthesis (Weitz-Schmidt, et al., 2001).  
 
1.6. Adverse effects of statin drugs 
 
Despite the favourable overall health benefits of statins, they have adverse effects 
of unknown molecular origins such as hepatotoxicity, renal dysfunction, muscular 
myopathies and in extreme cases fatal rhabdomyolysis (Gilles Labbe, 2008; 
Kromer and Moosmann, 2009). Hepatotoxicity seems to involve mitochondrial 
dysfunction as a major side-effect ultimately triggering apoptosis or necrosis of 
hepatocytes in cytolytic hepatitis conditions. Mitochondrial perturbations can also 
lead to diverse extrahepatic ailments such as hyperlactatemia, lactic acidosis, 
myopathy, rhabdomyolysis, pancreatitis, neuropathy or lipoatrophy (Dykens and 
Will, 2007; Gilles Labbe, 2008). Muscular myopathies are commonly seen in 
13 
 
statin use presenting in approximately 10% of patients undergoing treatment with 
statin drugs. Cerivastatin was voluntarily withdrawn from the market by Bayer 
Pharmaceuticals in 2001 due to increased cases of rhabdomyolysis (Furberg and 
Pitt, 2001).  
 
While muscular myopathies have been reported in all the statins on the market, 
the myotoxicity for Cerivastatin was higher than the other statins, perhaps related 
to their physiochemical properties (Fig.1.3). Such properties can alter the kinetic 
behaviour of drugs, including bioavailability, tissue distribution and metabolism - 
which may affect statin toxicity on muscular tissue. For example, inhibition of 
cytochrome P450 isozymes can lead to increased bioavailability of the lipophilic 
statins, hence increasing the potential for myotoxicity (Gilles Labbe, 2008; 
Kaufmann, et al., 2006).  
 
Isopentenyl pyrophosphate is required for the post-transcriptional maturation of 
selenocysteine-tRNA (an essential component of selenoprotein biosynthesis) and 
is inhibited by pharmacological perturbation of the mevalonate pathway by statin 
drugs. It has been noted that statin treatment of human HepG2 cells alters 
glutathione peroxidise expression, enzyme activity and steady state. The authors 
noted that there is limited crosstalk between the two pathways and therefore  
further investigation is needed into the hepatic side effects exhibited with the use 
of statin drugs (Kromer and Moosmann, 2009). 
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1.7. Cellular networks  
 
It is clear from the foregoing review that statins, like any useful therapeutic agent, 
affect numerous biochemical pathways in addition to their major target (HMG-
CoA-reductase). It is likely that tailoring their use will require a cross-pathway 
analysis as in the example of aspirin described above.  
 
It is a tenet of this thesis that molecular mechanisms underlying complex 
biochemical phenotypes across pathways may emerge from such genetic 
interaction studies. These novel approaches may indeed permit a more 
comprehensive prediction of gene function in cross-pathway networks (Boone, et 
al., 2007; Schadt and Lum, 2006; Tong, et al., 2004). Focussing more on statin 
mechanisms, Figure 1.8 is a summary diagram adapted from the literature of 
known sterol involvement in yeast (Henneberry and Sturley, 2005; Schekman, 
2002). Involved sub cellular organelles include the endoplasmic reticulum, Golgi 
apparatus, mitochondria and vacuole are intimately involved in these processes. 
HMG1 and HMG2, located in the ER, when inhibited by statin drugs may disrupt 
the cellular sterol homeostasis. It is unknown what effect that statin drugs have on 
related processes such as glycosylation, protein folding and degradation. This 
study attempts to identify some of the genetic interactions affecting the processes 
shown in Figure 1.8   thereby adding new data and a systematic approach to a 
better understanding of the mechanism and the pleiotropic effects of statin drugs. 
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Figure 1.8 Summary of yeast cell biology processes directly involved in this 
study. Namely those involved in sterol import, synthesis and trafficking, protein 
folding, protein trafficking and degradation, intracellular vesicle transport and the 
transport of isoprenoids (FPP, IPP and GGPP), and isoprenylated proteins such as 
Ras and Ras like proteins Rho, Rab, Rac, Ral and Rap (Henneberry and Sturley, 
2005; Schekman, 2002; Sturley, 2000; Van Aelst and Dae Souza-Schorey, 1997) 
 
 
 
1.8. Disease networks - genetic interactions 
 
Complex human diseases, such as cardiovascular disease and arthrosclerosis, are 
known to involve partial contribution of numerous genes that are often unrelated 
by biochemical pathway as seen in increasing numbers of QTL (quantitative trait 
loci) studies (Hopkins, 2008; Schadt, et al., 2009; Schadt and Lum, 2006). The 
problem with QTL studies is that they lack resolution to single genes. Alternative 
approaches of studying complexity such as genetic interaction networks may 
allow higher resolution. High-throughput screening tools have allowed the 
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assembly of genetic interaction networks on a genome-wide basis, such that a 
genetic interaction observed between two genes indicates functionality whether or 
not it is within known biochemical pathways. Genetic interactions observed in 
this study are mostly of the epistatic enhancement type that in its extreme form is 
called “synthetic lethality” (Boone, et al., 2007; Tong, et al., 2001; Tong, et al., 
2004). 
1.9. Yeast as a model organism 
 
Saccharomyces cerevisiae is a powerful model organism because of its 
comparatively simple genome, its genetic tractability and a range of unsurpassed 
genetic tools that can be applied, such as the yeast genome deletion set (YGDS) 
(Tong, et al., 2001; Tong, et al., 2004; Winzeler, et al., 1999). It is possible to 
uncover redundant and unknown cellular functions using high throughput genetics 
from which genetic interaction networks can be deduced, such as those described 
in Tong et al 2004.  
 
The YGDS comprises ~6300 gene-deleted strains of which ~1000 genes are 
termed “essential” as the strains are inviable and ~5000 are termed “non-
essential” since these deletion strains are viable (Winzeler, et al., 1999). Each 
strain in the YGDS has had a specific gene deleted and replaced by a gene 
cassette (KanMX4) conferring resistance to kanamycin. This deletion cassette has 
a unique molecular bar code surrounding every gene deletion. Construction of the 
YGDS has led to the development of a number of high-throughput assays which 
can be used to screen for particular phenotypes under a variety of growth 
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conditions.  S. cerevisiae  is an apt model organism for the study of human 
genetic diseases because up to 30% of genes implicated in human disease, contain 
a homologue in yeast (Bassett, et al., 1997; Foury, 1997).  
 
Synthetic genetic array analysis (SGA) allows systematic assessment of synthetic 
genetic interactions between a chosen query gene deletion strain and the entire 
“non-essential” genome. It relies on the ability of yeast to grow as haploids, mate 
to form diploids, undergo meiosis allowing selection of double-mutant haploids. 
Some of these non-essential gene double-mutants will result in unviable or less-
viable meiotic progeny (Boone, et al., 2007; Tong, et al., 2001; Tong, et al., 2004) 
defining a genetic interaction. A small molecule inhibitor may take the place of 
one of the deletion mutants also defining a genetic interaction as explained in the 
following diagram (Fig 1.9), reproduced from Parsons et al., 2004). 
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Figure 1.9 Diagrammatic comparison of genetic and chemical genetic 
interactions. Panel A shows a synthetic-lethal genetic interaction in which two 
single deletions which are individually viable but are inviable a double-mutant 
combination. Panel B shows a chemical–genetic interaction, in which a deletion 
mutant, which lacks the product of the deleted gene is hypersensitive to a 
normally sub lethal concentration of a small molecule inhibitor (Boone, et al., 
2007; Parsons, et al., 2004). 
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Chapter 2. Methods 
 
2.1. Query strain construction  
 
The strategy in this thesis used to discern genetic interactions is to create double 
deletion mutants from viable non-essential deletion mutant strains and test 
whether their combination is viable (no interaction) or non-viable (genetic 
interaction). Since only about 2-3% of all possible non-essential deletion strain 
double mutants are likely to be non-viable i.e. likely to interact (Tong, et al., 
2001) searching for evidence of genetic interactions is best done on a high-
throughput basis.  This is achieved by creating “query strains” utilising a deletion 
strain of a gene of interest of the opposite mating type to the YGDS and provided 
with a distinct (to the YGDS) selectable marker. The query strain (with a NatR 
marker) can then be mated en masse with the YGDS (with a KanR marker) and 
the appropriate double mutants selected by a combination of antibiotic selections.  
 
 HMG1 and HMG2 that encode HMG-CoA reductase are both “non essential” 
genes therefore the “one – step polymerase chain reaction gene disruption” 
method (Fig. 2.2) was used to generate HMG1 and HMG2 null mutants in query 
strains. The HMG1 query deletion was provided by J.T. Rauniyar from her 
Honours thesis work (Rauniyar and Atkinson, 2007, unpublished). Two gene 
deletion primers were constructed (HMG2 forward and reverse deletion) 
containing 55 base pairs (bp) of sequence homology to either the flanking 
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upstream (forward deletion primer) or downstream region (reverse deletion 
primer) of the HMG2 gene, excluding the start and stop codons, in addition to 
22bp of sequence homology at the 3’ end that is specific for the amplification of 
the cassette template (p4339, Invitrogen; Table 2.2). The resultant NatR 
(nourseothricin resistance) PCR product is thus contained within 55bp target 
sequences that are homologous for the flanking region of the HMG2 open reading 
frame (Fig. 2.2, adapted from Tong. 2005). This PCR product is transformed into 
the SGA starting strain Y7092 (MATα can1Δ::STE2pr-Sp_his5 lyp1Δ his3Δ1 
leu2Δ0 ura3Δ0 met15Δ0), with the transformants selected on YPD + 
nourseothricin (NAT) media. The correct targeting of the deletion cassette is 
verified by PCR using transformed genomic DNA as a template and external and 
internal cassette PCR primers (HMG2 confirmation forward and reverse, Table 
2.2) (Tong and Boone, 2005). 
 
 
 
 
 
   
Figure 2.1 PCR-mediated gene deletion used to construct 
the non-essential query strains. The lines outside of the 
boxes represent the primers used for the PCR reaction. The 
red lines represent the primer sequences (table 2.2) that 
anneal to the natMX4 cassette, the black lines represent the 
55bp-sequence specific to the upstream or downstream 
sequences of HMG2. 
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2.2. PCR amplification  
 
The HMG2 query strain PCR (see Table 2.1) was performed using the Quigen 
Hotstar Taq DNA polymerase Kit, with the following PCR cycling conditions: 15 
min initial denaturation at 94°C, then 35 cycles of 1 min at 94°C (denaturation), 1 
min at 54°C (annealing), 1 min at 72°C (extension), followed by final extension 
for 10 min at 72°C. The resulting PCR product (4µL) were run on a 2% agarose 
gel, stained with ethidium bromide and visualised under UV (ultraviolet) light. 
 
 
Reagent Volume 
10X PCR Buffer 10 μL 
dNTPs (5mM) 2 μL 
Forward primer(100pm) 2 μL 
Reverse primer (100pm) 2 μL 
Hotstar Taq 1 μL 
dd H20 82 μL 
P4339 1 μL 
Total  100 μL 
Table 2.1 Deletion PCR Reaction Conditions.  
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Table 2.2 Primers used for Δhmg2 query strain construction 
  
 
 
2.3. Transformation  
 
50 ml of YPD media was inoculated with Y7092 cells (5 x 106 cells/mL) and 
grown for 12 h at 30˚C on a shaker. When the cells reached an optical density 
(OD) of 1.13 at 600 nm (2.3 x 107 cells/mL) they were spun for five min at 2500 
rpm and washed twice with 10 mL 0.1 M lithium acetate and resuspended in 500 
µL of 0.1 M lithium acetate. Salmon sperm DNA (90 mg/mL) was denaturated by 
boiling for 10 min and placed on ice. Denatured salmon sperm DNA (10 µL) and 
HMG2 query strain PCR product (20 µL) were added to yeast cells (90 µL) and 
incubated at 30˚C for 15 minutes. 600µL Li-PEG solution (0.1 mM LiAc/ 5% 
Primer Sequence 
HMG2 
Deletion 
Forward 
ACTTAATTGTGTTCTTTCCAAATTAGTTCAACAAGGTTCCCA
CATACAACCTCAAACATGGAGGCCCAGAATACCCT 
HMG2 
Deletion 
Reverse 
TTAGAATAGCTAGACAATACAAAGATATAAAGTATCACCAT
GTAAACTACAAGAGCAGTATAGCGACCAGCATTCAC 
HMG2 
confirm 
Forward TCCCTTTCAACAGCGCGACA 
HMG2 
confirm 
Reverse AGCGCAGTGCTAGGCGATAA 
NAT 
confirm 
Reverse TACGAGACGACCACGAAGC 
NAT 
confirm 
Forward TGGAACCGCCGGCTGACC 
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PEG) was added and the cells were incubated at 30˚C for 30 min, at which time 
68µL dimethyl sulfoxide (DMSO) was added and the yeast subjected to heat 
shock at 42˚C for 15 min. The cells were then spun down at 1000 rpm for 2 min, 
the supernatant was removed and the yeast cells were resuspended in 800 µL of 
YPD and incubated at 30˚C for 4 h to allow expression of the antibiotic resistance 
gene product. Finally, to concentrate the cells, the tube was centrifuged at 2000 
rpm, the supernatant was removed and the cells were resuspended in 200 µL 
YPD. 100 μL of cell suspension was spread onto YPD plates containing the NAT 
antibiotic (100 µg/mL) to select for the resistant transformants (Gietz and 
Schiestl, 2007). 
 
 
2.4. PCR confirmation  
 
PCR on the transformed genomic DNA (gDNA) was performed to confirm the 
correct integration of the HMG2 query strain PCR product. Genomic DNA was 
extracted using the Zymo Research fungal/bacterial DNA kit from Nat-resistant 
colonies. The gDNA was used as the template in PCR utilising the confirmation 
HMG2 forward and reverse PCR primers which flank each integration site with 
an internal NatR cassette primer (Table 2.3). The following PCR cycling 
conditions: 15 min at 94°C, then 10 cycles of 30 s at 94°C, 30 s at 54°C, 2 min at 
72°C, followed by 25 cycles of: 30 s at 94°C, 30 s at 54°C, 2 min (plus 10 s each 
cycle) at 72°C followed by a final extension for 10 min at 78°C. 
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Reagent Volume (µl) 
10x Buffer 2.5 
dNTP (5mM) 0.8 
Fwd Primer HMG2 5' 0.2 
Rev Primer Nat 0.2 
Hotstar Taq 0.2 
ddH2O 16.1 
Template 5 
Total 25 
Table 2.3 Conformation PCR conditions. The initial primers were substituted for: 
HMG2 3’ (reverse) paired with the NAT forward primers in a separate reaction as 
in Table 2.2. 
 
 
2.5. Synthetic genetic array  
 
The MATa DMA is the YGDS maintained in 1536 format (384 strains in 
quadruplicate colonies) with a control border strain MATa his3Δ::kanR to ensure 
that colony sizes were not biased (Tong and Boone, 2005; Tong, et al., 2001; 
Tong, et al., 2004). Replica plating (pinning) was performed using an automated 
robotic system - the Singer RoToR HDA (Singer Instrument Co. Ltd, Somerset, 
UK). All media compositions and antibiotics are listed in Appendix 1. 
 
Mating the Query Strain with the DMA: The HMG1 or HMG2 MATα query 
strains (Nat resistant; hmg1Δ::NatR, hmg2Δ::NatR) were grown as a 1536 array 
format on rich media with antibiotic (YPD+NAT). The MATa deletion mutant 
array (DMA; G418 resistant) was also grown on rich media with the selective 
antibiotic (YPD+G418). The query strain was mated with the DMA by pinning 
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each deletion of the DMA on top of the query strain and incubated on rich media 
to produce diploid cells. 
 
MATa/α diploid selection. The resulting diploids (query + DMA) are then 
selected by pinning onto YEPD+G418/NAT media. This media allows only the 
diploids to grow, as haploids will only be either G418 or NAT resistant, not both, 
and thus will be inviable.  
 
Figure 2.2 Synthetic genetic array methodology (reproduced from Tong and 
Boone 2005). 
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Sporulation. The resulting diploids are then pinned onto media deficient in 
nutrients required for growth and incubated at a lower temperature to induce 
sporulation of the diploids. The resultant haploid spores will be a combination of 
wild-type, single or double mutants due to independent assortment of the 
chromosomes and recombination within the chromosomes. 
 MATa progeny selection. The spores are transferred onto synthetic media (SC – 
His/Arg/Lys + canavanine/thialysine) to allow for the selective germination of 
MATa meiotic progeny. To ensure selectivity, HIS3, a gene required for histidine 
biosynthesis, is deleted from both the MATα query strain and MATa deletion 
mutant array strains thus they require histidine supplementation for survival. 
Furthermore, the use of the STE2pr promoter linked to the Sch. pombe HIS5 gene 
(can1Δ::STE2pr-Sp_his5), which is able to complement S. cerevisiae HIS3, 
allows for specific selection of MATa haploids in media lacking histidine. STE2 
encodes the α-factor pheromone receptor which is only expressed in MATa, thus 
S. pombe his5 is only expressed in MATa cells and able to survive without the 
addition of histidine. Moreover, this genetic selection also prevents mating 
between MATa and MATα haploid cells. 
 
However, mitotic recombination can occur between homologous chromosomes, 
in MATa/α diploids, a crossover event can result in MATa/a or MATα/α diploids. 
To prevent this rare event from occurring, two recessive markers are introduced 
(can1Δ and lyp1Δ). The CAN1 gene encodes an arginine permease which allows 
canavanine (a toxic analogue of arginine) to enter the cells causing cell death. The 
LYP1 gene encodes a lysine permease that allows thialysine (a toxic analogue of 
lysine) to enter the cells causing cell death. The presence of wild type LYP1 and 
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CAN1 genes allows the respective antibiotics to enter the cells resulting in cell 
death. Whereas, Δlyp1 and Δcan1 cells do not have these permeases present, 
therefore, the cells are able to live in the presence of these toxic analogues. 
Including these genetic mutations into the query strains ensures the specific 
selection of MATa haploid progeny and substantially reduces the potential for 
false positives - this step is also repeated twice to assure MATa haploid selection.  
 
Double mutant selection. The MATa meiotic progeny undergoes two rounds of 
selection, first selecting for the DMA deletion mutants (G418 alone) and the 
second selecting for the query and DMA double mutants (G418 and NAT 
together).  
 
The selection of the DMA deletion mutants is achieved by pinning the MATa 
meiotic progeny onto SC - His/Arg/Lys + canavanine/thialysine/G418 media. 
Where, the G418 selects for the MATa DMA deletions (ΔGene1…5000::KanR). The 
second selection for the DMA + Query deletions is achieved by pinning the 
resulting MATa progeny onto SD/MSG – His/Arg/Lys + 
canavanine/thialysine/G418/NAT media, thus selecting for double deletions 
containing the query deletion (NatR) and DMA deletions. The progeny resulting 
from this step are the MATa (haploid) double mutants of every non-essential gene 
with the query gene mutation in which synthetic lethal interactions are observed 
and analysed.  
 
Haploid double mutants containing the query gene and the DMA (~5000 non 
essential genes) occupy fourteen 1536 colony plates where each individual strain 
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is pinned in quadruplicate. The neutral strains at the plate borders are excluded 
from the subsequent analysis to prevent the growth bias of more accessible 
nutrients at this plate location. The colonies are then scored for fitness. 
 
2.6. SGA analysis 
 
The fitness of each strain was determined by SESA (SGA Experiment Set 
Analyser; developed by Cameron Jack, Chemical Genetics VUW) which analyses 
the images of the final MATa double mutant SGA plates. The SGA results were 
compared against a control set of SGA results, ura3Δ::NatR (MATα ura3Δ::NatR 
can1Δ:: STE2pr-his5 lyp1Δ). The genetic background of hmg1Δ::NatR and 
hmg2Δ::NatR query strains included a URA3 deletion, therefore the deletion of 
HMG1 or HMG2 is the only variable in genetic background between the query 
strain and control. Comparison of hmg1Δ or hmg2Δ SGA results to the ura3Δ 
SGA results allows for the filtering of non-specific genetic interactions (frequent 
flyers). Also, any hits that have appeared in 3 or more previous independent SGA 
screens are deemed to be ‘frequent flyers’ and are discounted from the results. 
The frequent flyer hits can be explained by genes that are involved with mating or 
the sporulation process, therefore are uninformative to the assay. Finally the 
linkage genes (the genes that are in close physical proximity to the query gene 
locus) are also discounted as the genes around the query locus are expected to 
show no growth due to the decreased ability of genetic recombination to occur 
between these loci. This pattern of no growth of loci flanking the query gene is 
another method for confirming the query gene.  
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2.7. SGA scoring epistatic interactions in 
high-throughput  
 
Synthetic lethal (SL) and synthetic sick (SS) genetic interactions were inferred 
from reduced colony growth in which double mutants grew less than the expected 
combination of parental phenotypes (epitasis). 1536-colony plates were 
photographed and images analysed (gridding, segmenting and digitizing) and 
colony sizes recorded using ColonyHT software (Collins, et al., 2006; Collins). 
Colony size data were uploaded into a MySQL database that contained the 
standardised known colony position of each gene in the yeast deletion mutant 
array (DMA). 
 
Interactions were scored in high – throughput utilising a robust statistical 
algorithm for assessing epistatic colony sizes. Our colony size analysis software, 
SESA, combines replicate experiment and control data sets that were performed 
under the same growth conditions as the query and control respectively. Plate-to-
plate variation was controlled through calculating relative colony growth by 
taking the ratio of mutant colony area to the median control colony area on each 
plate, where each plate contained 144 ∆his3 mutants as controls (border strain). 
Experimental colony growth ratios were then compared to control plates where 
1536-colony plates of the DMA as an SGA using ura3∆ as a query gene (Tong, et 
al., 2001). Controls currently comprise 8 independent ura3∆ SGA’s (no expected 
interactions) and experimental SGAs comprised 3 independent experiments. 
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To improve statistical robustness against pinning errors, genetic drift and random 
growth defects, robust statistics of the form median ± 3*MAD (median absolute 
deviation) were used throughout. In SESA, confidence intervals were compared 
as per the (directional) standard method, forming each confidence interval by 
smoothed bootstrapping (two-tailed, α < 0.01, r = 1500), where the bandwidth of 
the smoothing function (Epanechnikov kernel) (Silverman, 1990) was inversely 
proportional to the number of independent replicates (Schenker, 2001). Such 
bootstrapping data were sampled from all available data from either control or 
experimental sets to better resolve the true distribution function. All test results 
were output to a text file along with a separate list of significant results. 
 
2.8. Gene ontology 
 
Gene Ontology (GO) is a controlled vocabulary used to describe the biology of a 
gene product in any organism. GO annotations are able to compare functional, 
process or cellular localisation associations made between gene products and the 
GO terms that describe them (Ashburner, et al., 2000; Gene Ontology 
Consortium, 2004). Statistically significant changes in GO term distribution 
compared to that of the whole genome suggest enrichment in the number of genes 
evolved in that particular process. The BiNGO plug-in (Maere, et al., 2005) for 
Cytoscape (Cline, et al., 2007) and the yeast GO Slim Mapper (SGD, 2009) were 
used for functional analysis of SGA and chemical genetic ‘hit’ genes. The fold 
change differences in distribution of GO terms for the ‘hit’ genes were compared 
to that of the whole genome.  
31 
 
2.9. Chemical genetic profiling 
 
The field of chemical genetics is based on the principle that small molecules can 
mimic the effects of genetic mutations (Fig 1.9). A loss-of-function mutation in 
the gene encoding a compound target can be mimicked by an inhibitory 
compound and vice versa. In chemical genetic profiling, YGDS strains are 
screened for hypersensitivity to a compound where the compound is present at a 
concentration that slightly inhibits wild-type growth. Genes identified in a 
chemical genetic screen will identify pathways that buffer the cell from the 
growth inhibitory effect of the drug. The chemical genetic profile of a drug is thus 
expected to have significant overlap with the genetic interaction profile generated 
by SGA analysis of the drug target (Boone, et al., 2007; Parsons, et al., 2004; 
Parsons, et al., 2006). 
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2.10. Chemicals and media for chemical genetic 
profiling 
 
 
Atorvastatin (Inter Chemical Hong Kong Ltd; WanChai, Hong Kong), was 
dissolved in dimethyl sulfoxide (DMSO, Sigma) at a stock concentration of 
50mM (Blank, et al., 2007). Cerivastatin (Chengdu Caikun Biological Products 
Co., Ltd.; Chengdu, Sichuan, China) was dissolved in DMSO at 10 mM (Yoshida, 
et al., 2001). Lovastatin (Ivychem; New Jersey, USA) exists in its inactive lactone 
form and is hydrolysed in vivo to its active hydroxy acid form in mammals, not 
fungi, therefore this drug must be hydrolysed prior to use in our assays. 
Lovastatin was dissolved in 100% ethanol and 0.25% wt/v NaOH, at 25 mM and 
hydrolysed at 60°C for 1 h (Lorenz and Parks, 1990). All stock solutions were 
stored at -200C. DMSO was used as a vehicle control in atorvastatin and 
cerivastatin chemical genetic screens while ethanolic NaOH was used as a vehicle 
control in lovastatin chemical genetic screens.  
 
SC media was chosen over standard rich (YPD) yeast media for use in all 
chemical experiments as it is chemically defined and does not contain yeast 
extract. Yeast extract is a major component of YPD and is made from 
concentrations of autolysed yeast. Yeast extract contains a variety of soluble 
peptides, amino acids and vitamins which could interfere with drug activity. Use 
of SC over YPD allows for alleviation of drug interactions with media 
components instead of cellular targets. 
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2.11. Spot dilution assays 
 
Serial spot dilution assays were performed to identify the minimal inhibitory drug 
concentration (MIC) to be used in the chemical genetic screen (Parsons, et al., 
2004). Haploid wild-type yeast strain BY4741 (MATa), hmg1Δ (MATα 
hmg1Δ::NatR can1Δ::STE2pr-his5 lyp1Δ), hmg2Δ (MATα hmg2Δ::NatR can1Δ:: 
STE2pr-his5 lyp1Δ) and his3Δ (MATa his3Δ::KanR) were used in this assay. The 
BY4741 strain contains the same genetic background as the non-essential haploid 
YGDS. Cultures were grown overnight to saturation (~2x108 cells/mL) and 
diluted by eight serial 10-fold dilutions in a 96-well plate. 5 µl of each cell 
dilution was spotted onto SC agar plates containing varying concentrations of 
atorvastatin, cerivastatin or lovastatin. The plates were incubated for 48 h at 300C 
after which images were taken and growth was compared by SESA to non-treated 
control plates. 
 
2.12. Chemical genetic screens 
 
The haploid non-essential YGDS (MATa) was maintained on SC+G418 agar and 
replicated onto SC plates containing 25µM atorvastatin, 20µM cerivastatin or 
150µM lovastatin. Sensitivity of each deletion strain is assayed by comparison to 
no drug diluent controls after 48 h (300C) using Colony HT and SESA. These 
screens were repeated in triplicate. Double mutant chemical screens were also 
performed using the resulting double mutants obtained from the hmg1Δ and 
hmg2Δ SGA (MATa xxxΔ::KanR his3Δ1 leu2Δ0 met15Δ0 hmg1Δ::NatR 
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can1Δ::STE2pr-his5 lyp1Δ0). The double mutants were then pinned onto 
atorvastatin (hmg1Δ 7µM, hmg2Δ 17.5µM), cerivastatin (hmg1Δ 3µM, hmg2Δ 
10µM) or lovastatin (hmg1Δ 30µM, hmg2Δ 80µM and compared to that of the 
hmg1Δ and hmg2Δ SGA for phenotypic enhancement (Parsons, et al., 2004).  
 
2.13. Ergosterol quantification 
 
Yeast strains were grown to saturation in synthetic complete media at 300C 
harvested by centrifugation at 40C and washed 3 times with ddH20 and stored at -
800C. The pellet was lyophilised, weighed, re-suspended in 20 mL distilled H20 
with 10 g of potassium hydroxide and refluxed for 3 h. Non saponifiable lipids 
were extracted from the cooled mixture three times with 100 mL diethyl ether 
(Scharlau, analytical grade), the combined extracts washed 3 times with distilled 
H20 (50 mL) and dried with anhydrous Na2SO4 (Scharlau, analytical grade). The 
dried ether fraction was then evaporated and the residue kept at -200C. Prior to 
HPLC analysis the dried extracts were resuspended in 100% methanol (Scharlau, 
HPLC grade) and passed through a 0.22 µm filter. Sterols were separated by 
HPLC using an Agilent 1200 series chromatograph fitted with a Phenomenex 
Gemini 5µM octadecysilyl - silica column and an Agilent 1100 series diode array 
detector. Methanol: H20 (95:5, v/v) was used as the mobile phase with a flow rate 
of 1 mL/min. The HPLC separation was performed at 400C and ergosterol was 
detected by absorbance at 282 nm. Ergosterol was quantified by comparing to that 
seen in a purified ergosterol standard (Sigma) (Bocking, et al., 2000; Gessner and 
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Schmitt, 1996; Jedlickova, et al., 2008; Lamacka and Sajbidor, 1997; Yuan, et al., 
2008; Zhou, et al., 2002).   
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Chapter 3. Results of SGAs 
 
3.1.  Query strain construction 
 
 Genetic interactions surrounding HMG1 and HMG2 using SGA analysis were 
elucidated with specific query strains comprising the deletion strain of the gene of 
interest (query gene) provided with a selectable marker in place of the query gene. 
The commercially available yeast deletion set does not provide query strains 
which must be constructed de novo with the appropriate antibiotic marker to 
provide for mating strain and haploid selection. In this chapter the query strains 
were Δhmg1::NatR and Δhmg2::NatR. The query strains may be robotically mass 
mated to the YGDS creating haploid double mutants allowing discernment of 
those displaying epistatic genetic interactions.  
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Figure 3.1 HMG2 query strain construction. 1A 1% agarose gel, lane 1 1Kb+ 
DNA ladder (Invitrogen), lane 2 the 1126bp nat MX4 cassette (p4339). 1B 
HMG2 query strain confirmation, lane one 1Kb+ DNA ladder, lane 2 
hmg2Δ::NAT confirmation forward 585bp, lane 3 hmg2Δ::NAT confirmation 
reverse 609bp. 1C schematic diagram of the resulting hmg2Δ::NAT PCR. 
 
 
 
The HMG1 and HMG2 query strains were constructed using the PCR mediated 
gene disruption method (see Chapter 2). Specific PCR products were generated 
using primers specific for each gene (see Table 2.2, Chapter 2). These primers 
were utilised in PCR using the template p4339 which contains the nat MX4 
cassette. The correct size 1126bp PCR product is shown in Fig 3.1. This PCR 
product was used to transform Y7092 and NAT resistant (NatR) colonies were 
obtained. To confirm correctness of the insert in genomic DNA, flanking primers 
were used to generate a confirmation PCR product. As seen in Fig 3.1, the PCR 
products of the correct size (585bp and 609bp of HMG2 forward and HMG2 
reverse respectively) were obtained verifying that the constructed strains could be 
used as query strains.  
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3.2. HMG1 SGA  
 
 The ∆hmg1 query strain was mass mated with all the other deletion strains of the 
non essential set creating a genome-wide SGA. 50 phenotypic enhancement (PE) 
interactions were scored (hits) and are shown in Table 3.1. These hits appeared in 
4 independent SGA screens performed (3 screens were previously performed by 
J.T Rauniyar, 2007) noting that each SGA is done in triplicate. A SGA typically 
displays a chromosomally contiguous set of genes that are physically adjacent to 
the query gene locus (YML075C) that do not recombine and therefore appear to 
be in linkage disequilibrium. Genes of this linkage group (LG) are not counted as 
SGA epistatic hits but are a useful indication that the SGA is working correctly. 
The LG (Table 3.2, Fig. 3.2) for Δhmg1 appeared in all four SGA screens, thus 
confirming the HMG1 gene was the gene that was replaced with the nat MX4 
cassette (hmg1Δ::NatR). Note the contiguous numbering of the genes in the LG 
observed in Table 3.2. 
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Table 3.1: Δhmg1 PE query gene interactions  
ORF Gene Process Description 
YLR131C ACE2 
Cytoskeleton 
assembly Transcription factor/cytokinesis 
YOR058C ASE1 Cell Cycle mitotic spindle 
YPL069C BTS1 
Lipid 
Biosynthesis 
Geranylgeranyl diphosphate 
synthase 
YNL275W BOR1 Transport Boron efflux  
YER061C CEM1 Lipid biosynthesis mitochondrial/fatty acid synthase 
YNL130C CPT1 Lipid biosynthesis Phosphaidylcholine biosynthisis 
YNR010W CSE2 Cell Cycle Transcription factor/RNA pol II 
YGR092W DBF2 Cell Cycle Transcription factor/ mitosis 
YDR440W DOT1 
Protein 
modification Gene silencing 
YGL222C EDC1 RNA processing mRNA decapping 
YNL080C EOS1 Glycosylation N-Glycosylation 
YNL280C ERG24 Lipid biosynthesis Ergosterol Biosynthisis 
YGL002W ERP6 Transport Er/Golgi Traffic 
YML094
W GIM5 
Cytoskeleton 
assembly 
Translocation- heterohexameric 
cochaperone prefoldin complex 
YLR192C HCR1 Translation subunit of eIF3 
YLR450W HMG2 Lipid biosynthesis Subunit of HMG-CoA reductase 
YNL106C INP52 Lipid biosynthesis 
Polyphosphatidylinositol 
phosphatase 
YGL016W KAP122 Transport 
Karyopherin β nuclear transport/ 
poss PDR 
YGL173C KEM1 RNA processing 
mRNA decay, Ribosomal 
maturation 
YGL236C MTO1 RNA processing Translation/Mitochondria tRNA 
YGL221C NIF3 Unknown detected in mitochondria 
YEL016C NPP2 other 
Nucleotide 
pyrophosphatase/phosphodiesteras
e 
YGL248W PDE1 other 
cAMP phosphodiesterase - cAMP 
signalling 
YMR201C RAD14 other Nucleotide excision repair factor 1 
YER162C RAD4 other Nucleotide excision repair factor 2 
YNL294C RIM21 other cell wall construction/pH response 
YHL025W SNF6 RNA processing 
Transcriptional 
regulation/chromatin remodelling 
YKL081W TEF4 Translation Translation elongation factor  
YGR138C TPO2 Transport Polyamine transport protien 
YGR072W UPF3 RNA processing nonsense mediated mRNA decay 
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YKL041W VPS24 Transport 
ESCRT III - transmembrane 
protiens to MVB 
YDR369C XRS2 Cell cycle DNA repair/Meiotic recombination 
YNL064C YDJ1 Transport Protien chaperone 
YFR057W  Unknown Putative protein unknown function 
YGR012W  Unknown 
Putative cystine synthase/ localised 
to Mitochondria 
YLR200W YKE2 
Protein 
Modification folding of α/βtublin and actin  
 
YLR346C  
 
Unknown 
 
putative protein unknown function 
found in mitochondria 
YNL241C ZWF1 Other G6PD 1st step in PPP  
Table 3.1 Δhmg1 PE query gene interactions. GO terms and annotations are 
extracts from the Saccharomyces Genome Database (SGD, 2009).  
  
  
ORF  Gene 
YML066C SMA2 
YML067C ERV41 
YML068W ITT1 
YML070W DAK1 
YML071C COG8 
YML072C TCB5 
YML074C FPR3 
YML075C HMG1 
YML076C WAR1 
Table 3.2 Linkage group genes surrounding HMG1. 
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Figure 3.2 Example of HMG1 SGA showing linkage group genes. From left: 
YML066C, YML067C, YML068W, YML070W, YML071C, YML072C, 
YML074C, YML075C, YML076C. 
 
 
 
The HMG1 SGA resulted in 50 PE interactions, eight of which are linkage genes. 
Interestingly, when analysed with BiNGO (Maere, et al., 2005), only six (BTS1, 
CEM1, CPT1, ERG24, HMG2, INP52) out of 42 genes are involved in lipid 
metabolism (P-value 0.0024) , however, there is a group of nine gene products 
(BTS1, CEM1, ERP6, HMG2, MTO1, NIF3, TEF4, YGR012W, YLR346C) 
which are localized to the mitochondria (P-value = 0.21) . BTS1 is of particular 
interest as, it encodes geranylgeranyl diphosphate synthase which synthesises 
geranylgeranyl pyrophosphate (Jiang, et al., 1995) located downstream of HMG-
CoA reductase (Fig1.4) and is involved in geranylgeranylation of small GTP 
binding proteins that mediate vesicular traffic. 
 
There are also ten (BOR1, CPT1, EOS1, ERP6, HMG2, KAP122, RIM1, TPO2, 
VPS24 and YGR012W) membrane localized gene products (P-value=0.25), six 
genes (BOR1, ERP6, KAP122, TPO2, VPS24, and YDJ1) involved in cellular 
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transport/ trafficking (P-value = 0.089) and four (CPT1, EOS1, ERG24 and 
HMG2) gene products localized to the endoplasmic reticulum (P-value = 0.12). 
 
3.3. HMG2 SGA  
 
 Using Δhmg2 as a query strain, 56 phenotypic enhancement interactions were 
scored (hits) and are shown in Table 3.3. These hits appeared across 3 SGA 
screens. The LG genes close to the HMG2 locus (YLR450W, Table 3.4, Fig. 3.3) 
as previously explained has been discounted from the list of epistatic genetic 
enhancement interactions.  
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Table 3.3: Δhmg2 PE query gene interactions 
ORF Gene Process Description 
YPL069C BTS1 
Lipid 
Biosynthesis 
Geranylgeranyl diphosphate 
synthase 
YCR063W BUD31 RNA processing cell cycle/budding 
YIR023W DAL81 RNA processing Nitrogen degradation pathway 
YGR092W DBF2 Cell Cycle Transcription factor/ mitosis 
YBR078W ECM33 Other 
GPI anchored/unknown 
function/phos. In mitochondria 
YNL080C EOS1 Glycosylation N-Glycosylation 
YLR192C HCR1 Translation subunit of eIF3 
YML075C HMG1 Lipid biosynthesis Subunit of HMG-CoA reductase 
YLR384C IKI3 RNA processing subunit of elongator complex 
YOL108C INO4 Lipid biosynthesis 
Transcription factor - depression of 
inositol-cholene reg. genes 
YNL106C INP52 Lipid biosynthesis 
Polyphosphatidylinositol 
phosphatase 
YHR082C KSP1 
Protein 
Modification 
Ser/Thr kinase - nuclear 
translocation 
YLL006W MMM1 Transport 
import and assembly of 
mitochondrial outer membrane 
proteins 
YGL136C MRM2 RNA processing 
Mitochondrial 2' O-ribose 
methyltransferase 
YEL016C NPP2 other 
Nucleotide 
pyrophosphatase/phosphodiesteras
e 
YOL044W PEX15 Transport Peroxisomal biogenesis 
YBR093C PHO5 Other 
Repressible acid phosphatase/ 
secretory pathway 
YNL294C RIM21 Other cell wall construction/pH response 
YLR048W RPS0B Cell Cycle 
RIM101 pathway - cell wall 
construction 
 
YOR293W 
RPS10
A Translation 
Component of 40S ribosomal 
subunit 
YLR441C RPS1A Translation 
Ribosomal protein of the 40S 
ribosomal subunit 
YML063W RPS1B Translation 
Ribosomal protein of the 40S 
ribosomal subunit 
 
YLL002W 
 
RTT109 
 
Protein 
Modification Cell cycle/DNA damage 
YKL212W SAC1 Transport 
Phosphatidylinositol phosphate 
phosphatase/ER + Golgi 
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YNL236W SIN4 RNA processing Subunit of RNA pol II 
YDR073W SNF11 RNA processing 
Chromatin 
remodelling/transcriptional 
regulation 
YHR066W SSF1 RNA processing 
Constituent of 66S pre - ribosomal 
particles 
YLR452C SST2 Other GTPase activating protein/mating 
YHR181W SVP26 Transport COP II/golgi + ER 
YDR126W SWF1 
Protein 
Modification 
Palmitoyl transferase acts on 
SNAREs 
YPL180W TCO89 Other subunit of TORC1 
YDR207C UME6 Cell Cycle 
Transcriptional regulator of 
meiotic genes 
YGR105W VMA21 
Protein 
Modification 
Assembly of V-ATPase/localised 
to \ER 
YOR083W WHI5 Cell Cycle Repressor of G1 transcription 
YHR138C  Unknown 
Putative protein of unknown 
function 
YLR200W  
Protein 
Modification folding of α/βtublin and actin  
YLR455W  Unknown 
Putative protein of unknown 
function 
YLR460C  Unknown 
Putative protein of unknown 
function 
YPR024W YME1 
Protein 
Modification 
degradation of misfolded/unfolded 
mitochondrial gene products 
YNL241C ZWF1 Other G6PD 1st step in PPP  
Table 3.3 Δhmg2 PE query gene interactions. Go terms and annotations are 
extracts from the Saccharomyces Genome Database (SGD, 2009).  
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Table 3.4 Linkage group  
genes surrounding HMG2 
 
 
 
 
Figure 3.3 Example of HMG2 SGA showing linkage group genes. From top left: 
YLR441C, YLR444C, YLR 446W, YLR448W, YLR449W, YLR450W, 
YLR451W, YLR452C, YLR453C, YLR454W, YLR455W, YLR460C 
 
 
 
ORF Gene 
YLR441C RPS1A 
YLR444C   
YLR 446W   
YLR448W RPL6B 
YLR449W FPR4 
YLR450W HMG2 
YLR451W LEU3 
YLR452C SST2 
YLR453C RIF2 
YLR454W FMP27 
YLR455W   
YLR460C   
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The HMG2 SGA resulted in 56 PE interactions, 12 of which are linkage genes. 
When analysed with BiNGO (Maere, et al., 2005) five (BTS1, HMG1, INO4, 
INP52 and SAC1) out of 44 genes are involved in lipid metabolism (P-value = 
0.024) and there is a group of seven genes (BTS1, ECM33, HMG1, MMM1, 
MRM2, SAC1 and YME1) which are localized to the mitochondria (P-value = 
0.5). BTS1 (see HMG1 SGA) is located ‘downstream’ of the HMG-CoA 
reductase genes in the mevalonate pathway (Fig1.4) (Garza, et al., 2009b; Jiang, 
et al., 1995). 
 
There are also 15 (ECM33, EOS1, HMG1, MMM1, NPP2, PEX15,RIM21, 
SAC1, SST2, SVP26, SWF1, TCO89, VMA21, YME1 and YNLO80C) 
membrane localized genes (P-value = 0.23), six genes (MMM1, IKI13, BTS1, 
PEX15, RPS0B, and SVP26) involved in cellular transport/ trafficking (P-value 
=0.09), 12 genes (DAL81, IKI3, INO4, RTT109, SIN4, UME6, WHI5, HCR1, 
RPS0B, RPS10A, RPS1A and RPS1B) involved in transcription/translation (P = 
0.004) and seven genes (PEX15, HMG1, SAC1, SVP26, SWF1, VMA21 and 
YNL080C) localized to the endoplasmic reticulum (P-value = 0.0032).  
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3.4. HMG1 and HMG2 SGA Discussion 
 
The genes that appeared as hits in both HMG1 and HMG2 are depicted in a 
network graph shown in Figure 3.4, generated by Cytoscape (Cline, et al., 2007). 
Cytoscape was used as it is freely available and the BiNGO plugin (Maere, et al., 
2005) was used as its ability to a characterize and group genes based on their GO 
terms exceeds that of other available software.  
 
The network diagram (Fig. 3.4) shows although HMG1 and HMG2 are duplicated 
genes, they are non – essential. However, the gene product HMG-CoA reductase 
is essential, thus a haploid strain carrying a null mutation for both HMG1 and 
HMG2 enzymes is inviable. When there is a null mutation in either HMG1 or 
HMG2 the other is able to fully compensate HMG-CoA reductase activity for the 
null mutation (Basson, et al., 1987; Musso, et al., 2008; Scannell, et al., 2007). 
There is a small overlap (10/86 genes, ZWF1, RIM21, YNL080C, NPP2, BTS1, 
INP52, YKE2, HCR1, YEL014C and DBF2) of shared synthetic lethal 
connections between ∆hmg1 and ∆hmg2, reflecting common functions of the 
duplicated genes, that share 93% homology at the COOH- terminal region 
residues 618-1026 of HMG1 and 614-1022 of HMG2 at the catalytic domain 
(Basson, et al., 1988). Apart from this small overlap the two genes encoding the 
same enzyme have totally different SL genetic profiles, suggesting that during the 
whole genome duplication (known to have occurred in yeast) (Musso, et al., 
2008) they each developed individual cellular roles.  
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Federovitch, et al., 2008 have investigated the protein products of HMG1 and 
HMG2, observing that Hmg1p and Hmg2p have mechanistically distinct roles 
with respect to ER remodelling. They suggest that these observations may 
underlie the known coupling of sterol synthesis to phospholipid synthesis seen in 
mammalian cells (Federovitch, et al., 2008).  
 
  
Figure 3.4 Cytoscape network graph showing HMG1 and HMG2 screens. The 
genes are grouped based on their GO terms (cellular process) generated with 
BiNGO. 
 
The increased mitochondrial enrichment of genetic interactions in the HMG1 and 
HMG2 SGA’s may play an important role in the mitochondrial electron transport 
chain. The isoprenoid intermediates farnesyl pyrophosphate and geranylgeranyl 
pyrophosphate (BTS1) are precursors of isoprenoid end products including 
ubiquinone, which the highest concentration found in the mitochondrial inner 
membrane (Dimster-Denk, et al., 1999). BTS1 has recently been described as a 
potent regulator of HMG-CoA reductase degradation in yeast (Garza, et al., 
2009b) and has been reported to cause increased ubiquination and degradation of 
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Hmg2p. Hmg1p is stable, whereas Hmg2p undergoes sterol pathway regulated 
degradation via the HMG-CoA reductase degradation (HRD) pathway (see 
chapter 7 for further discussion). SAC1, ERG24 and INO4 are of interest because 
they are involved in phosphatidylinositol synthesis. 
 
ZWF1, appeared in both HMG1 and HMG2 SGA’s and encodes the cytoplasmic 
protein Zwf1p (glucose-6-phosphate dehydrogenase, EC 1.1.1.49) which 
catalyses the first step of the pentose phosphate pathway (PPP). The primary role 
of the PPP in yeast when grown on a fermentable carbon source is to produce 
NADPH. When ZWF1 is inhibited, this decreases the cells ability to generate 
NADPH from NADP+.  The production of the malic enzyme up-regulated to 
compensate and increase the rate of NADPH synthesis in the mitochondria 
(Blank, et al., 2005). Increased enrichment for mitochondrial hit genes that appear 
in both the HMG1 and HMG2 SGA screens may be due to oxidative damage 
caused by the increased amount of NADP+ within the mitochondria. 
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Chapter 4. Chemical-genetic interactions 
of statin drugs 
 
The central assumption of the newly described field of chemical genetics 
(Hillenmeyer, et al., 2008; Parsons, et al., 2004; Parsons, et al., 2006) is that a 
‘small molecule perturbagen’ (SMP) binds specifically to a gene product and 
alters its function, mimicking a mutation in the corresponding gene. Thus, 
epistatic interactions between a mutant and an SMP may be defined and further 
used to define functional genetic interaction networks. To pursue this approach, it 
is necessary to define a SMP (i.e. inhibitor drug) concentration that slightly 
inhibits growth, but does not kill cells. In the following results, therefore, the term 
“chemical-genetic screens” is used to describe this mode of epistatic 
measurement. For the sake of clarity in the following description, “phenotypic 
enhancements” are growth reducing epistatic interactions and are the main focus 
of this dissertation where ‘synthetic lethality’ is an extreme form of phenotypic 
enhancement reduced growth. On the other hand, the term “phenotypic 
suppression” refers to enhanced growth (cf wild type) of a double deletion mutant 
combination. The literature at times uses the terms and “alleviating” and 
“aggravating” for phenotypic suppression and phenotypic enhancement epistatic 
interactions respectively (Boone, et al., 2007), bearing in mind that the phenotype 
being a enhanced or aggravated is reduced growth. 
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4.1. Spot dilution assays 
 
Spot dilution assays are standard yeast protocols that encompass two variables, 
namely drug concentration and the number of cells spotted as a colony grown on 
solid agar. The two-way variation allows a better estimate of the drug 
concentration that is inhibitory rather than overtly toxic. Use of drugs at less than 
an LD50 was deemed optimal to estimate PE chemical genetic interactions in 
subsequent chemical genetic screens. Thus, prior to chemical genetic screening, 
spot dilution assays were used as a pilot study to assess the growth inhibitory 
effects of atorvastatin and cerivastatin on wild type cells (BY4741), and on the 
deletion strains Δhmg1 and Δhmg2 (Fig 4.1). Lovastatin spot assays had 
previously been performed by J.T. Rauniyar in her honours thesis in 2007. Based 
on the results from the spot assays, concentrations were selected for the chemical-
genetic screens that reduced growth. On this basis, atorvastatin was used at 25 
µM, cerivastatin at 20 µM and lovastatin at 150 µM as these concentrations 
showed approximately 20% growth inhibition compared to wild type yeast. 
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Figure 4.1 Spot assays for statin drug working concentrations. 10x8 - 10x1 
cells/mL serially diluted onto SC media containing varying concentrations of 
Atorvastatin or Cerivastatin. A-C, Atorvastatin 10 µM - 70 µM, A =BY4741, B = 
Δhmg1, C= Δhmg2. D-F, Cerivastatin 1µM - 15µM. D = BY4741, E = Δhmg1, F 
= Δhmg2. 
 
 
4.2. Chemical genetic screens 
 
 Statin drugs were used as SMPs in chemical genetic screens mimicking the 
effects of double haploid mutants that occur in SGA analysis. All chemical 
genetic screens were performed by robotically pinning the formatted non-essential 
gene deletion set (YGDS) of approximately 4800 strains onto solid agar plates 
containing the drug in 1536 colony format, followed by incubation for 48 h at 
300C. Plates were imaged utilising Colony HT (Collins) in the Chemical Genetics 
Laboratory’s digital imaging system – a system capable of segregating and 
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measuring the size of colonies on the 1536-format solid media plates. Images 
were further analyzed with SESA, to assess the statistical significance of colony 
size differences as epistatic events. Controls for the drugs were DMSO for 
atorvastatin and cerivastatin or ethanol for lovastatin. SESA produced a list of PE 
“hits” which was then manually edited for deletion-gene combinations that tend to 
show up whatever the screen, termed ‘frequent flyers’, which were removed. 
Genes reported as multidrug resistant, “MDR”, (Hillenmeyer, et al., 2008; 
Parsons, et al., 2004; Parsons, et al., 2006) were noted by bold-formatting in 
Tables 4.1 - 4.6. The results from three independent experiments are shown in 
Tables 4.1 – 4.6 and are shown in graphical format in Figs. 4.2 & 4.3. 
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Table 4.1: Atorvastatin chemical genetic PE interactions 
ORF Gene Process Description 
YLR242C ARV1 Lipid Biosynthesis 
Transport of 
Glycosylphosphatidylinositol 
intermediates; sterol 
distribution and sphingolipid 
metabolism 
YNL242W ATG2 Transport 
Membrane protein, Vesicle 
formation 
YJL095W BCK1 Protein modification MAP KKK; PKC signalling 
YER155C BEM2 Cytoskeleton assembly 
Rho GTPase activating 
protein; cytoskeleton 
organisation 
YNL271C BNI1 Cell cycle 
Formin linear actin filament 
formation 
YNL233W BNI4 Cell cycle 
Targeting subunit for Glc7p 
protein phosphatase 
YPL069C BTS1 Lipid Biosynthesis 
Geranylgeranyl diphosphate 
synthase 
YGR217W CCH1 Transport Voltage gated Ca channel 
YKL190W CNB1 Other 
Calcineurin B; stress response 
TF 
YGR092W DBF2 Cell cycle 
Ser/Thr kinase: transcription 
and stress response 
YAL026C DRS2 Transport 
Aminophohpholipid 
translocase (flippase); post 
golgi secretory vesicles 
YML008C ERG6 Lipid Biosynthesis 
Δ-sterol C-methyltransferase, 
converts zymosterol to 
fecosterol  
YCR089W FIG2 Cell cycle 
Cell wall adhesion; expressed 
during mating 
YEL042W GDA1 Transport 
Guanosine diphosphate 
located in golgi 
YPR160W GPH1 Metabolite Biosynthesis Glycogen phosphororylase 
YML075C HMG1 Lipid Biosynthesis 
One of two isoenzymes 
encoding HMG-CoA 
reductase 
YJR075W HOC1 Other  
α-1,6-mannosyltransferase- 
cell wall mannan biosynthesis 
 
YNL291C 
 
MID1 
 
Transport 
 
N-Glycosylated protein of ER 
membrane 
YLR332W MID2 Transport 
O-Glycosylated PM protein, 
cell wall integrity sensor 
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YDR245W MNN10 Protein modification 
Golgi mannosyltransferase 
complex; elongation of 
mannan backbone 
YKL098W MTC2 Unknown Protein of unknown function 
 
YBL024W 
 
NCL1 
 
RNA Processing 
 
S-adenosyl-L-methionine-
dependent tRNA; m5C-
methyltransferase 
YJR073C OPI3 Lipid Biosynthesis 
Phospholipid 
methyltransferase; 
phosphotidylcholine 
biosynthesis 
YJL212C OPT1 Transport 
Proton coupled oligopeptide 
transporter of the PM 
YDR071C PAA1 Other polyamine acetyltransferase 
YOR265W RBL2 Cytoskeleton assembly Microtubule morphogenesis 
YJL204C RCY1 Transport 
F-Box protein recycling PM 
proteins 
YOR035C SHE4 Cytoskeleton assembly 
Regulates myosin 
function/endocytosis/actin 
polarization 
YHR030C SLT2 Protein modification 
Ser/Thr kinase MAP kinase; 
PKC1 signalling; cell cycle 
YEL031W SPF1 Protein modification 
P-type ATPase; ion transporter 
of the ER membrane; Ca2+ 
homeostasis 
YHL022C SPO11 Cell cycle 
Meiosis; meiotic 
recombination - forms DSB's 
YDR293C SSD1 Other Cell integrity; TOR pathway 
YDR297W SUR2 Lipid Biosynthesis 
Sphinganine C4-hydroxylase; 
sphingolipid biosynthesis 
YJL187C SWE1 Cell cycle 
Protein kinase; regulated 
G2/M transition 
YPL105C SYH1 Unknown May interact with ribosomes 
YGR105W VMA21 Other 
Membrane protein required for 
vacuolar H+ ATPase function 
 
YJR099W 
 
YUH1 
 
Protein modification 
Ubiquitin C-terminal 
hydrolase; generates 
monoubiquitin 
YDR541C   Unknown 
Putative dihydrokaempferol 4-
reductase 
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YLR346C Unknown Putative protein of unknown 
function 
YPL272C   Unknown 
Putative protein of unknown 
function 
Table 4.1 Atorvastatin chemical genetic PE interactions, bold indicate MDR 
genes. GO process and annotations were retrieved from the Saccharomyces 
Genome Database.  
 
The three chemical genetic screens performed on 25 µM atorvastatin resulted in 
41 PE interactions (table 4.1) when analysed with SESA, the atorvastatin plates 
were compared to that of a DMSO (solvent) control and assessed for growth. The 
41 genes were then analysed based on gene ontology. GO is useful for grouping 
genes but is a work in progress as its localisation category of genes is not yet 
agreed on – for example ERG6 in some GO databases is located to the ER where 
it is known to also to be located in lipid droplets (Maass, et al., 2009; Zehmer, et 
al., 2008). Eight of 41 genes (ARV1, ERG6, HMG1, MID1, OPI3, SPF1, SUR2 
and VMA21) were annotated as being localised to the endoplasmic reticulum, Six 
of 41 genes (ARV1, BTS1, ERG6, HMG1, OPI3, and SUR2) are genes involved 
in lipid synthesis carried out in the ER, which is also the main location of the 
target enzyme HMG-CoA reductase.  
 
Furthermore, there are seven genes displaying PE interactions (BEM2, BTS1, 
ERG6, HMG1, OPI3, SPF1, and SYH1) that are localised to the mitochondria. 
These are likely due to inhibition of isoprenylated proteins namely those involved 
in the electron transport chain (ubiquinone) and small GTP binding proteins 
which mediate intracellular membrane vesicular traffic (Jiang, et al., 1995). BTS1 
(see Chapter 3) reflects the activities of other (non-sterol) enzymes in the HMG-
CoA reductase pathway as described in the Introduction (Chapter 1), this gene has 
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been described by Garza et al. 2009 as a potent regulator of HMG-CoA reductase 
and would be a most interesting gene to follow-up in further studies. 
 
 
Table 4.2: Atorvastatin chemical genetic PS interactions 
ORF Gene Process Description 
YLL006W MMM1 Transport 
Mitochondrial outer 
membrane; import and 
assembly of outer 
membrane β barrel 
proteins 
YLL009C COX17 Other Cu metallochaperone 
YCR063W BUD31 RNA Processing Cell cycle/budding 
YLR114C AVL9 Transport 
Exocytic transport form 
Golgi 
YKR024C DBP7 RNA Processing 
Putative ATP dependent 
RNA helicase of the 
DEAD box family 
YJL131C AIM23 Unknown 
Putative protein of 
unknown function 
YKL098W YKL098W Unknown 
Protein of unknown 
function 
YLR410W VIP1 Other 
Inositol hexakisphosphate 
and inositol 
heptakisphosphate kinase 
YLL041C SDH2 
Metabolite 
Biosynthesis 
Iron sulfur protein subunit 
of succinate 
dehydrogenase 
YKL037W YKL037W Unknown  
Putative protein of 
unknown function 
YLR038C COX12 Other 
Subunit Vib of cyc c 
oxidase 
YLR024C UBR2 Protein modification Cytoplasmic E3 ligase 
YOL004W SIN3 Protein modification 
Histone deacetylase 
transcriptional repression; 
meiosis  
Table 4.2 Atorvastatin chemical genetic PS interactions, GO process and 
annotations were retrieved from the Saccharomyces Genome Database 
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The enrichment in ER/lipid synthesis genes in statin chemical genetic interactions 
suggests that the unknown genes displaying interactions in the chemical genetic 
tables also belong in these same categories – a useful hypothesis that could be 
tested in follow on work to this dissertation. 
 
The three independent chemical-genetic screens performed on 25 µM atorvastatin 
resulted in 14 PS interactions (Table 4.2) as analysed with SESA. The 14 genes 
were then analysed based on gene ontology, with 5/14 genes (AIM23, COX12, 
COX17, MMM1 and SDH2) being found to localise to the mitochondria, four of 
which (COX12, COX17 MMM1 and SDH2) are in the outer membrane. This is a 
significant enrichment of chemical genetic interactions implying that 
enzymes/functions probably occur in the isoprene pathways, known to be 
inhibited by statins, resulting in a compensating up-regulation. 
 
 
 
 
 
 
 
 
 
 
 
 
59 
 
Table 4.3: Cerivastatin chemical genetic PE interactions 
ORF Gene Process Description 
YOR141C ARP8 Other 
nuclear actin related protein; 
Chromatin remodeling 
YLR242C ARV1 Lipid Biosynthesis 
Transport of 
Glycosylphosphatidylinositol 
intermediates 
YNL242W ATG2 Transport 
Membrane protein, Vesicle 
formation 
YBL089W AVT5 Transport 
Putative transporter; GABA 
glycine transport 
YJL095W BCK1 Protein modification MAP KKK; PKC signaling 
YER155C BEM2 
Cytoskeleton 
assembly 
Rho GTPase activating 
protein; cytoskeleton 
organisation 
YNL271C BNI1 Cell cycle 
Formin linear actin filament 
formation 
YNL233W BNI4 Cell cycle 
Targeting subunit for Glc7p 
protein phosphatase 
YPL069C BTS1 Lipid Biosynthesis 
Geranylgeranyl diphosphate 
synthase 
YOR026W BUB3 Cell cycle 
Kinetochore checkpoint 
WD40; prophase/metaphase 
YGR217W CCH1 Transport Voltage gated Ca channel 
YLR330W CHS5 Transport 
Golgi to PM transport; 
exomer complex 
YKL190W CNB1 Other 
Calcineurin B; stress 
response TF 
YJR084W CSN12 Other 
Subunit of Cop9 
signalosome 
 
 
 
YGL110C 
 
 
 
CUE3 
 
 
 
Protein modification 
Protein of unknown 
function; Poss. 
intramolecular 
monoubiquination 
YGR092W DBF2 Cell cycle 
Ser/Thr kinase: transcription 
and stress response 
YAL026C DRS2 Transport 
Aminophohpholipid 
translocase (flippase); post 
golgi secretory vesicles 
YGL043W DST1 RNA Processing 
Transcription elongation 
factor TFIIS 
YGL054C ERV14 Transport COPII coated vesicles 
YCR089W FIG2 Cell cycle 
Cell wall adhesion; 
expressed during mating 
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YEL042W 
 
GDA1 
 
Transport 
Guanosine diphosphate 
located in golgi 
YPR160W GPH1 
Metabolite 
Biosynthesis Glycogen phosphororylase 
 
YJR090C 
 
GRR1 
 
Protein modification 
 
F-Box component of SCF 
Ubiquitin ligase complex 
YML075C HMG1 Lipid Biosynthesis 
One of two isoenzymes 
encoding HMG-CoA 
reductase 
YJR075W HOC1 Other  
α-1,6-mannosyltransferase- 
cell wall mannan 
biosynthesis 
YOL108C INO4 Lipid Biosynthesis 
transcription factor - 
depression od inositol-
choline reg. genes 
YJL124C LSM1 RNA Processing 
LSM protein; cytoplasmic 
mRNA degradation 
YOR306C MCH5 Transport PM riboflavin transporter 
YNL291C MID1 Transport 
N-Glycosylated protein of 
ER membrane 
YLR332W MID2 Transport 
O-Glycosylated PM protein, 
cell wall integrity sensor 
YDR245W MNN10 Protein modification 
Golgi mannosyltransferase 
complex; elongation of 
mannan backbone 
YPR118W MRI1 Other 
5'- methylthioribose-1-
phosphate isomernase; 
methionine salvage pathway 
YBL024W NCL1 RNA Processing 
S-adenosyl-L-methionine-
dependent tRNA; m5C-
methyltransferase 
YMR145C NDE1 
Metabolite 
Biosynthesis 
Mitochondrial external 
NADH dehydrogenase;type 
II NADPH quinone 
oxireductase 
YJR073C OPI3 Lipid Biosynthesis 
Phospholipid 
methyltransferase; 
phosphotidylcholine 
biosynthesis 
YGR038W ORM1 Protein modification 
required for resistance to 
UPR inducing agents 
YDR071C PAA1 Other polyamine acetyltransferase 
 
YCR077C 
 
 
PAT1 
 
 
RNA Processing 
Topo II associated 
deadenylation dependent 
mRNA decapping 
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YCR020C 
 
 
PET18 
 
Metabolite 
Biosynthesis 
Respiratory growth and 
stability of mitochondrial 
genome 
YOL001W PHO80 RNA Processing 
Cyclin; regulates phosphate 
metabolism 
YNL201C PSY2 Other 
subunit of protein 
phosphatase complex 
YER162C RAD4 Other 
subunit of Nuclear excision 
repair factor 2 
YDL090C RAM1 Protein modification 
β subunit of CAAX 
farnesyltransferase; a-factor 
and Ras proteins 
YJL204C RCY1 Transport 
F-Box protein recycling PM 
proteins 
YGL045W RIM8 Cell cycle 
Unknown function - 
essential for anaerobic 
growth 
YLL046C RNP1 RNA Processing 
Ribonucleoprotein contains 2 
RNA recognition motifs 
YBL027W RPL19B Translation 
Component of 60s ribosomal 
subunit 
YNL096C RPS7B Translation 
Component of 40s ribosomal 
subunit 
YOR035C SHE4 
Cytoskeleton 
assembly 
Regulates myosin 
function/endocytosis/actin 
polarization 
YBR103W SIF2 Cell cycle 
WD40 repeat subunit of 
SET3 Histone deacetylase 
complex; sporulation 
YNL236W SIN4 RNA Processing 
RNA pol II mediator 
complex; transcriptional 
regulation 
YBL007C SLA1 
Cytoskeleton 
assembly 
Cytoskeletal protein binding 
protein; assembly of cortical 
actin cytoskeleton 
YHR030C SLT2 Protein modification 
Ser/Thr kinase MAP kinase; 
PKC1 signaling; cell cycle 
YMR016C SOK2 Other 
Regulation of cAMP PKA 
signal transduction pathway 
 
 
 
YEL031W 
 
 
 
SPF1 
 
 
 
Protein modification 
P-type ATPase; ion 
transporter of the ER 
membrane; Ca2+ 
homeostasis 
YCR081W SRB8 RNA Processing 
Subunit of RNA pol II; 
glucose repression 
YDR293C SSD1 Other Cell integrity; TOR pathway 
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YJL187C SWE1 Cell cycle 
Protein kinase; regulated 
G2/M transition 
 
YPL105C 
 
SYH1 
 
Unknown 
 
May interact with ribosomes 
YDR213W UPC2 Lipid Biosynthesis 
SREBP - induces 
transcription of sterol 
biosynthetic genes 
YEL013W VAC8 Transport 
Phosphorylated vacuolar 
membrane protein 
(cytoplasm to vacuole 
targeting) 
YGL212W VAM7 Transport 
Component of vacuole 
SNARE complex 
YGR105W VMA21 Other 
Membrane protein required 
for vacuolar H+ ATPase 
function 
 
 
 
YML097C 
 
 
 
VPS9 
 
 
 
Transport 
Guanine nucleotide 
exchange factor involved in 
vesicle mediated vacuolar 
protein transport 
YLR337C VRP1 
Cytoskeleton 
assembly 
Proline rich actin associated 
protein 
YBR111C YSA1 Other 
Nudix hydrolase; ADP-
ribose pyrophosphate 
YJR099W YUH1 Protein modification 
Ubiquitin C-terminal 
hydrolase; generates 
monoubiquitin 
YBR269C   Unknown 
Putative protein of unknown 
function 
YDR541C   Unknown 
Putative dihydrokaempferol 
4-reductase 
YEL007W   Unknown 
Putative protein; Poss. 
Gluconate transporter 
inducer  
YGL081W   Unknown 
Putative protein of unknown 
function 
YGR122W   Unknown 
Putative protein of unknown 
function 
YJL160C   Unknown 
Putative protein of unknown 
function 
YKR016W   Unknown 
Mitochondrial protein of 
unknown function 
YLR346C   Unknown 
Putative protein of unknown 
function 
YPL041C   Unknown Protein of unknown function 
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YPL066W 
 
Unknown 
Putative protein of unknown 
function 
YPL272C   Unknown 
Putative protein of unknown 
function 
Table 4.3 Cerivastatin chemical genetic PE interactions, bold indicate MDR 
genes. GO process and annotations were retrieved from the Saccharomyces 
Genome Database 
 
The chemical screens performed on 20 µM cerivastatin yielded 78 PE 
interactions (Table 4.3) when analysed with SESA. GO analysis of PE genes 
showed 11/78 gene products (BEM2, BTS1, FCJ1, FMP21, HMG1, NDE1, OPI3, 
SPF1, SYH1, YLR346C and YSA1) are localised to the mitochondria, 8 genes 
(ARV1, ERV14, HMG1, MID1, OPI3, ORM1, SPF1 and VMA21) are localised 
to the ER, and 8 genes (ARV1, CHS5, DRS2, ERV14, GDA1, HOC1, MNN10 
and RCY1) are localised to the Golgi apparatus. Some are localised to both 
organelles and are involved in vesicle transport between the Golgi and ER. Where 
VMA21 is required for the assembly of the V-ATPase complex (Graham and 
Stevens, 1999), ERV1 is an integral component of COPII vesicular transport 
(Otte, et al., 2001), ARV1 is involved in intracellular sterol distribution (Fei, et 
al., 2008) along with transport of glycosylphosphatidylinositol intermediates into 
the ER (Kajiwara, et al., 2008). Moreover, ARV1 is also involved with HOC1 and 
MNN10 which are localised to the Golgi and mediate the elongation of the 
polysaccharide mannan backbone (Jungmann, et al., 1999). The RCY1 protein is 
involved in the recycling of SNARE proteins from the plasma membrane via 
endocytosis. Thus, cerivastatin disrupts vesicular transport of proteins within the 
secretory pathway when compared to that of atorvastatin and lovastatin. 
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Seventeen genes (ARV1, ATG2, AVT5, CCH1, CHS5, DRS2, ERV14, MCH5, 
MID1, RCY1, RIM8, SLA1, SPF1, VAC8, VAM7, VPS9 and VRP1) are 
involved in intracellular vesicular transport.  
 
Six lipid biosynthesis genes showed PE interactions with cerivastatin, namely 
ARV1, BTS1, HMG1, INO4, OPI3 and UPC2; and atorvastatin interacted with 
ARV1, BTS1, ERG6, HMG1, OPI3 and SUR2 showing commonality in the lipid 
synthesis and degradation genes, ARV1 and BST1. The others fall generally in 
lipid pathway genes and are likely to be significant in the mode of action of the 
drugs.  
 
ERG3, INO4 and OPI3 genes are present in the cerivastatin screen, where OPI3 
catalyses the last two steps in phosphatidylinositol choline biosynthesis (Nikoloff 
and Henry, 2003) and ERG3 catalyses the formation of episterol, a precursor in 
ergosterol biosynthesis (Lees, et al., 1995). In contrast, INO4 is involved in 
transcriptional regulation of expression of a large number of genes including a 
subset that are regulated by inositol and choline and involved in phospholipid, 
fatty acid and sterol biosynthesis (Santiago and Mamoun, 2003).  
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Table 4.4: Cerivastatin chemical genetic PS interactions 
ORF Gene Process Description 
YLL006W MMM1 Transport 
Mitochondrial outer 
membrane; import and 
assembly of outer membrane β 
barrel proteins 
YAL048C GEM1 Transport 
tail anchored outer 
mitochondrial membrane 
GTPase 
YDL033C SLM3 RNA Processing 
tRNA-specific 2-thiouridylase; 
thiolation of wobble base of 
mitochondrial tRNAs 
YLL009C COX17 Other Cu metallochaperone 
YLR410W VIP1 Other 
Inositol hexakisphosphate and 
inositol heptakisphosphate 
kinase 
YNL170W YNL170W Unknown 
Dubious ORF unlikly to 
encode a functional protein 
YKL157W APE2 Other Aminopeptidase ysII 
YOR065W CYT1 
Metabolite 
Biosynthesis 
Cyt c1, component of 
mitochondrial respiratory chain 
YKL098W YKL098W Unknown Protein of unknown function 
YHR116W COX23 
Metabolite 
Biosynthesis 
mitochondrial intermembrane 
space protein; Cu homeostasis 
YLR038C COX12 Other Subunit Vib of cyc c oxidase 
YEL033W YEL033W Unknown Predicted metabolic role 
YOR053W YOR053W Unknown 
Dubious ORF unlikely to 
encode a protein 
YBR132C AGP2 
Lipid 
Biosynthesis Polyamide permiase 
YOR008C-A 
YOR008C-
A Unknown  
Putative protein of unknown 
function 
YHR206W SKN7 Other 
Nuclear response regulator and 
transcription factor; induction 
of heat shock genes 
YOR196C LIP5 
Metabolite 
Biosynthesis 
biosynthesis of coenzyme 
lipoic acid 
YMR256C COX7 
Metabolite 
Biosynthesis 
Subunit VII of cyt c oxidase; 
electron transport 
 
 
YBR266C 
 
 
SLM6 
 
Cytoskeleton 
assembly 
 
Potential role in actin 
cytoskeleton organization 
YDL136W RPL35B Translation 
Component of 60s ribosomal 
subunit 
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YNL169C PSD1 
Lipid 
Biosynthesis 
Phosphatidylserine 
decarboxylase of the inner 
mitochondrial membrane 
 
YOR085W 
 
OST3 
 
Protein 
modification 
 
g subunit of the 
olgiosaccharyltransferase in 
ER; N-glycosylation 
YJL131C YJL131C Unknown 
Putative protein of unknown 
function 
YKL037W YKL037W Unknown  
Putative protein of unknown 
function 
YEL007W YEL007W Unknown 
Putative protein; Poss. 
Gluconate transporter inducer  
YNR041C COQ2 
Metabolite 
Biosynthesis 
Para hydrozybenzoate 
polyprenyl transferase; CoQ 
Synthesis 
YKL109W HAP4 Other 
activator of global gene 
expression - heme activated 
YLR114C AVL9 Transport Exocytic transport form golgi 
YEL013W VAC8 Transport 
Phosphorylated vacuolar 
membrane protein (cytoplasm 
to vacuole targeting) 
YDR512C EMI1 Cell cycle 
Transcriptional induction of 
early meiosis 
YOR014W RTS1 Translation 
B-type regulatory subunit of 
PP2A 
YKL168C KKQ8 Unknown Putative Ser/Thr kinase 
YPR065W ROX1 RNA Processing 
Heme dependent repressor of 
hypoxic genes - contains an 
HMG domain 
YDR393W SHE9 Other 
Mitochondrial inner membrane 
protein - morphology 
YOL009C MDM12 
Protein 
modification 
transmission of mitochondria 
to daughter cells 
YDL182W LYS20 Other 
Homocitrate synthase 
isoenzyme 
YLR061W RPL22A Translation 
Component of 60s ribosomal 
subunit 
YDL079C MRK1 
Protein 
modification 
Glycogen synthase kinase 3; 
stress response/protein 
degradation 
 
 
YHR181W 
 
 
SVP26 
 
 
Transport 
 
Membrane protein Golgi/ER; 
COPII transport 
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YOR125C 
 
CAT5 
Metabolite 
Biosynthesis 
 
CoQ synthesis 
YOL008W COQ10 
Metabolite 
Biosynthesis CoQ binding protein 
YLR393W ATP10 Other 
mitochondrial inner membrane 
protein; F1F0 ATP synthase 
YMR100W MUB1 
Protein 
modification 
interacts with E2 and E3 
enzymes; ubiquitylation and 
degradation 
YBR076W ECM8 Other Unknown function 
YOL032W OPI10 
Lipid 
Biosynthesis 
Possible role in phospholipid 
biosynthesis 
YKR016W FMP13 Unknown 
Mitochondrial protein of 
unknown function 
YKR092C SRP40 Transport 
Nucleolar - ser rich; 
preribosome assembly or 
transport 
YHR067W HTD2 
Lipid 
Biosynthesis 
mitochondrial 3-hydroxyacyl-
thioester dehydratase; fatty 
acid biosynthesis 
YPL156C PRM4 Other Pheromone regulated protein 
YNL180C RHO5 Other 
Small GTPase of Rho/Rac; 
PKC signaling 
YNL111C CYB5 
Lipid 
Biosynthesis 
Cyt b5 sterol and lipid 
biosynthesis 
YKR074W YKR074W Unknown 
Putative protein of unknown 
function 
YHR009C YHR009C Unknown 
Putative protein of unknown 
function 
YPR084W YPR084W Unknown 
Putative protein of unknown 
function 
YDR486C VPS60 Transport 
Cytoplasmic and vacuolar 
membrane protein involved in 
endosome to vacuole transport 
YKR007W MEH1 Other Component of EGO complex 
YOL049W GSH2 
Metabolite 
Biosynthesis Glutathione synthase 
YER057C HMF1 Other  p14.5 protein family 
YJL105W SET4 Unknown 
Unknown function; contains a 
SET domain 
YBR235W YBR235W Unknown Putative Ion transporter 
YLR368W MDM30 
Protein 
modification 
F-Box protein, associates with 
mitochondria 
YGL031C RPL24A Translation 
Ribosomal protein L30 of 60s 
ribosomal subunit 
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YMR305C SCW10 Other Cell wall protein 
YDL061C RPS29B Translation 
Component of 40s ribosomal 
subunit 
YKL010C UFD4 
Protein 
modification 
E3 ligase; interacts with 26s 
proteasome 
YOL081W IRA2 Other 
GTPase activating protein; 
negatively regulates RAS 
YGL167C PMR1 Transport 
Ca2+/Mn2+ P-type ATPase; 
Golgi transport 
Table 4.4 Cerivastatin chemical genetic PS interactions, GO process and 
annotations were retrieved from the Saccharomyces Genome Database. 
 
Table 4.4 shows the PS interactions that resulted from the three chemical screens 
performed utilising 20 µM cerivastatin. There were 72 phenotypic suppression 
interactions (Table 4.4) evident when cerivastatin plates were compared to that of 
a DMSO control and assessed for growth. There were a large number of genes 
specific for cerivastatin not shared by the other statins for example 24 genes 
(AIM23, APE2, ATP10, CAT5, COQ10, COQ2, COX12, COX17, COX23, 
COX7, CYT1, FCJ1, GEM1, HTD2, IRA2, LIP5, LYS20, MDM12, MDM30, 
MMM1, PSD1, SHE9, SLM3 and UFD4) localised to the mitochondria, 4 of 
which are involved in cellular respiration/generation of precursor metabolites and 
energy (COQ10, COX23, COX7 and CYT1). Furthermore, 6 genes (AGP2, 
CYB5, MMM1, OST3, SCW10 and SVP26) were localised to the endoplasmic 
reticulum and 14 genes (AGP2, AVL9, COX17, GEM1, MDM12, MDM30, 
MMM1, PMR1, SLM6, SRP40, SVP26, VAC8, VPS60 and YBR235W) are 
involved intracellular vesicular transport. Besides this concentration of genes 
involving lipid and membrane biosynthesis there were many other epistatic 
genetic interactions with unrelated processes. Cerivastatin might show such an 
increased number of chemical genetic interactions consistent with its known 
propensity for side effects (Fuhrmans, et al.; Tuffs, 2001).  
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Table 4.5: Lovastatin chemical genetic PE interactions 
ORF Gene Process Description 
YLR242C ARV1 Lipid Biosynthesis 
Transport of 
Glycosylphosphatidylinositol 
intermediates;  
YNL242W ATG2 Transport 
Membrane protein, Vesicle 
formation 
YJL095W BCK1 Protein modification MAP KKK; PKC signalling 
YER155C BEM2 
Cytoskeleton 
assembly 
Rho GTPase activating protein; 
cytoskeleton organisation 
YNL271C BNI1 Cell cycle 
Formin linear actin filament 
formation 
YNL233W BNI4 Cell cycle 
Targeting subunit for Glc7p 
protein phosphatase 
YGL007W BRP1 Unknown 
Dubious ORF - deletion leads 
to polyamine resistance 
YPL069C BTS1 Lipid Biosynthesis 
Geranylgeranyl diphosphate 
synthase 
YGR217W CCH1 Transport Voltage gated Ca channel 
YKL190W CNB1 Other 
Calcineurin B; stress response 
TF 
YGL110C CUE3 Protein modification 
Protein of unknown function; 
Poss. intramolecular 
monoubiquination 
YGR092W DBF2 Cell cycle 
Ser/Thr kinase: transcription 
and stress response 
YDR440W DOT1 Protein modification 
Nucleosomal Histone 
associated with 
transcriptionally active genes 
 
YAL026C 
 
DRS2 
 
Transport 
 
Aminophohpholipid translocase 
(flippase); post golgi secretory 
vesicles 
YGL043W DST1 RNA Processing 
Transcription elongation factor 
TFIIS 
YCR089W FIG2 Cell cycle 
Cell wall adhesion; expressed 
during mating 
YEL042W GDA1 Transport 
Guanosine diphosphate located 
in golgi 
YPR160W GPH1 
Metabolite 
Biosynthesis Glycogen phosphororylase 
 
 
YFL031W 
 
 
HAC1 
 
 
Protein modification 
Basic leucine zipper TF; UPR 
regulation 
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YML075C HMG1 Lipid Biosynthesis 
One of two isoenzymes 
encoding HMG-CoA reductase 
YJR075W HOC1 Other  
α-1,6-mannosyltransferase- cell 
wall mannan biosynthesis 
YNL291C MID1 Transport 
N-Glycosylated protein of ER 
membrane 
YLR332W MID2 Transport 
O-Glycosylated PM protein, 
cell wall integrity sensor 
YDR245W MNN1 Protein modification 
Golgi mannosyltransferase 
complex; elongation of mannan 
backbone 
YMR224C MRE11 Cell cycle 
Repair of double stranded 
brakes; telomere stability 
YBL024W NCL1 RNA Processing 
S-adenosyl-L-methionine-
dependent tRNA; m5C-
methyltransferase 
YJR073C OPI3 Lipid Biosynthesis 
Phospholipid methyltransferase; 
phosphotidylcholine 
biosynthesis 
YGR101W PCP1 Protein modification Mitochondrial serine protease 
  RAM1 Protein modification   
YJL204C RCY1 Transport 
F-Box protein recycling PM 
proteins 
 
YOR035C 
 
SHE4 
 
Cytoskeleton 
assembly 
 
Regulates myosin 
function/endocytosis/actin 
polarization 
YBL007C SLA1 
Cytoskeleton 
assembly 
Cytoskeletal protein binding 
protein; assembly of cortical 
actin cytoskeleton 
YHR030C SLT2 Protein modification 
Ser/Thr kinase MAP kinase; 
PKC1 signalling; cell cycle 
YGL127C SOH1 Cell cycle Subunit of RNA pol II; meiosis 
YEL031W SPF1 Protein modification 
P-type ATPase; ion transporter 
of the ER membrane; Ca2+ 
homeostasis 
YCR081W SRB8 RNA Processing 
Subunit of RNA pol II; glucose 
repression 
YDR293C SSD1 Other Cell integrity; TOR pathway 
YJL187C SWE1 Cell cycle 
Protein kinase; regulated G2/M 
transition 
YPL105C SYH1 Unknown May interact with ribosome’s 
 
 
YJR099W 
 
 
YUH1 
 
 
Protein modification 
 
Ubiquitin C-terminal hydrolase; 
generates monoubiquitin 
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YDR541C   Unknown 
Putative dihydrokaempferol 4-
reductase 
YGL081W   Unknown 
Putative protein of unknown 
function 
YPL272C   Unknown 
Putative protein of unknown 
function 
Table 4.5 Lovastatin chemical genetic PE interactions, bold indicate MDR genes. 
GO process and annotations were retrieved from the Saccharomyces Genome 
Database 
 
The chemical screens performed on 150 µM lovastatin yielded 43 PE interactions 
(Table 4.5) when analysed with SESA, the lovastatin plates were compared to 
that of a DMSO (carrier) control and assessed for growth. There were 8 gene 
products (BEM2, BTS1, HMG1, MRE11, OPI3, PCP1, SPF1, and SYH1) 
localised to the mitochondria, these compared to those found with cerivastatin 
(BEM2, BTS1, FCJ1, FMP21, HMG1, NDE1, OPI3, SPF1, SYH1, YLR346C, 
YSA1). Six genes (ARV1, DRS2, GDA1, HOC1, MNN10 and RCY1) were 
localised to the Golgi apparatus compared to cerivastatin (ARV1, CHS5, DRS2, 
ERV14, GDA1, HOC1, MNN10 and RCY1) and 5 localised to the ER.  
 
Moreover, there were also 9 genes (ARV1, ATG2, CCH1, DRS2, MID1, PCP1, 
RCY1, SLA1, and SPF1) involved in cellular transport and 5 genes (ARV1, 
BTS1, HAC1, HMG1 and OPI3) cf atorvastatin 6 genes (ARV1, BTS1, ERG6, 
HMG1, OPI3 and SUR2) involved in lipid biosynthesis. HAC1 is of particular 
interest as it is a known regulating element in the unfolded protein response 
(Welihinda, et al., 1997) which though non-essential appears to become essential 
in the presence of lovastatin. 
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Table 4.6 Lovastatin chemical genetic PS interactions 
ORF Gene Process Description 
YLL006W MMM1 Transport 
Mitochondrial outer membrane; 
import and assembly of outer 
membrane β barrel proteins 
YLL009C COX17 Other Cu metallochaperone 
YNL322C KRE1 Other 
Cell wall glycoprotein; β-
glucan assembly 
YKR024C DBP7 RNA Processing 
Putative ATP-dependent RNA 
helicase of the DEAD box 
family 
YBR132C AGP2 Lipid Biosynthesis Polyamine permiase 
YDR332W IRC3 Unknown 
Putative protein of unknown 
function 
YCR028C-A RIM1 Other 
Single stranded DNA binding 
protein; mitochondrial genome 
maintenance 
YNL199C GCR2 
Metabolite 
Biosynthesis 
Transcriptional activator of 
genes involved in glycolysis 
YLL040C VPS13 Protein modification 
Protein of unknown function; 
involved in sporulation, 
vacuolar sorting and golgi 
retention 
YPL156C PRM4 Other Pheromone regulated protein 
YOL032W OPI10 Lipid Biosynthesis 
Possible role in phospholipid 
biosynthesis 
YDL033C SLM3 RNA Processing 
tRNA-specific 2-thiouridylase; 
thiolation of wobble base of 
mitochondrial tRNAs 
YLL041C SDH2 
Metabolite 
Biosynthesis 
Iron sulfur protein subunit of 
succinate dehydrogenase 
YCR063W BUD31 RNA Processing Cell cycle/budding 
Table 4.6 Lovastatin chemical genetic PS interactions, GO process and 
annotations were retrieved from the Saccharomyces Genome Database. 
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Table 4.6 shows the PS interactions that resulted from the three chemical screens 
performed on 150 µM lovastatin which resulted in 15 PS interactions (Table 4.6) 
when analysed with SESA. These include 7 gene products (COX17, IRC3, 
MMM1, RIM1, SDH2, SLM3, and VPS13) localised to the mitochondria and 2 
genes (AGP2 and MMM1) localised to the ER. There were also 4 genes (AGP2, 
COX17, MMM1, and VPS13) involved in cellular transport and 2 genes (GCR2 
and SDH2) involved in the generation of precursor metabolites and energy. 
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4.3. Discussion  
 
There are several significant points arising from the experiments described in this 
chapter. Though the epistatic interactions described do not attribute quantitative 
significance to the interactions shown, for example in Figure 4.2, focussing on 
interactions around the lipid pathways provide for some interesting observations. 
 
Firstly, of the 32 overlapping PE genes in the GO network (Ashburner, et al., 
2000) shared by all the statins, 4 genes, namely ARV1,BTS1, HMG1 and OPI3 
are involved in lipid biosynthesis. Statins putatively act only on HMG-CoA-
reductase, but the commonality of genetic interactions with these other genes 
forces consideration of statin action within a compensating network rather than as 
a single gene phenotype. Drugs, in general, like statins might be better understood in 
the context of genetic networks - a concept that has appeared in recent literature 
(Hopkins, 2008; Schadt, et al., 2009).  
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Figure 4.2 Cytoscape network graph showing the phenotypic enhancement 
interactions from the chemical genetic screens performed on atorvastatin, 
cerivastatin and lovastatin. The genes are grouped based on their GO terms 
(cellular process) generated with BiNGO (Maere, et al., 2005). 
 
 
 
 
 
 
 
 
 
76 
 
 
Figure 4.3 Cytoscape network graph showing the phenotypic suppression 
interactions from the chemical genetic screens performed on atorvastatin, 
cerivastatin and lovastatin. The genes are grouped based on their GO terms 
(cellular process). 
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Secondly, it has been reported that Hmg1p is stable (Federovitch, et al., 2008), 
whereas Hmg2p undergoes sterol pathway mediated degradation. The BTS1 gene, 
a key regulator of Hmg2p (described in Chapter 3), can promote entry of Hmg2p 
into the HMG-CoA reductase degradation (HRD) pathway (Garza, et al., 2009b) 
after misfolding caused by statins. The unfolded protein probably induces the 
unfolded protein response (UPR), in which HAC1 is an integral member 
(Welihinda, et al., 1997). From the data presented in this chapter it can be 
suggested that HMG2 has a more diverse role within the ER, via initiation of the 
UPR, and in agreement with the literature (Brown and Goldstein, 1980; Chun, et 
al., 1990; Cronin, et al., 2000; Federovitch, et al., 2008; Loertscher, et al., 2006), 
HMG2 is regulated in a different manner to that of HMG1.  
 
 
 
Thirdly, the PS results (i.e. instances in which drug-mutant combinations grew 
better than controls, Fig. 4.3) two genes namely COX17 and MMM1, were 
common to all three statin drugs. MMM1 is an ER membrane protein which links 
the ER to the mitochondria and promotes intra - organelle Ca2+ and phospholipid 
transport (Kornmann, et al., 2009). Therefore, the PS interaction of MMM1 with 
statin drugs may be the outcome of decreased Ca2+ levels in the ER. Furthermore, 
the PE interactions of MID1/CCH1, for which their main role consists of 
importing Ca2+  into the ER when secretory levels decrease (Locke, et al., 2000). 
Thus, it can be postulated that the cell is attempting to buffer the PE interactions 
by attempting to increase Ca2+ via an alternative route.  
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Fourthly, out of the combined 82 PE interactions seen in all statins, 28 are 
localised to or involved in mitochondrial function, refocusing our understanding 
of statin effects to include both ER and mitochondria. This point leads to the PS 
results in which genes involved in ubiquinone synthesis and distribution (CAT5, 
COQ10 and COQ2) are utilised to compensate for the decreased level of the 
isoprenoid precursor farnesyl pyrophosphate. A number of genes were also 
involved in the mitochondrial respiratory chain (COX12, COX17, COX23, 
COX7, CYT1, COX7 and SDH2). This suggests that alterations in the 
mitochondrial respiratory chain may compensate for another perturbed process. 
Moreover, there are genes involved in lipid biosynthesis (AGP2, CYB5, HTD2 
and PSD1) that are also implicated in mitochondrial function.  
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Chapter 5. Double mutant chemical 
genetic interactions of statin drugs with 
their target genes 
 
HMG-CoA reductase is encoded by duplicated reductase genes namely HMG1 
and HMG2 but their genetic interactions (separately) are unknown as this requires 
testing epistatic interactions of one of the pair in the absence of the other. This 
question is technically difficult to resolve by genetic means alone since the 
combination of Δhmg1 and Δhmg2 in the same cell is lethal. Fortunately, 
chemical genetics provides a simplifying approach by utilising Δhmg1 and Δhmg2 
SGA’s (i.e.Δhmg1 in a genome-wide combination of deletion mutants, likewise 
Δhmg2) plus statins as inhibitors of the remaining intact gene to determine its 
genetic interactions. In this Chapter these experiments are called “Δhmg1 Δxxx + 
statins” and “Δhmg2 Δxxx + statins”. This approach has the potential to dissect 
out the individual genetic interactions of these HMG-CoA reductases providing 
information on the differing cellular roles played by HMG1 and HMG2.  
 
The screens described in this chapter were designed to utilise the query gene 
strains Δhmg1 and Δhmg2 (separate SGAs) mated onto the deletion set. The 
haploid double mutants, Δhmg1 Δxxx, or Δhmg2 Δxxx, were then grown in the 
presence (separately) of each of the three statins in turn. These screens were 
performed as usual on agar plates with SC media minus histidine, arginine and 
lysine plus canavanine, thialysine, G418 and NAT. The double mutants were 
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replica pinned onto the drug containing selective media, grown for 48 h at 300C, 
the resulting plates were imaged by COLONY HT and analysed with SESA using 
the appropriate control (DMSO for atorvastatin and cerivastatin or ethanol for 
lovastatin). After analysis with SESA any deletion strains (Δxxx) that alone 
displayed epistatic interactions with Δhmg1, Δhmg2, atorvastatin, cerivastatin or 
lovastatin were removed from further consideration. As previously described 
deletion strains representing genes we have termed “frequent flyers” and Δxxx 
deletion strains reported as multidrug resistant (Hillenmeyer, et al., 2008; 
Parsons, et al., 2004; Parsons, et al., 2006) were also noted. 
  
5.1. Pilot Study: double mutant growth on 
statin drugs 
 
Prior to application of the double mutant chemical genetic screen methodology 
just described, growth assays were performed to assess the growth inhibitory 
effects of atorvastatin, cerivastatin and lovastatin on solid medium in 1536 
format as “controls” for the eventual Δhmg1 Δxxx and Δhmg2 Δxxx double mutant 
assays. These pilot studies used the SGA border strain growth as controls (see 
Methods) namely Δhmg1:: NatRΔhis3::KanR (Figs 5.1-5.3) and 
Δhmg2::NatRΔhis3::KanR (Figs. 5.4-5.6) to determine the concentration of statin 
needed to observe effects in SGA format for the Δhmg1 Δxxx + statins and Δhmg2 
Δxxx + statins experiments to be described later in this Chapter. Colonies were 
grown in 1536 format on SC media minus histidine, arginine and lysine plus 
canavanine, thialysine, G418 and Nat plates, which were then replica pinned onto 
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plates containing varying concentrations of atorvastatin (2-25 µM), cerivastatin 
(2-25 µM) and lovastatin (10-75 µM) and grown for 48 h at 300C. The plates 
were then photographed (Figs.5.1-5.6) and growth was evaluated via comparison 
to a no drug control (carrier, DMSO or ethanol).  
 
 
Figure 5.1 Double mutant chemical-genetic screen pilot for atorvastatin working 
concentrations in robotically pinned SGA formatted Δhmg1 Δhis3. A DMSO 
control; B 2 µM; C 5 µM; 7 µM; 10 µM 
 
Figure 5.2 Double mutant chemical-genetic screen pilot for cerivastatin working 
concentrations in robotically pinned SGA formatted Δhmg1 Δhis3. A DMSO; B 2 
µM; C 3 µM; D 4 µM; E 5 µM; F 6 µM 
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Figure 5.3 Double mutant chemical-genetic screen pilot for lovastatin working 
concentrations in robotically pinned SGA formatted Δhmg1 Δhis3. A DMSO; B 
20 µM; C 30 µM; D 40 µM; E 50 µM 
 
 
Figure 5.4 Double mutant chemical-genetic screen pilot for atorvastatin working 
concentrations in robotically pinned SGA formatted Δhmg2 Δhis3. A DMSO; B 
10 µM; C 15 µM; D 17.5 µM; E 20 µM 
 
 
 
Figure 5.5 Double mutant chemical-genetic screen pilot for cerivastatin working 
concentrations in robotically pinned SGA formatted Δhmg2 Δhis3. A DMSO; B 5 
µM; C 7.5 µM; D 10 µM; E 12.5 µM 
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Figure 5.6 Double mutant chemical-genetic screen pilot for lovastatin working 
concentrations in robotically pinned SGA formatted Δhmg2 Δhis3. A DMSO; B 
60 µM; C 65 µM; D 70 µM; E 75 µM; F 80 µM 
 
Figures 5.1 – 5.6 show the effect of atorvastatin, cerivastatin and lovastatin on 
the growth of Δhmg1 Δhis3 and Δhmg2 Δhis3 when maintained in 1536 format. 
The plates do not show differences readily discernable by eye but colony size 
differences with increasing statin were discernable by SESA for use as control 
information. Determining effective drug concentration in this way (rather than 
spot assays described in previous chapters) provides a more accurate drug 
concentration assessment in genome-wide SGA screening experiments performed 
on solid media. This is because the Singer RoToR colony printing robot used to 
replicate the plates transfers relatively large numbers of yeast cells by contrast to 
spot assays that start with relatively few cells per plate. Based on the pilot screens 
shown in figures 5.1-5.6 the following concentrations were used in the double 
mutant chemical genetic screens: Δhmg1+Δxxx atorvastatin 7 µM, cerivastatin 3 
µM and lovastatin 30 µM; Δhmg2+Δxxx atorvastatin 17.5 µM, cerivastatin 10 
µM and lovastatin 80 µM. The original data for these screens are shown in 
Appendix 3 (Tables B1 – B6). 
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5.2. Atorvastatin + Δhmg1 Δxxx double mutant 
chemical genetic screens  
 
 This experiment tests the atorvastatin chemical genetic epistatic interactions of 
HMG2 in the absence of HMG1. Three Δhmg1 double mutant chemical screens, 
i.e. Δhmg1 Δxxx + statins were performed on 7 µM atorvastatin and analysed with 
SESA. These experiments resulted in 38 PE interactions, after adjusting the wider 
list of “gene hits” by discounting the DMSO controls, the genes that appeared as 
hits in the Δhmg1 query gene SGA without statin and deletion strains that showed 
sensitivity to 25 µM atorvastatin alone in the chemical genetic screen. The 38 
genes were then analysed by gene ontology using the yeast GO Slim Mapper 
(SGD, 2009) and BiNGO (Maere, et al., 2005). 
 
This analysis showed that 8 of 38 gene products (AIM34, COQ2, FAB1, GNP1, 
HMI1, IMG2, IRA2 and VPS21) were localised to the mitochondria (P-value 
=0.42) , 4/38 genes (IMG2, ITT1, RPL20B and TIF1) involved in translation (P-
value = 0.035), 11 of 38 genes (EDE1, GNP1, SEC66, SLA1, VAM3, VPS21, 
VPS27, VPS4, VPS9, WHI2 and YDR387C) were involved in transport (P-value 
= 0.73), significantly including 8 of 11 transport genes (EDE1, SLA1, VAM3, 
VPS21, VPS27, VPS4, WHI2 and SEC66) that were involved in vesicle mediated 
transport (P-value = 0.0041). An interpretation of these interactions is that if 
HMG1 and its epistatically interacting genes are shut off and HMG2 is 
simultaneously inhibited with atorvastatin, the cells attempt to maintain 
membrane/lipid homeostasis by anterograde and retrograde transport 
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mechanisms. Five of 38 genes were involved in lipid biosynthesis namely COQ2, 
DGA1, FAB1, SUR1 and VPS4 (P-value = 0.016) with 4 of 39 genes (DGA1, 
KRE27, SEC66 and VPS4) showing localisation to the endoplasmic reticulum (P-
value = 0.24).  
 
 The VPS21 gene in the mitochondria is a GTPase required for transport and 
sorting of vacuolar hydrolases. This gene requires geranylgeranylation for 
complete functionality, similar to that of IRA2. These results again (cf Chapter 4) 
implicate the importance of mitochondrial processes (inhibition of isoprenoid 
intermediates in the mevalonate pathway) in the mechanism of statins.  
 
5.3. Atorvastatin + Δhmg2 Δxxx double 
mutant chemical genetic screens 
 
This experiment tests the atorvastatin chemical genetic epistatic interactions of 
HMG1 in the absence of HMG2. The three Δhmg2 double mutant chemical 
screens performed on 17.5 µM atorvastatin resulted in 136 PE interactions 
(Appendix 3) when analysed with SESA (after a wider-list of hits was adjusted 
for the various controls as described above for Δhmg1). The 138 genes were then 
analysed based on gene ontology using the yeast GO Slim Mapper (SGD, 2009). 
 
Gene ontology analysis of the 136 phenotypic enhancement interactions showed 
24 of 136 gene products (ADH4, AIM34, CAT5, CHD1, COX14, ECM33, 
FAB1, GAS1, GET1, GNP1, HMI1, IRA2, ISC1, MRE11, PET122, PET8, 
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PFK2, QCR2, SNF1, SWS2, TAZ1, TPS2, VPS21 and YSA1) were localised to 
the mitochondria (P-value = 0.4), and 14 of 136 genes (CHO2, ERG2, FEN1, 
GET1, GET2, GUP1, ILM1, ISC1, LAS21, OST4, PMT2, SEC66, VPS4 and 
YTA7) were localised to the endoplasmic reticulum (P-value= 0.038). There were 
also 17/136 genes (CHO2, DEP1, DGA1, ERG2, FAB1, FEN1, GUP1, HST3, 
INP51, ISC1, LAS21, SUR1, TAZ1, TLG2, VAC14, VPS4 and YTA7) involved 
in lipid biosynthesis (P-value = 6.08x10-4) and 38/136 genes (PMP3, WHI2, 
RVS161, GNP1, VRP1, VPS53, PEX5, PET8, VPS51, VPS74, CHS5, SEC66, 
GET2, GET1, EDE1, QCR2, GUP,1 ERD1, CCZ1, PEX10, FEN1, VPS9, 
VAM3, VAC14, SLA1, VAM7, VAM6, TLG2, VPS41, VPS4, MON1, VID22, 
SLM4, VPS24, RVS167, VPS21, VPS27 and RUD3) that were involved in 
cellular transport (P-value = 0.0029) including 24 of the 38 genes (CCZ1, CHS5, 
EDE1, FEN1, GET1, GET2, MON1, RIM8, RUD3, RVS161, RVS167, SLA1, 
TLG2, VAM3, VAM7, VPS21, VPS24, VPS27, VPS4, VPS51, VPS53, VPS74, 
VRP1 and WHI2) involved in vesicle mediated transport (P-value = 8.87x10-7). 
 
There were 7 of 33 transport genes (GET1, RUD3, SEC66, VPS27, VPS51, 
VPS53 and VPS74) that are involved in/with ER-golgi transport, VPS51 and 
VPS53 are 2 of 4 members of the Golgi-associated retrograde protein (GARP) 
complex which is required for the recycling of proteins from endosomes to the 
late Golgi (Siniossoglou and Pelham, 2002). Again an interim conclusion is that 
cells deprived of HMG Co- A reductase genes and their immediate enhancing 
epistatic interacting genes attempt to maintain lipid/membrane homeostasis by 
utilising otherwise cryptic membrane cycling genetic interactions.  
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5.4. Cerivastatin + Δhmg1 Δxxx double mutant 
chemical genetic screens  
 
This experiment tests the cerivastatin chemical genetic epistatic interactions of 
HMG2 in the absence of HMG1. The three Δhmg1 double mutant chemical 
screens performed on 3 µM cerivastatin resulted in 31 PE interactions (Appendix 
3) when the cerivastatin plates were analysed with SESA, and the wider list 
adjusted for controls as described above. The 31 genes were then analysed based 
on gene ontology using the yeast GO Slim Mapper (SGD, 2009) and BiNGO 
(Maere, et al., 2005). 
 
Gene ontology analysis of the 31 PE interactions (Appendix 3) resulted in 6 of 36 
gene products (AIM34, COQ2, ERG6, IRA2, SNF1 and YME1) localised to the 
mitochondria (P-value = 0.59), 4 of 36 genes (COQ2, ERG6, GET2 and VPS4) 
localised to the ER  (P-value = 0.16) and were also involved in lipid biosynthesis 
(P-value = 0.036), 6 of 31 genes (GET2, DGA1, VPS27, VPS4, WHI2 and 
YDR387C) involved in cellular transport (P-value = 0.7), with 4 of 5 genes 
(WHI2, GET2, VPS4 and VPS27) involved in vesicle mediated transport (P-value 
= 0.09).  
 
Similar to the result seen in the Δhmg1 atorvastatin screen, GET2, VPS27 and 
VPS4 are involved in ER/Golgi transport and retention. Moreover, there are 5 of 
31 genes (ITT1, RPL20B, RPS21B, SNF1 and TIF1) involved in translation (P-
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value = 0.459). Interestingly, TIF1 (eukaryotic initiation factor 4a) is also a 
duplicate gene (TIF1 and TIF2). 
5.5. Cerivastatin + Δhmg2 Δxxx double mutant 
chemical genetic screens  
 
This experiment tests the cerivastatin chemical genetic epistatic interactions of 
HMG1 in the absence of HMG2. The three Δhmg2 double mutant chemical 
screens performed on 10 µM cerivastatin resulted in 123 PE interactions 
(Appendix 3) when analysed with SESA and the wider list adjusted for controls as 
described above. The 123 PE genes were then analysed based on gene ontology 
using the yeast GO Slim Mapper (SGD, 2009) and BiNGO (Maere, et al., 2005). 
 
Gene ontology analysis of the PE interactions (Appendix 3) resulted in 24 of 123 
gene products (ADH4, AIM34, ARC18, CHD1, COX14, ECM33, ERG6, GAS1, 
GET1, GNP1, GPA2, IRA2, ISC1, MRE11, NEM1, NUT1, PET8, PFK2, SNF1, 
SWS2, VMR1, VPS1, VPS21 and YPT7) localised to the mitochondria (P-value 
= 0.07), 16 of 123 genes (ERG2, ERG3, ERG6, GET1, GET2, GUP1, ILM1, 
ISC1, LAS21, OST4, PMT2, RCE1, SEC66, SUR2, SWH1 and VPS4) localised 
to the endoplasmic reticulum (P-value = 1.24x10-3) along with 10 genes (GET2, 
COG8, GET1, ISC1, TLG2, VPS53, VPS51, SWH1, MON2 and RUD3) that 
were localised to the Golgi (P-value = 6.29x10-3).  
 
Moreover, there are 12 genes (DGA1, ERG2, ERG3, ERG6, FAT1, GUP1, ISC1, 
LAS21, SUR1, SUR2, TLG2 and VPS4) involved in lipid biosynthesis (P-value = 
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4.6x10-4) including ERG2, ERG3, ERG6 which are specifically involved in 
ergosterol production. The absence of these genes seriously perturbs ergosterol 
production in yeast (see Chapter 6: Ergosterol quantification) perhaps explaining 
that 37 of 123 genes (AGP1, ARN1, CCZ1, COG8, EDE1, ERG3, FAT1, GET1, 
GET2, GNP1, GUP1, MON1, MON2, PET8, PEX5, PMP3, RUD3, RVS161, 
RVS167, SEC66, SWH1, TLG2, TPM1, URE2, VAM3, VMR1, VPS1, VPS21, 
VPS24, VPS27, VPS4, VPS41, VPS51, VPS53, VPS8, WHI2 and YPT7) 
involved in cellular transport (P-value = 1.5x10-4) including 24 genes (CCZ1, 
COG8, EDE1, ERG3, GET1, GET2, MON1, MON2, RUD3, RVS161, RVS167, 
SWH1, TLG2, TPM1, VAM3, VPS21, VPS24, VPS27, VPS4, VPS51, VPS53, 
VPS8, WHI2, YPT7) specific to vesicle mediated transport (P-value = 5.9x10-9) 
now displayed genetic enhancements in compensation to decreased cellular sterol 
availability.  
 
These results are consistent with those seen in the double mutant Δhmg2 
atorvastatin chemical screen, in which they resulted in genes (COG8, GET1, 
GET2, MON2, RUD3, SEC66, TLG2, VPS1, VPS27, VPS41, VPS51 and 
VPS53) involved in ER/Golgi transport, including the retrograde transport GARP 
complex genes which are required for the recycling of proteins from endosomes 
to the late Golgi (Siniossoglou and Pelham, 2002).  
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5.6. Lovastatin + Δhmg1 Δxxx double mutant 
chemical genetic screens  
 
This experiment tests the lovastatin chemical genetic epistatic interactions of 
HMG2 in the absence of HMG1. The three Δhmg1 double mutant chemical 
screens performed on 30 µM lovastatin resulted in 86 PE interactions (Appendix 
3) when analysed with SESA and the wider list adjusted for controls as described 
above. The 86 PE genes were then analysed based on gene ontology using the 
yeast GO Slim Mapper (SGD, 2009) and BiNGO (Maere, et al., 2005). 
 
Upon GO slim term analysis, the Δhmg1 30µM lovastatin chemical genetic screen 
resulted in 3 of 22 gene products (IRA2, MDM12 and SNF1) localised to the 
mitochondria (P-value = 0.7) and ER (GET2, ORM2 and VMA21) P-value = 
0.074), 5 of 22 genes (GET2, MDM12, RVS161, VPS27 and YDR387C) 
involved in cellular transport (P-value = 0.45) including GET2, RVS161 and 
VPS27 which were involved in vesicle mediated transport (P-value = 0.14).  
 
Moreover, consistent with the Δhmg1 atorvastatin and cerivastatin double mutant 
chemical genetic screens there are 4 genes (ITT1, RPL20B, SNF1, and TIF1) 
involved in translation (P-value = 0.5). Conversely, there is only one gene 
(DGA1) involved in lipid homeostasis via triglyceride storage droplets. This may 
be due to the absence of HMG1 whose main function is lipid biosynthesis, in 
contrast to that of HMG2 whose role is thought to be more diverse (Basson, et al., 
1988; Basson, et al., 1986; Federovitch, et al., 2008).  
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5.7. Lovastatin + Δhmg2 Δxxx double mutant 
chemical genetic screens  
This experiment tests the lovastatin chemical genetic epistatic interactions of 
HMG1 in the absence of HMG2. The three Δhmg2 double mutant chemical 
screens performed on 80 µM lovastatin resulted in 111 PE interactions (Appendix 
3) when analysed with SESA and the wider list adjusted for controls as described 
above. The 111 PE interactions were then analysed based on gene ontology using 
the yeast GO Slim Mapper (SGD, 2009) and BiNGO. 
 
Of the 111 PE interactions 18 gene products (AEP2, AIM34, CHD1, CSF1, 
ECM33, ERG6, GAS1, GET1, GNP1, IMP2, IRA2, ISC1, MDM12, PET8, 
SNF1, VPS1, YPT7 and YSA1) localised to the mitochondria (P-value = 0.6), 15 
of 111 genes (ERG2, ERG3, ERG6, GET1, GET2, GUP1, ILM1, ISC1, LAS21, 
OST4, PMT2, SEC66, SUR2, SVP26 and VPS4) localised to the ER (P-value= 
339x10-4) including 3 integral sterol biosynthesis genes ERG2, ERG3 and ERG6.  
 
Furthermore, there were 14 genes (CWH43, DEP1, DGA1, ERG2, ERG3, ERG6, 
FAT1, GUP1, INP51, ISC1, LAS21, SUR2, TLG2 and VPS4) involved in lipid 
biosynthesis (P-value = 8.5x10-4) also with similarity to the other two screens of 
this type there were 31 of 111 genes (AGP1, CCZ1, ERG3, FAT1, GET1, GET2, 
GNP1, GUP1, IMP2, MDM12, MTH1, PET8, RUD3, RVS161, RVS167, SEC66, 
SVP26, TLG2, VAM3, VAM7, VPS1, VPS24, VPS27, VPS4, VPS41, VPS51, 
VPS53, VPS9, VRP1, WHI2 and YPT7) involved in cellular transport (4.5x10-4) 
with 20 genes (WHI2, ERG3, RVS161, YPT7, VAM3, VRP1, VAM7, SVP26, 
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TLG2, VPS53, VPS41, VPS51, VPS4, GET2, GET1, VPS24, RVS167, CCZ1, 
VPS27 and RUD3) involved solely in vesicle mediated transport (P-value = 
1.89x10-6). 
 
These results are consistent with those seen in the double mutant Δhmg2 
atorvastatin and cerivastatin chemical screens, in which GET1, GET2, MDM12, 
RUD3, SEC66, SVP26, TLG2, VPS1, VPS27, VPS41, VPS51 and VPS53 are 
involved in ER/Golgi transport. Of note are the retrograde transport GARP 
complex genes (VPS51 and VPS53) which are required for the recycling of 
proteins from endosomes to the late Golgi (Siniossoglou and Pelham, 2002).  
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5.8. Discussion: statins + Δhmg1 Δxxx double 
mutant chemical genetic screens  
 
The three Δhmg1 double mutant chemical genetic screens performed on 7 µM 
atorvastatin, 3 µM cerivastatin and 30 µM lovastatin resulted in 54 PE 
interactions (Appendix 3, Fig 5.7), 13 of which are shared by all three statins, 3 
are shared between lovastatin and cerivastatin and 7 are shared between 
atorvastatin and cerivastatin. It is probable that genetic interactions shared by two 
out of the three statins are due to a dosage effect, i.e. the dose of the third statin 
may not have been high enough to exhibit that particular growth defect. If this is a 
correct interpretation of results, 23 genes could be said to be shared by the three 
statins, therefore comprising a list of the direct genetic interactions revealed by 
statin action in the absence of HMG1. In addition to the shared commonality of 
statin basic genetic interactions, atorvastatin shows 17 unique interactions as 
compared to 8 for cerivastatin and 5 for lovastatin. If these are “off-target” 
interactions as already noted they should be of interest in studies aimed at 
providing “better statins”.  
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Figure 5.7 HMG1 based interactions. Cytoscape network graph showing the 
phenotypic enhancement interactions from the chemical genetic screens 
performed on atorvastatin, cerivastatin and lovastatin. The genes are grouped 
based on their GO terms (cellular process). 
 
When the 13 genes that interacted with all three statins underwent GO analysis, 
there was only one gene involved in lipid synthesis (DGA1). DGA1 is 
diacylglycerol acyltransferase, an integral enzyme in de novo synthesis and 
storage of triacylglycerols in lipid particles (Sorger and Daum, 2002). There are 
five lipid biosynthesis genes in the whole 54 PE interactions around HMG2, 
perhaps because HMG2 has functions other than lipid biosynthesis.  
 
Many of the genetic interactions described involve the ubiquitin – proteasome 
pathway, a pathway has been implicated in the cellular response to stress and 
oxidative damage. When cells are stressed they generate an increased number of 
misfolded proteins (a phenotype associated with Δkre27) which are a prime target 
for ubiquitin mediated degradation. This is mediated by UBC4 (an E2 ubiquitin 
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conjugating enzyme) and BRE1 (an E3 ubiquitin ligase), and can rapidly deplete 
free ubiquitin (Hanna, et al., 2003). If there is a shortage of free ubiquitin, it can 
be compensated for by the induction of UBI4, a polyubiquination gene which can 
in turn, bind VPS27, required for the sorting of ubiquinated proteins destined for 
degradation (Bilodeau, et al., 2002). In contrast to UBI4, UBP6 (which interacts 
with all statins under these conditions) opposes polyubiquination and releases free 
polyubiquitin chains and its resistance to oxidative stress is significantly 
decreased (Crosas, et al., 2006).  
 
The inhibition of ubiquinone synthesis can lead to oxidative damage (ubiquinone 
is an antioxidant) and a decrease in ATP production via oxidative 
phosphorylation. In humans, disruption of the mitochondrial respiratory chain 
frequently causes mitochondrial encephalomyopathies, generally in organs with 
high energy requirements, such as muscle (Quinzii, et al., 2006). These studies 
reveal a dependence on COQ2 in the respiratory chain. Its disruption leads to 
oxidative damage/stress, causing proteins to become unfolded/misfolded, 
therefore the need for ubiquination of the damaged proteins to target them to the 
proteasome for degradation. 
 
Genes involved with suppression of the translation (TIF1, RPL20B and ITT1) of 
constitutive mRNAs at the initiation step are known to synergise with an ER 
stress response (Brostrom, et al., 1997; Sheikh and Fornace, 1999). Furthermore, 
DOA1 is required for recycling ubiquitin from proteasome-bound ubiquitinated 
proteins being transported to the vacuole/proteasome where it associates with 
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Vps4p, a protein involved with Vps27p in sorting of proteins in the multivesicular 
body (Amerik, et al., 2000; Ren, et al., 2008).  
 
There is a possibility that the interactions described above are occurring under 
these experimental conditions as COQ2, which catalyses the second committed 
step in the ubiquinone synthesis pathway and interacts with atorvastatin and 
Cerivastatin. Furthermore the YME1 gene product is responsible for degradation 
of unfolded/misfolded mitochondrial proteins (Leonhard, et al., 1999).  
 
5.9. Discussion: statins + Δhmg2 Δxxx double 
mutant chemical genetic screens  
 
The three Δhmg2 double mutant chemical genetic screens performed on 17.5 µM 
atorvastatin, 10 µM cerivastatin and 80 µM lovastatin resulted in 197 PE 
interactions (Appendix 3, Fig 5.8), 62 of which are shared by all three statins, 15 
are shared between lovastatin and cerivastatin, 16 are shared between lovastatin 
and atorvastatin and 21 are shared between atorvastatin and cerivastatin. As 
noted above, genes that are share interactions affected by two out of the three 
statins may be due to a dosage effect, i.e. the dose of the third statin may not have 
been high enough to exhibit that particular growth defect. Accepting this proviso, 
114 genes could be said to be shared by the three statins, therefore comprising the 
most direct mechanism of statin action on HMG1 in the absence of HMG2. The 
genes not shared by HMG1 and HMG2 are of interest in their own right, and may 
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also be of importance in statin side effects. Atorvastatin shows 37 unique 
interactions as compared to 27 for cerivastatin and 19 for lovastatin. 
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Figure 5.8 HMG2 based interactions. Cytoscape network graph 
showing the phenotypic enhancement interactions from the 
chemical genetic screens performed on atorvastatin, cerivastatin 
and lovastatin. The genes are grouped based on their GO terms 
(cellular process). 
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When the 62 genes of the null HMG2 set which are common to all statins are 
analysed based on GO slim – process (SGD, 2009), there were 8 genes involved 
in lipid biosynthesis. However, when added to those that interact with two statins 
and the individual hits there are 22 lipid biosynthesis genes that show genetic 
interactions with HMG1 in the absence of HMG2.  
 
The lipid biosynthesis genes represented (22 genes) have diverse cellular roles, 
including sterol biosynthesis, sphingolipid biosynthesis, triacylglycerol (TAG) 
biosynthesis and phospholipid biosynthesis. There are three genes (ERG3, ERG6 
and ERG2) directly involved in ergosterol biosynthesis (Veen and Lang, 2005), 
and are downstream from HMG – CoA reductase in the mevalonate pathway 
(Fig1.4). DGA1 is of particular interest since it also shows up in all the HMG2-
based screens (see below). It is involved with triglyceride synthesis/utilisation 
possibly reflecting that when all other avenues are shut off for lipid homeostasis, 
the cells resort to triglyceride (lipid) storage (Petschnigg, et al., 2009). 
 
It is clear that many more genes involved in lipid synthesis and membrane cycling 
processes appeared in the statins + Δhmg2 Δxxx double mutant chemical genetic 
screens than the statins + Δhmg1 Δxxx counterparts leading to the conclusion that 
the HMG1 isoenzyme is the more important enzyme in these processes pointing 
to a more specific role of HMG1 in sterol biosynthesis and its compensating 
membrane recycling processes. Another valid conclusion could be that HMG2 is 
more redundant in these processes than HMG1, therefore resulting in less 
extensive genetic interaction networks. 
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Figure 5.9 Graph of GO processes involving HMG1 showing enrichment for 
vesicle mediated transport genetic interactions. 
 
GO term analysis by BiNGO (Fig.5.9) shows that the processes and the secretory 
pathway organelles enriched in the statins + Δhmg2 Δxxx double mutant chemical 
genetic screen are statistically significant (P-value <0.05) especially that of 
vesicle mediated and vacuolar transport including anterograde and retrograde 
transport (GET1, GET2, VPS1, VPS53 and UBP3) and protein sorting to the 
multivesicular body (VPS24, VPS27, VPS4 and DOA1). This situation is unlike 
the majority of those mentioned in the HMG1 double mutant chemical genetic 
screen.  
 
However, the data also support the idea that HMG2 has different roles than that of 
its ‘duplicate’.  For example, Hmg2p may be involved in the HRD-ubiquitin 
mediated degradation pathway which is not associated with Hmg1p. This 
explanation coincides with the increase in ubiquitin related genes in the statins + 
Δhmg1 Δxxx screen, where ubiquitin is an essential mediator for Hmg2p 
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degradation. It is concluded that inhibition of Hmg2p rather than Hmg1p leads to 
a severe disruption of the ubiquitin/proteasome pathway. 
 
 A recent study performed by Petschnigg, et al., 2009 suggested that 
diacylglycerol (DAG), a potent signalling molecule, may involve the 
mitochondria and be associated with the generation of reactive oxygen species 
when overproduced. Furthermore, there is a distinct relationship between with 
lipid droplets (mainly containing TAG) and peroxisomes, where degradation of 
fatty acid occurs. Thus, disruption of the relationship between lipid droplets and 
peroxisome leads to a disruption of membrane homeostasis. This coupled with a 
depletion of sterol esters as a result of perturbed sterol synthesis may in turn lead 
to the inhibition of membranous vesicular transport of lipid droplets among other 
cargoes (Petschnigg, et al., 2009). 
 
 A relationship has been described by Fei, et al., 2009 that closely links conditions 
of ER stress which leads to an increase in lipid droplets possibly as a self 
protective mechanism employed by a range of eukaryotic cells. Moreover, lipid 
trafficking from other cellular compartments to the ER is also enhanced under 
stress conditions possibly providing increased substrate availability for the 
synthesis  de novo of TAG (via DGA1) and sterol esters (Fei, et al., 2008; Fei, et 
al., 2009). This explanation is supported by the data presented in this and the 
previous chapter showing that when sterol ester synthesis is inhibited the cell 
mobilises the use of lipid storage droplets.  
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Chapter 6. Ergosterol quantification 
 
In order to associate a quantitative phenotype with specific genotypes, a 
biochemical assay for ergosterol was applied and optimised as part of this 
dissertation. The assay development is reported here (with an example of its use) 
as a separate chapter, as existing methods (previously described in the literature) 
were unsuitable, requiring too much starting material and were insufficiently 
reproducible. The assay involves a saponification reaction with potassium 
hydroxide, followed by a liquid: liquid extraction of non-saponifiable lipids with 
diethyl ether. The resulting lipids are then dried and quantified with HPLC. 
Initially this assay required a large amount of lyophilised yeast (approximately 3g 
i.e. ~800 mL culture) but improved experimental design enabled a reduction of 
the required amount of yeast to about ~400 mL of cells achieving reproducible 
results.  
 
The assay was optimised using two haploid and one diploid strain (BY4741, 
BY7092 and BY4743 respectively). In another assay reported in the literature 
(Eisenkolb, et al., 2002; Schulz and Prinz, 2007) the deletion mutants Δerg3 and 
Δerg6 were found to have decreased ergosterol levels by comparison to an 
ergosterol standard.  
 
The optimised assay was applied to two mollisoside (Yibmantasisri, Northcote, 
Bellows, unpublished data) yeast strains (in BY7092 MATα background) 
generated by Ploi Yibmantasisri (PhD candidate, Chemical Genetics, VUW) that 
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confer resistance to this marine natural product (isolated from the sponge 
Australostichopus mollis). The putative target of this drug has been identified 
(Yibmantasiri and Bellows, unpublished) via linkage mapping of the resistant 
strain to be NCP1 gene. NCP1 regulates ERG11, an essential gene that catalyzes 
the C-14 demethylation of lanosterol in the ergosterol pathway (Daum, et al., 
1999; Turi and Loper, 1992). Utilising the assay developed as part of this 
dissertation, the Mollisoside resistant mutant was found to have decreased 
ergosterol levels providing strong supporting evidence that the target of 
Mollisoside in Saccharomyces cerevisiae is NCP1. 
 
6.1. Ergosterol standard  
 
In order to quantify ergosterol, a standard curve was generated using purified 
ergosterol (Sigma), at half log dilutions (0.001 – 1.0 mg/mL) injected into the 
chromatograph (see Chapter 2), and absorbance was measured at 282nm 
(Lamacka and Sajbidor, 1997) after which the area under the peak was calculated 
(mAU2) as a reference to generate a standard curve (Fig 6.1 and 6.2). When 
calculated and plotted the resulting r value was 0.9998 (P value < 0.005).  
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Figure 6.1 Ergosterol standard HPLC chromatographs. Top - Bottom 0.001 
mg/mL, 0.0316 mg/mL, 0.1 mg/mL, 0.316 mg/mL and 1.0 mg/mL, with the 
retention time (shown at the top of peaks) of approximately 19.8 min. 
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Figure 6.2 Ergosterol Concentration Standardisation. Half 
log dilutions from 1 mg/mL – 0.001 mg/mL. 
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6.2. Method optimisation 
 
Initially 800mL yeast cultures (BY4743, BY4741 and Δerg3) were grown to 
saturation, for ergosterol quantification. These cultures gave a 2.4-3 gm yeast 
pellet (lyophilised). The ergosterol was then extracted, dried and stored at -200C. 
The ergosterol was then resuspended in either 10 or 20 mL methanol (HPLC 
grade, Scharlau) dependent on solubility and filtered through a 0.22 µm filter. In 
light of the sensitivity of the HPLC and as can be observed from Fig 6.2 the error 
bars increase as the ergosterol concentration increases, therefore samples were 
diluted at 1:10 – 1:30. It was found that ergosterol extracted from an 800 mL 
wild-type culture far exceeded levels required to detect it in HPLC. In contrast, 
the Δerg3 mutant strain showed no measurable ergosterol (<0.001 mg/mL) and its 
use was discontinued in the optimisation of this assay. It was however replaced 
with the Δerg6 strain, which has been reported to produce a decreased amount of 
ergosterol (Eisenkolb, et al., 2002). 
 
 
Table 6.1 Ergosterol content of wild-type and mutant strains 
 
 
 
 
 
Strain 
4741 
10mL 
4741 
100mL 
4741 
400mL 
4741 
800mL 
4743  
800mL 
Δerg6 
10mL 
Δerg6 
100mL 
Ergosterol 
content mg/gm 
(Avg.) 1.179 0.688 0.808 0.799 0.799 0.359 0.492 
Std dev 0.425 0.214 0.074 0.088 0.113 0.141 0.112 
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 Improvements in the assay were made to reduce the culture size required whilst 
continuing to obtain reproducible results. This was carried out using 400 mL, 100 
mL, 50 mL and 10 mL culture sizes (Table 6.1 and Fig 6.3). The results showed 
(Figure 6.3; raw data see Appendix 2) that as the culture size decreases, the 
variation (standard deviation) increases. Based on the optimisation experiments 
400mL is the minimum culture size required to achieve reproducible 
quantification of ergosterol from yeast by the assay described in this dissertation.  
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Figure 6.3 Ergosterol quantification results in different sample 
sizes. 800 mL cultures BY4741, BY4743; 400mL 4741, 100mL, 
50 mL and 10 mL cultures of BY4741, Δerg6. 
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6.3. Mollisoside resistant mutants 
The ergosterol content of two individual strains that show resistance to a SMP, 
mollisoside, was compared to that of wild type (BY7092). The graph shown in 
Figure 6.4 shows the resistant molr1 and molr2 strains show 50% and 60% 
reduced ergosterol respectively (Table 6.2 and Fig6.4, Appendix 2) providing 
supporting evidence that NCP1 is the target gene of Mollisoside. 
Strain BY7092 molr1  molr2  
Ergosterol content Avg. 
mg/gm dry weight  1.009 0.615 0.489 
Std dev 0.0614 0.012 0.051 
Table 6.2 Ergosterol content of molr1 and molr2 mutants 
  
 
 
 
Figure 6.4 Ergosterol quantification mollisoside resistant mutants molr1 and 
molr2 compared to wild type (BY7092). 
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6.4. Discussion 
The observed results in this chapter present a method that has been applied to 
yeast with the ability to extract and quantify ergosterol on a smaller scale than 
reported in the literature. However, the size of the assay will limit future 
experiments based on the required culture size if SMP’s to be assayed are 
available in limited quantities. 
 
Nonetheless, the assay has proved very useful. Evidence has been provided to 
support independent evidence (Yibmantasiri and Bellows, unpublished) of the 
putative target of mollisoside in Saccharomyces cerevisiae, which in turn can be 
applied to strains that show sensitivity to the statin drugs. In future work, this 
assay may be used with chemical or genetic perturbations, thereby providing 
phenotypic data that can be compared to that of data from the chemical genetic 
and genetic screens discussed in this thesis. Future improvements may make 100 
mL cultures a feasible starting point for obtaining such ergosterol phenotypes, but 
in the interim, as the mollisoside results show, the assay was able to provide 
critical confirmatory phenotypic data. 
 
 
 
 
 
  
111 
 
Chapter 7. General Discussion, 
Conclusions and Future Directions 
 
Researching gene function has taken a new dimension with the ability to apply 
genome-wide analysis of epistasis between gene pairs that indicate functional 
connections between the double mutant components. Chemical genomics is part 
of this new approach in which a well-chosen SMP may substitute for a mutation, 
particularly in the ablation of gene function mimicking deletion mutations 
(Hillenmeyer, et al., 2008; Parsons, et al., 2004; Parsons, et al., 2006; Schuldiner, 
et al., 2005). Thus the combination of deletion mutant analysis and SMPs 
provides a powerful approach to such systematic epistasis measurements which 
has been applied in investigation of statin drug mechanisms.  
 
7.1. Epistasis 
 
Epistasis is ‘an interaction between non-allelic genes where a combination of 
their effects exceeds the sum (multiplication) of the expected effects of the 
individual genes’. Masking epistasis as described by Bateson (1909, cited in 
Phillips, 1998), is a particular case in which a gene masks the effects of another 
where the locus being masked is said to be hypostatic to that of the other locus 
(Phillips, 1998) an example being BTS1 mutations that leads to growth defect 
interactions surrounding HMG2 and genes further downstream of the BTS1 gene. 
Fisher (1918, cited in Phillips, 1998) describes a more generalised mechanism of 
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epistasis, where the phenotype of a given double mutant exceeds the summed or 
multiplicative combined effects of its components. Synthetic lethality in this 
(Fisher) definition is an extreme case of an aggravating interaction and can be 
observed in the interactions of particular Δhmg1 Δxxx and Δhmg2 Δxxx 
combinations where xxx might for example be DGA1. In explanation, the cell can 
tolerate loss in sterol synthesis and triacylglycerol synthesis alone, but when 
combined as in Δhmg1 Δdga1 or Δhmg2 Δdga1 the result is synthetic lethality. 
This dissertation has mostly focussed on synthetic lethal phenotypes and its less 
drastic growth reducing form, phenotypic enhancement (PE) though particularly 
pronounced examples of phenotypic suppression (PS) i.e. growth enhanced 
phenotypes are also discussed in the following sections. 
 
7.2. Isoprenoid compensatory pathways 
within the mitochondria 
 
Though statin action has long been thought of as inhibition of HMG CoA-
reductase it is clear from this dissertation that such inhibition must be considered 
in context of several other major intermediary pathways. The isoprenoid 
pathways, Chapters 3 & 4, describe genes downstream of mevalonate (Figs.1.4 
and 1.6)  involved with isoprenylation that include the depletion of intracellular 
pools of geranylgeranyl pyrophosphate which in turn decreases the isoprenylation 
of the Rho GTPases RhoA and Rac1 (Zhong, et al., 2005). The present work 
observed that there are three Rho GTPases (BEM1, GRR1 and SSD1) that interact 
with the statins. BEM1 and SSD1 deletion mutants are sensitive to all three statins. 
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Significantly, these genes regulate the kinase/phosphatase activity for which 
BCK1 (mitogen-activated protein (MAP) kinase kinase kinase signalling 
pathway), and SLT2 (PKC1-mediated signalling pathway) which also show a PE 
interaction with the statins (Chapter 4). These five PE interactions play an 
important role in cell growth where inhibition of Rho GTPases by statins, via 
decreased isoprenylation, leads to a significant enrichment in phenotypic 
suppression interactions via GEM1, RHO5 consistent with previous studies (Kim, 
et al., 1994). These interactions highlight Rho activation via geranylgeranylation, 
suggesting that the inhibitory effects of statins have important interactions 
additional to inhibition of ergosterol synthesis (cholesterol in mammals). 
 
7.3. Statin compensating genes 
 
Along with HMG1, three other lipid biosynthesis genes interacted with all the 
statin drugs namely ARV1, BTS1 and OPI3. BTS1 as discussed in Chapters 3 & 4 
is involved with the regulation of Hmg2p; ARV1 is an important factor 
contributing to sterol storage and transport within the cell where Δarv1 null 
mutants accumulate abnormal internalised unesterfied sterols (Fei, et al., 2008) 
and OPI3 catalyzes the last two steps in de novo phosphatidylcholine biosynthesis 
within the ER (Daum, et al., 1998). A recent study has proposed that in addition 
to sterol transport, ARV1 may be involved in glycosylphosphtidylinositol 
biosynthesis (Morihisa and Taroh, 2009). Defects in phosphatidylcholine 
synthesis generally lead to disruptions in membrane structure and can cause 
structural as well as chemical imbalances in the membrane bilayers. This, coupled 
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with altered sterol levels as a result of statin treatment, can cause unwanted 
hydrophilic substances to enter the cell most of which would be excluded under 
normal conditions (McMaster, 2001). Thus, continuing the conclusion of the 
previous discussion section, statins in inhibiting primary sterol synthesis through 
HMG-CoA-reductases cause changes to the compensatory functions of OPI3 
(phospholipid synthesis) to BTS1 with its effect on geranylgeranylation and to 
ARV1 with its involvement in sterol/lipid transport. These three genes are good 
projects for further investigation as other cellular and environmental variables 
affecting them (e.g. individual gene expression differences or contraindicating 
drugs) could result in side effects.  
 
7.4.  Vesicular transport 
 
 The theme of compensating genes in statins action can be extended when 
considering membrane recycling processes. A strong pattern of gene-usage 
involving anterograde and retrograde vesicular transport emerges in response to 
eliminating HMG1 and its genetic/chemical genetic interactions. It is likely such 
pathways are always part of a cellular homeostasis and become emphasised when 
stress such as gene deletion (or effective gene ablation by SMPs) is affected. 
Chapter 5 describes a number of genes that interact solely with statins + Δhmg2 
Δxxx, which are involved in vesicular transport, including 2 out of 3 members 
(GET1 and GET2) of the Golgi – ER trafficking (GET) complex. This complex 
mediates the insertion of tail anchored proteins into the ER membrane 
(Schuldiner, et al., 2005). These characteristic transmembrane proteins are found 
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throughout the secretory pathway, the nuclear envelope, peroxisomes and 
mitochondria (Wattenberg and Lithgow, 2001). They play important roles within 
the secretory pathway such as enabling vesicular traffic including many of the 
small peripheral membrane anchored proteins (SNAREs) that mediate fusion of 
secretory vesicles in secretory pathway events (Schuldiner, et al., 2008). Absence 
of GET1/GET2 causes secretion of proteins with the HDEL ER retention marker 
instead of being returned by retrograde Golgi to ER transport (Schuldiner, et al., 
2005). Though noted (Schuldiner, et al., 2005; Schuldiner, et al., 2008) deletion of 
any genes of the GET complex leads to a secretion phenotype similar to that seen 
in a Kar2p strain lacking the HDEL receptor, these authors did not specify a role 
in anterograde transport. The current results (Chapter 5) show that in the absence 
of HMG2 coupled with inhibition of Hmg1p by statins, retrograde transport is 
also disrupted.  
 
 The genes VPS51 and VPS53 described as showing epistatic interactions with 
statins + Δhmg2 Δxxx in Ch 5, are integral components of the four-member Golgi 
associated retrograde protein (GARP) complex which is involved in retrograde 
transport from early endosomes to the late Golgi. Moreover, TLG2, a SNARE 
protein (described above) interacts with the GARP complex, which in turn 
facilitates vesicle fusion within the Trans Golgi Network (TGN). However, it has 
been described that these and other protein facilitators interact with specific Rab 
proteins (Conibear, et al., 2003), coupling membrane recognition with the 
activation of Rab GTPase which are inhibited by geranylgeranylation (Garza, et 
al., 2009b). These results extend the notion that genes involved in membrane 
recycling beyond the ER-Golgi step of the secretory pathway are also affected by 
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statins, as might be expected if cells are compensating for loss of viable 
membrane by recycling. 
 
7.5.  Other lipid synthesis genes 
 
 A lipid biosynthesis gene that showed interaction under all conditions described 
in Chapter 5 is DGA1, an integral component in the de novo synthesis of TAG 
lipid droplet formation, a pool that also affects membrane trafficking within the 
cell (Petschnigg, et al., 2009). Relatedly, when the ER becomes stressed (such as 
the conditions presented in Chapters 4 & 5) lipid droplet formation increases. It is 
of interest that changes in lipid droplet dynamics have been associated with a 
number of pathological conditions including obesity, type 2 diabetes, fatty liver 
and atherosclerosis (Fei, et al., 2009).  
 
7.6. The HRD – ubiquitin pathway 
 
Although Hmg1p and Hmg2p are both structurally and enzymatically similar, 
differences exist in the way cells respond to these proteins and their cellular 
distribution and structure within the ER (Federovitch, et al., 2008). Furthermore, 
the Hmg1p protein is stable, whereas Hmg2p undergoes rapid HRD-mediated 
degradation via the ubiquinone – proteasome pathway (Garza, et al., 2009a) 
pointing to dissimilar roles (with respect to the ubiquinone – proteasome 
degradation pathway) requiring further analysis.  
 
117 
 
 All the statins show interactions with SPF1, whose gene product is responsible 
for Ca2+ ion homeostasis in the ER and for the regulation of Hmg2p degradation 
in the ER (Cronin, et al., 2000). The interactions described in Chapter 4 also 
suggest MID1 (and CCH1 a voltage gated Ca2+ channel) regulates Hmg2p 
degradation functioning as a Ca2+ cation channel in the ER. These data are 
consistent with the observations of Cronin et al 2000 and suggest that Hmg2p 
degradation via the HRD – ubiquitin mediated pathway is regulated by Ca2+ 
signalling. 
  
The ERAD pathway is tightly coupled with the HRD pathway responsible for the 
degradation on Hmg2p (Garza, et al., 2009a). If Hmg2p is perturbed by statins 
then it may become misfolded presenting as a target for this pathway. A summary 
of results discussed thus far is that when under chemical genetic perturbation, the 
sterol/lipid ratio alters the fluidity properties of the membrane initiating the 
unfolded protein response (Ron and Walter, 2007) for proteins like Hmh2p. In the 
UPR, the recognition of misfolded proteins by the transmembrane sensor Ire1p 
activates the transcription factor Hac1p which then in turn activates a distinct set 
of genes involved in UPR, ERAD and proteasome processes (Cox and Walter, 
1996; Jonikas, et al., 2009). The involvement of UPR, hence ERAD and the 
proteasome, may be evidenced by lovastatin showing a PE interaction with 
HAC1.  An investigation of the other statins at higher concentrations might also 
show involvement of HAC1. 
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7.7. Statins and quantitative traits 
 
Most traits are complex made up of partial quantitative contributions of a number 
of genes as the QTL literature (e.g.  Schadt and Lum, 2006) has shown. 
Individuals show variation in the quantitative contributions of the component 
genes making up a trait. This perspective is useful in accounting for observations 
in Ch 3, 4, and 5 that detail enhancing or suppressing effects of genes in relation 
to statins, a perspective, that combined with the concept of  network drug  effects 
(Hopkins, 2008) allows an explanation of statin pleiotropy.   
 
For example, in relation to the results of this thesis, an individual might have 
decreased or repressed ARV1, BTS1 or OPI3 expression as a heritable genetic trait 
(Schadt and Lum, 2006; Steinmetz, et al., 2002). Were this the case, therapeutic 
intervention with statins might cause symptoms of a deficiency because of these 
gene functions being unable to compensate for statins, even if these underlying 
traits were asymptomatic. Such an individual would most likely experience 
unwanted side effects should they take a statin drug.  A number of specific 
hypotheses could follow from these suppositions just discussed that should 
provide fruitful avenues to follow in further investigation into the pleiotropic 
effects of statin drugs. 
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7.8. Overall conclusions  
 
The aim of this thesis was to study the genetic networks surrounding important 
enzymes of sterol synthesis, regulation and inhibition by use of statin drugs in 
cells. This thesis elucidates the involvement of numerous genes pointing to key 
genes and processes which could not otherwise have been discerned. 
 
 A number of important points emerge from this work. Firstly, genetic interaction 
networks have been elucidated that are not necessarily an obvious consequence of 
statin effects and in fact are cryptic until “unmasking” as described in Chapter 5, 
such as in membrane retrograde transport that appears when HMG1 enzyme is 
inhibited by statins in the absence of compensating HMG2 enzyme. 
 
Secondly, SGA analysis of the isoenzymes HMG1 and HMG2 showed some, but 
surprisingly little overlap in their genetic interactions supporting a view of 
independent roles of the two genes in addition to their known commonality in 
HMG-CoA reductase. The results of this dissertation strongly suggest that statin 
use targeting HMG CoA-reductase requires genes in multiple pathways acting as 
a network to maintain cellular homeostasis.  From this point of view, statins 
would fit the description of “network acting drugs” as is now being discussed 
(Hopkins, 2008; Schadt, et al., 2009; Schadt and Lum, 2006). 
 
 
\ 
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Thirdly, strong evidence is presented showing involvement of genes acting within 
the ubiquitin – proteasome pathway. This coupled with the known mechanism of 
HRD degradation of Hmg2p leads to the suggestion of a role for Hmg2p in the 
initiation of the UPR. 
 
 Fourthly, when HMG1 and its epistatically interacting genes are shut off (with 
null mutation) and HMG2 is simultaneously shut off with a statin, it is apparent 
that the cell attempts to maintain membrane/lipid homeostasis via anterograde and 
retrograde transport mechanisms, including the mobilisation of lipid storage 
droplets. 
 
 
7.9. Future directions  
 
A number of possibilities are raised by this work which could be usefully further 
investigated. A potentially fruitful line of enquiry relates to the unknown genes 
showing similar GO enrichments to the known genes variously discussed. 
Enrichment of ER/lipid synthesis genes in statin chemical genetic interactions 
suggests that genes displaying unknown functions, namely YGL081W, 
YDR541C, YLR346C and YPL272C belong to the same functional category. The 
genetic interaction function of these genes could be elucidated by SGA analysis, 
possibly leading to similar results as those described in Chapter 3, after which, the 
double mutants could be applied to statin drugs or even other drugs that are 
known to effect ergosterol synthesis in by different mechanisms (e.g. Nystatin). 
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This experiment could place any or all of YGL081W, YDR541C, YLR346C and 
YPL272C in ergosterol pathways or to others if they belong elsewhere.  
 
The genes that show phenotypic enhancement interactions with all the statins 
(BTS1, ARV1, OPI3) along with those that show phenotypic suppression 
interactions (COX17 and MMM1) may underlie a complex phenotype of statin 
effects because they do not lie in any one specific biochemical pathway. Could 
they relate to side effects experienced by those taking statins because of known 
variations in the expression of these genes relating to known human 
genetic/metabolic defects or contraindicated drugs? 
 
One way to resolve this question could involve searching relevant databases for 
homology of these genes with ones that are annotated as being involved in human 
diseases or for being the primary targets of other therapeutic drugs. One could 
also analyse complex traits by investigating whether the mRNAs for the specific 
genes above behave as a heritable quantitative traits (Mackay, et al., 2009; 
Steinmetz, et al., 2002). It is possible these genes could be responding variably in 
statin treated individuals. In a third approach, cells could be treated with statin 
and screened against drug libraries with the possibility of uncovering epistatically 
interacting drugs, which in turn may lead to lower dose and increased efficacy 
with respect to minimising side effects and a greater reduction in sterol levels. 
This concept could be extended to testing the United States Food and Drug 
Administration library of approved drugs for contraindications affecting 
expression of BTS1, ARV1, OPI3, COX17 and MMM1. 
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As described in Chapter 5, when cells are deprived of sterol biosynthesis they 
appear to maintain sterol/lipid homeostasis by utilisation of the lipid storage 
droplets and membrane recycling. A compelling line of research would be to 
investigate mechanisms with high-throughput automated confocal microscopy 
(available in this laboratory), following a DGA1-GFP reporter gene. Subcellular 
location phenotypes are likely to be more sensitive and revealing than the simple 
growth assays described in most of this dissertation. 
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Appendix 1 Media and components  
YPD (Agar) 
 
Distilled Water    1000mL 
Yeast extract (BD)    10g 
Peptone (BD)     20g 
Adenine (sigma)    0.12g 
Agar (Invitrogen)    20g 
40% Glucose (sigma)    50mL 
Autoclave (121°C for 22 minutes) and cool to 65°C, before adding 
glucose and antibiotics (YPD broth is prepared as above without the 
addition of agar. 
 
 
SD complete (Agar) 
 
Distilled Water     1000mL 
Yeast nitrogen base (BD)    1.7g 
w/o amino acids or ammonium sulphate 
MSG (BDH)      1g 
Amino acid (sigma) mixture to suit   2g  
Agar (BD)      20g 
40% Glucose (Sigma)     50mL 
Autoclave and cool to 65°C, add glucose and antibiotics if needed 
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Enriched Sporulation (Agar) 
 
Potassium Acetate   10g 
Yeast extract    1g 
Glucose    0.5g  
Amino acid supplement  0.1g 
(His/Leu/Lys/Ura) 
Agar     20g 
 
 
Antibiotics  Stock   Working  
 
ClonNat 100mg/mL in H2O  100μg/mL 
 
G418  200mg/mL in H2O  200μg/mL 
 
Canavanine 50mg/mL in H2O  50μg/mL 
 
Thialysine 50mg/mL in H2O  50μg/mL 
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Appendix 2: Ergosterol quantification 
data 
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Table A.1 Ergosterol quantification data analysis 
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Table B.1: Atorvastatin +Δ hmg1 Δxxx PE interactions 
YMR003W AIM34 
Protein of unknown function; GFP-fusion protein localizes to the 
mitochondria; null mutant is viable and displays reduced frequency of 
mitochondrial genome loss 
YNR041C COQ2 
Para hydroxybenzoate: polyprenyl transferase, catalyzes the second step 
in ubiquinone (coenzyme Q) biosynthesis 
YOR245C DGA1 
Diacylglycerol acyltransferase, catalyzes the terminal step of 
triacylglycerol (TAG) formation, acylates diacylglycerol using acyl-CoA 
as an acyl donor, localized to lipid particles 
YKL213C DOA1 
WD repeat protein required for ubiquitin-mediated protein degradation, 
forms complex with Cdc48p, plays a role in controlling cellular 
ubiquitin concentration; also promotes efficient NHEJ in 
postdiauxic/stationary phase 
YBL047C EDE1 
Key endocytic protein involved in a network of interactions with other 
endocytic proteins, binds membranes in a ubiquitin-dependent manner, 
may also bind ubiquitinated membrane-associated proteins 
YFR019W FAB1 
1-phosphatidylinositol-3-phosphate 5-kinase; vacuolar membrane kinase 
that generates phosphatidylinositol (3,5)P2, which is involved in 
vacuolar sorting and homeostasis 
YDR508C GNP1 
High-affinity glutamine permease, also transports Leu, Ser, Thr, Cys, 
Met and Asn; expression is fully dependent on Grr1p and modulated by 
the Ssy1p-Ptr3p-Ssy5p (SPS) sensor of extracellular amino acids 
YJL101C GSH1 
Gamma glutamylcysteine synthetase catalyzes the first step in 
glutathione (GSH) biosynthesis; expression induced by oxidants, 
cadmium, and mercury 
YOL095C HMI1 
Mitochondrial inner membrane localized ATP-dependent DNA helicase, 
required for the maintenance of the mitochondrial genome; not required 
for mitochondrial transcription; has homology to E. coli helicase uvrD 
YCR071C IMG2 Mitochondrial ribosomal protein of the small subunit 
YOL081W IRA2 
GTPase-activating protein that negatively regulates RAS by converting 
it from the GTP- to the GDP-bound inactive form, required for reducing 
cAMP levels under nutrient limiting conditions, has similarity to Ira1p 
and human neurofibromin 
YML068W ITT1 
Protein that modulates the efficiency of translation termination, interacts 
with translation release factors eRF1 (Sup45p) and eRF3 (Sup35p) in 
vitro, contains a zinc finger domain characteristic of the TRIAD class of 
proteins 
YIL027C KRE27 
Member of a transmembrane complex required for efficient folding of 
proteins in the ER; null mutant displays induction of the unfolded 
protein response, and also shows K1 killer toxin resistance 
YOR360C PDE2 
High-affinity cyclic AMP phosphodiesterase, component of the cAMP-
dependent protein kinase signaling system, protects the cell from 
extracellular cAMP, contains readthrough motif surrounding termination 
codon 
YML016C PPZ1 
Serine/threonine protein phosphatase Z, isoform of Ppz2p; involved in 
regulation of potassium transport, which affects osmotic stability, cell 
cycle progression, and halotolerance 
YBR260C RGD1 
GTPase-activating protein (RhoGAP) for Rho3p and Rho4p, possibly 
involved in control of actin cytoskeleton organization 
YPL089C RLM1 
MADS-box transcription factor, component of the protein kinase C-
mediated MAP kinase pathway involved in the maintenance of cell 
integrity; phosphorylated and activated by the MAP-kinase Slt2p 
YOR312C RPL20B 
Protein component of the large (60S) ribosomal subunit, nearly identical 
to Rpl20Ap and has similarity to rat L18a ribosomal protein 
YBR171W SEC66 
Non-essential subunit of Sec63 complex (Sec63p, Sec62p, Sec66p and 
Sec72p); with Sec61 complex, Kar2p/BiP and Lhs1p forms a channel 
competent for SRP-dependent and post-translational SRP-independent 
protein targeting and import into the ER 
YBL061C SKT5 
Activator of Chs3p (chitin synthase III), recruits Chs3p to the bud neck 
via interaction with Bni4p; has similarity to Shc1p, which activates 
Chs3p during sporulation 
YBL007C SLA1 
Cytoskeletal protein binding protein required for assembly of the cortical 
actin cytoskeleton; interacts with proteins regulating actin dynamics and 
proteins required for endocytosis; found in the nucleus and cell cortex; 
has 3 SH3 domains 
YPL057C SUR1 
Probable catalytic subunit of a mannosylinositol phosphorylceramide 
(MIPC) synthase, forms a complex with probable regulatory subunit 
Csg2p; function in sphingolipid biosynthesis is overlapping with that of 
Csh1p 
YKR059W TIF1 
Translation initiation factor eIF4A, identical to Tif2p; DEA(D/H)-box 
RNA helicase that couples ATPase activity to RNA binding and 
unwinding; forms a dumbbell structure of two compact domains 
connected by a linker; interacts with eIF4G 
YBR082C UBC4 
Ubiquitin-conjugating enzyme (E2), mediates degradation of abnormal 
or excess proteins, including calmodulin and histone H3; interacts with 
many SCF ubiquitin protein ligases; component of the cellular stress 
response 
YLL039C UBI4 
Ubiquitin, becomes conjugated to proteins, marking them for selective 
degradation via the ubiquitin-26S proteasome system; essential for the 
cellular stress response; encoded as a polyubiquitin precursor comprised 
of 5 head-to-tail repeats 
YFR010W UBP6 
Ubiquitin-specific protease situated in the base subcomplex of the 26S 
proteasome, releases free ubiquitin from branched polyubiquitin chains; 
works in opposition to polyubiquitin elongation activity of Hul5p 
YOR106W VAM3 
Syntaxin-related protein required for vacuolar assembly; functions with 
Vam7p in vacuolar protein trafficking; member of the syntaxin family of 
proteins 
YOR089C VPS21 
GTPase required for transport during endocytosis and for correct sorting 
of vacuolar hydrolases; localized in endocytic intermediates; detected in 
mitochondria; geranylgeranylation required for membrane association; 
mammalian Rab5 homolog 
 
 
YNR006W 
 
 
VPS27 
Endosomal protein that forms a complex with Hse1p; required for 
recycling Golgi proteins, forming lumenal membranes and sorting 
ubiquitinated proteins destined for degradation; has Ubiquitin Interaction 
Motifs which bind ubiquitin (Ubi4p) 
   
 
 
 
YPR173C 
 
 
 
VPS4 
AAA-ATPase involved in multivesicular body (MVB) protein sorting, 
ATP-bound Vps4p localizes to endosomes and catalyzes ESCRT-III 
disassembly and membrane release; ATPase activity is activated by 
Vta1p; regulates cellular sterol metabolism 
 
 
 
YML097C 
 
 
VPS9 
A guanine nucleotide exchange factor involved in vesicle-mediated 
vacuolar protein transport; specifically stimulates the intrinsic guanine 
nucleotide exchange activity of Vps21p/Rab5: similar to mammalian ras 
inhibitors; binds ubiquitin 
 
 
 
YOR043W 
 
 
 
WHI2 
 
Protein required, with binding partner Psr1p, for full activation of the 
general stress response, possibly through Msn2p dephosphorylation; 
regulates growth during the diauxic shift; negative regulator of G1 cyclin 
expression 
YOR083W WHI5 
Repressor of G1 transcription that binds to SCB binding factor (SBF) at 
SCB target promoters in early G1; phosphorylation of Whi5p by the 
CDK, Cln3p/Cdc28p relieves repression and promoter binding by Whi5; 
periodically expressed in G1 
YMR294W-
A   
Dubious open reading frame unlikely to encode a functional protein, 
substantially overlaps YMR295C; deletion causes sensitivity to unfolded 
protein response-inducing agents 
YDR387C   
Putative transporter, member of the sugar porter family; YDR387C is 
not an essential gene 
YLR444C   
Dubious open reading frame unlikely to encode a functional protein, 
based on available experimental and comparative sequence data 
YMR295C   
Protein of unknown function that associates with ribosomes; green 
fluorescent protein (GFP)-fusion protein localizes to the cell periphery 
and bud; YMR295C is not an essential gene 
YNR071C   Putative protein of unknown function 
 
Table B.2: Cerivastatin + Δhmg1 Δxxx PE interactions 
YMR003W AIM34 
Protein of unknown function; GFP-fusion protein localizes to the 
mitochondria; null mutant is viable and displays reduced frequency of 
mitochondrial genome loss 
YNR041C COQ2 
Para hydroxybenzoate: polyprenyl transferase, catalyzes the second step 
in ubiquinone (coenzyme Q) biosynthesis 
YIR023W DAL81 
Positive regulator of genes in multiple nitrogen degradation pathways; 
contains DNA binding domain but does not appear to bind the 
dodecanucleotide sequence present in the promoter region of many 
genes involved in allantoin catabolism 
YOR245C DGA1 
Diacylglycerol acyltransferase, catalyzes the terminal step of 
triacylglycerol (TAG) formation, acylates diacylglycerol using acyl-
CoA as an acyl donor, localized to lipid particles 
YKL213C DOA1 
WD repeat protein required for ubiquitin-mediated protein degradation, 
forms complex with Cdc48p, plays a role in controlling cellular 
ubiquitin concentration; also promotes efficient NHEJ in 
postdiauxic/stationary phase 
YKL191W DPH2 
Protein required, along with Dph1p, Kti11p, Jjj3p, and Dph5p, for 
synthesis of diphthamide, which is a modified histidine residue of 
translation elongation factor 2 (Eft1p or Eft2p); may act in a complex 
with Dph1p and Kti11p 
YML008C ERG6 
Delta(24)-sterol C-methyltransferase, converts zymosterol to fecosterol 
in the ergosterol biosynthetic pathway by methylating position C-24; 
localized to both lipid particles and mitochondrial outer membrane 
YER083C GET2 
Subunit of the GET complex; involved in insertion of proteins into the 
ER membrane; required for the retrieval of HDEL proteins from the 
Golgi to the ER in an ERD2 dependent fashion and for meiotic nuclear 
division 
YJL101C GSH1 
Gamma glutamylcysteine synthetase catalyzes the first step in 
glutathione (GSH) biosynthesis; expression induced by oxidants, 
cadmium, and mercury 
YOL081W IRA2 
GTPase-activating protein that negatively regulates RAS by converting 
it from the GTP- to the GDP-bound inactive form, required for reducing 
cAMP levels under nutrient limiting conditions, has similarity to Ira1p 
and human neurofibromin 
YML068W ITT1 
Protein that modulates the efficiency of translation termination, interacts 
with translation release factors eRF1 (Sup45p) and eRF3 (Sup35p) in 
vitro, contains a zinc finger domain characteristic of the TRIAD class of 
proteins 
YOR360C PDE2 
High-affinity cyclic AMP phosphodiesterase, component of the cAMP-
dependent protein kinase signaling system, protects the cell from 
extracellular cAMP, contains readthrough motif surrounding 
termination codon 
YOR312C RPL20B 
Protein component of the large (60S) ribosomal subunit, nearly identical 
to Rpl20Ap and has similarity to rat L18a ribosomal protein 
YJL136C RPS21B 
Protein component of the small (40S) ribosomal subunit; nearly 
identical to Rps21Ap and has similarity to rat S21 ribosomal protein 
   
 
 
 
YDR477W 
 
 
 
SNF1 
AMP-activated serine/threonine protein kinase found in a complex 
containing Snf4p and members of the Sip1p/Sip2p/Gal83p family; 
required for transcription of glucose-repressed genes, thermotolerance, 
sporulation, and peroxisome biogenesis 
YDR073W SNF11 
Subunit of the SWI/SNF chromatin remodeling complex involved in 
transcriptional regulation; interacts with a highly conserved 40-residue 
sequence of Snf2p 
YGL115W SNF4 
Activating gamma subunit of the AMP-activated Snf1p kinase complex 
(contains Snf1p and a Sip1p/Sip2p/Gal83p family member); activates 
glucose-repressed genes, represses glucose-induced genes; role in 
sporulation, and peroxisome biogenesis 
YKR059W TIF1 
Translation initiation factor eIF4A, identical to Tif2p; DEA(D/H)-box 
RNA helicase that couples ATPase activity to RNA binding and 
unwinding; forms a dumbbell structure of two compact domains 
connected by a linker; interacts with eIF4G 
YLL039C UBI4 
Ubiquitin, becomes conjugated to proteins, marking them for selective 
degradation via the ubiquitin-26S proteasome system; essential for the 
cellular stress response; encoded as a polyubiquitin precursor comprised 
of 5 head-to-tail repeats 
YFR010W UBP6 
Ubiquitin-specific protease situated in the base subcomplex of the 26S 
proteasome, releases free ubiquitin from branched polyubiquitin chains; 
works in opposition to polyubiquitin elongation activity of Hul5p 
YNR006W VPS27 
Endosomal protein that forms a complex with Hse1p; required for 
recycling Golgi proteins, forming lumenal membranes and sorting 
ubiquitinated proteins destined for degradation; has Ubiquitin 
Interaction Motifs which bind ubiquitin (Ubi4p) 
YPR173C VPS4 
AAA-ATPase involved in multivesicular body (MVB) protein sorting, 
ATP-bound Vps4p localizes to endosomes and catalyzes ESCRT-III 
disassembly and membrane release; ATPase activity is activated by 
Vta1p; regulates cellular sterol metabolism 
YOR043W WHI2 
Protein required, with binding partner Psr1p, for full activation of the 
general stress response, possibly through Msn2p dephosphorylation; 
regulates growth during the diauxic shift; negative regulator of G1 
cyclin expression 
YOR083W WHI5 
Repressor of G1 transcription that binds to SCB binding factor (SBF) at 
SCB target promoters in early G1; phosphorylation of Whi5p by the 
CDK, Cln3p/Cdc28p relieves repression and promoter binding by Whi5; 
periodically expressed in G1 
YPR024W YME1 
Catalytic subunit of the mitochondrial inner membrane i-AAA protease 
complex, which is responsible for degradation of unfolded or misfolded 
mitochondrial gene products; mutation causes an elevated rate of 
mitochondrial turnover 
YMR294W-
A   
Dubious open reading frame unlikely to encode a functional protein, 
substantially overlaps YMR295C; deletion causes sensitivity to 
unfolded protein response-inducing agents 
YDR387C   
Putative transporter, member of the sugar porter family; YDR387C is 
not an essential gene 
 
   
 
 
 
 
YMR295C 
Protein of unknown function that associates with ribosomes; green 
fluorescent protein (GFP)-fusion protein localizes to the cell periphery 
and bud; YMR295C is not an essential gene 
YDR186C   
Putative protein of unknown function; may interact with ribosomes, 
based on co-purification experiments; green fluorescent protein (GFP)-
fusion protein localizes to the cytoplasm 
YGL242C   Putative protein of unknown function; deletion mutant is viable 
YNR071C   Putative protein of unknown function 
      
 
Table B.3: Lovastatin + Δhmg1 Δxxx PE interactions 
YDL074C BRE1 
E3 ubiquitin ligase, forms heterodimer with Rad6p to monoubiquinate 
histone H2B-K123, which is required for the subsequent methylation of 
histone H3-K4 and H3-K79; required for DSBR, transcription, 
silencing, and checkpoint control 
YIR023W DAL81 
Positive regulator of genes in multiple nitrogen degradation pathways; 
contains DNA binding domain but does not appear to bind the 
dodecanucleotide sequence present in the promoter region of many 
genes involved in allantoin catabolism 
YOR245C DGA1 
Diacylglycerol acyltransferase, catalyzes the terminal step of 
triacylglycerol (TAG) formation, acylates diacylglycerol using acyl-
CoA as an acyl donor, localized to lipid particles 
YKL213C DOA1 
WD repeat protein required for ubiquitin-mediated protein degradation, 
forms complex with Cdc48p, plays a role in controlling cellular 
ubiquitin concentration; also promotes efficient NHEJ in 
postdiauxic/stationary phase 
YER083C GET2 
Subunit of the GET complex; involved in insertion of proteins into the 
ER membrane; required for the retrieval of HDEL proteins from the 
Golgi to the ER in an ERD2 dependent fashion and for meiotic nuclear 
division 
YJL101C GSH1 
Gamma glutamylcysteine synthetase catalyzes the first step in 
glutathione (GSH) biosynthesis; expression induced by oxidants, 
cadmium, and mercury 
YOL081W IRA2 
GTPase-activating protein that negatively regulates RAS by converting 
it from the GTP- to the GDP-bound inactive form, required for reducing 
cAMP levels under nutrient limiting conditions, has similarity to Ira1p 
and human neurofibromin 
YML068W ITT1 
Protein that modulates the efficiency of translation termination, interacts 
with translation release factors eRF1 (Sup45p) and eRF3 (Sup35p) in 
vitro, contains a zinc finger domain characteristic of the TRIAD class of 
proteins 
 
 
 
YOL009C 
 
 
 
MDM12 
Mitochondrial outer membrane protein, required for transmission of 
mitochondria to daughter cells; component of the ERMES complex that 
links the ER to mitochondria; may influence import and assembly of 
outer membrane beta-barrel proteins 
YLR350W ORM2 
Evolutionarily conserved protein with similarity to Orm1p, required for 
resistance to agents that induce the unfolded protein response; human 
ortholog is located in the endoplasmic reticulum 
YOR360C PDE2 
High-affinity cyclic AMP phosphodiesterase, component of the cAMP-
dependent protein kinase signaling system, protects the cell from 
extracellular cAMP, contains readthrough motif surrounding 
termination codon 
YOR153W PDR5 
Plasma membrane ATP-binding cassette (ABC) transporter, multidrug 
transporter actively regulated by Pdr1p; also involved in steroid 
transport, cation resistance, and cellular detoxification during 
exponential growth 
 
 
 
 
 
 
 
 
YPL089C 
 
 
RLM1 
MADS-box transcription factor, component of the protein kinase C-
mediated MAP kinase pathway involved in the maintenance of cell 
integrity; phosphorylated and activated by the MAP-kinase Slt2p 
YOR312C RPL20B 
Protein component of the large (60S) ribosomal subunit, nearly identical 
to Rpl20Ap and has similarity to rat L18a ribosomal protein 
YCR009C RVS161 
Amphiphysin-like lipid raft protein; interacts with Rvs167p and 
regulates polarization of the actin cytoskeleton, endocytosis, cell 
polarity, cell fusion and viability following starvation or osmotic stress 
YDR477W SNF1 
AMP-activated serine/threonine protein kinase found in a complex 
containing Snf4p and members of the Sip1p/Sip2p/Gal83p family; 
required for transcription of glucose-repressed genes, thermotolerance, 
sporulation, and peroxisome biogenesis 
YKR059W TIF1 
Translation initiation factor eIF4A, identical to Tif2p; DEA(D/H)-box 
RNA helicase that couples ATPase activity to RNA binding and 
unwinding; forms a dumbbell structure of two compact domains 
connected by a linker; interacts with eIF4G 
YFR010W UBP6 
Ubiquitin-specific protease situated in the base subcomplex of the 26S 
proteasome, releases free ubiquitin from branched polyubiquitin chains; 
works in opposition to polyubiquitin elongation activity of Hul5p 
YGR105W VMA21 
Integral membrane protein that is required for vacuolar H+-ATPase (V-
ATPase) function, although not an actual component of the V-ATPase 
complex; functions in the assembly of the V-ATPase; localized to the 
yeast endoplasmic reticulum (ER) 
YNR006W VPS27 
Endosomal protein that forms a complex with Hse1p; required for 
recycling Golgi proteins, forming lumenal membranes and sorting 
ubiquitinated proteins destined for degradation; has Ubiquitin 
Interaction Motifs which bind ubiquitin (Ubi4p) 
YOR083W WHI5 
Repressor of G1 transcription that binds to SCB binding factor (SBF) at 
SCB target promoters in early G1; phosphorylation of Whi5p by the 
CDK, Cln3p/Cdc28p relieves repression and promoter binding by Whi5; 
periodically expressed in G1 
YDR387C   
Putative transporter, member of the sugar porter family; YDR387C is 
not an essential gene 
YMR295C   
Protein of unknown function that associates with ribosomes; green 
fluorescent protein (GFP)-fusion protein localizes to the cell periphery 
and bud; YMR295C is not an essential gene 
 
 
Table B.4: Atorvastatin + Δhmg2 Δxxx PE interactions 
YGL256W ADH4 
Alcohol dehydrogenase isoenzyme type IV, dimeric enzyme 
demonstrated to be zinc-dependent despite sequence similarity to iron-
activated alcohol dehydrogenases; transcription is induced in response to 
zinc deficiency 
YMR003W AIM34 
Protein of unknown function; GFP-fusion protein localizes to the 
mitochondria; null mutant is viable and displays reduced frequency of 
mitochondrial genome loss 
YDL074C BRE1 
E3 ubiquitin ligase, forms heterodimer with Rad6p to monoubiquinate 
histone H2B-K123, which is required for the subsequent methylation of 
histone H3-K4 and H3-K79; required for DSBR, transcription, silencing, 
and checkpoint control 
YOR125C CAT5 
Protein required for ubiquinone (Coenzyme Q) biosynthesis; localizes to 
the matrix face of the mitochondrial inner membrane in a large complex 
with ubiquinone biosynthetic enzymes; required for gluconeogenic gene 
activation 
YBR131W CCZ1 
Protein involved in vacuolar assembly, essential for autophagy and the 
cytoplasm-to-vacuole pathway 
YER164W CHD1 
Nucleosome remodeling factor that functions in regulation of 
transcription elongation; contains a chromo domain, a helicase domain 
and a DNA-binding domain; component of both the SAGA and SLIK 
complexes 
YGR157W CHO2 
Phosphatidylethanolamine methyltransferase (PEMT), catalyzes the first 
step in the conversion of phosphatidylethanolamine to 
phosphatidylcholine during the methylation pathway of 
phosphatidylcholine biosynthesis 
YBR023C CHS3 
Chitin synthase III, catalyzes the transfer of N-acetylglucosamine 
(GlcNAc) to chitin; required for synthesis of the majority of cell wall 
chitin, the chitin ring during bud emergence, and spore wall chitosan 
YLR330W CHS5 
Component of the exomer complex, which also contains Csh6p, Bch1p, 
Bch2p, and Bud7p and is involved in export of selected proteins, such as 
chitin synthase Chs3p, from the Golgi to the plasma membrane 
YDL155W CLB3 
B-type cyclin involved in cell cycle progression; activates Cdc28p to 
promote the G2/M transition; may be involved in DNA replication and 
spindle assembly; accumulates during S phase and G2, then targeted for 
ubiquitin-mediated degradation 
YPL256C CLN2 
G1 cyclin involved in regulation of the cell cycle; activates Cdc28p 
kinase to promote the G1 to S phase transition; late G1 specific 
expression depends on transcription factor complexes, MBF (Swi6p-
Mbp1p) and SBF (Swi6p-Swi4p) 
YML129C COX14 
Mitochondrial membrane protein, involved in translational regulation of 
Cox1p and assembly of cytochrome c oxidase (complex IV); associates 
with complex IV assembly intermediates and complex III/complex IV 
supercomplexes 
YNR010W CSE2 
Subunit of the RNA polymerase II mediator complex; associates with 
core polymerase subunits to form the RNA polymerase II holoenzyme; 
component of the Med9/10 module; required for regulation of RNA 
polymerase II activity 
YIR023W DAL81 
Positive regulator of genes in multiple nitrogen degradation pathways; 
contains DNA binding domain but does not appear to bind the 
dodecanucleotide sequence present in the promoter region of many genes 
involved in allantoin catabolism 
YAL013W DEP1 
Transcriptional modulator involved in regulation of structural 
phospholipid biosynthesis genes and metabolically unrelated genes, as 
well as maintenance of telomeres, mating efficiency, and sporulation 
YOR245C DGA1 
Diacylglycerol acyltransferase, catalyzes the terminal step of 
triacylglycerol (TAG) formation, acylates diacylglycerol using acyl-CoA 
as an acyl donor, localized to lipid particles 
YKL213C DOA1 
WD repeat protein required for ubiquitin-mediated protein degradation, 
forms complex with Cdc48p, plays a role in controlling cellular ubiquitin 
concentration; also promotes efficient NHEJ in postdiauxic/stationary 
phase 
YDR440W DOT1 
Nucleosomal histone H3-Lys79 methylase; methylation is required for 
telomeric silencing, meiotic checkpoint control, and DNA damage 
response 
YBR078W ECM33 
GPI-anchored protein of unknown function, has a possible role in apical 
bud growth; GPI-anchoring on the plasma membrane crucial to function; 
phosphorylated in mitochondria; similar to Sps2p and Pst1p 
YBL047C EDE1 
Key endocytic protein involved in a network of interactions with other 
endocytic proteins, binds membranes in a ubiquitin-dependent manner, 
may also bind ubiquitinated membrane-associated proteins 
YDR414C ERD1 
Predicted membrane protein required for the retention of lumenal 
endoplasmic reticulum proteins; mutants secrete the endogenous ER 
protein, BiP (Kar2p) 
YMR202W ERG2 
C-8 sterol isomerase, catalyzes the isomerization of the delta-8 double 
bond to the delta-7 position at an intermediate step in ergosterol 
biosynthesis 
YFR019W FAB1 
1-phosphatidylinositol-3-phosphate 5-kinase; vacuolar membrane kinase 
that generates phosphatidylinositol (3,5)P2, which is involved in vacuolar 
sorting and homeostasis 
YCR034W FEN1 
Fatty acid elongase, involved in sphingolipid biosynthesis; acts on fatty 
acids of up to 24 carbons in length; mutations have regulatory effects on 
1,3-beta-glucan synthase, vacuolar ATPase, and the secretory pathway 
YGR196C FYV8 
Protein of unknown function, required for survival upon exposure to K1 
killer toxin 
YMR307W GAS1 
Beta-1,3-glucanosyltransferase, required for cell wall assembly and also 
has a role in transcriptional silencing; localizes to the cell surface via a 
glycosylphosphatidylinositol (GPI) anchor; also found at the nuclear 
periphery 
YGL020C GET1 
Subunit of the GET complex; involved in insertion of proteins into the 
ER membrane; required for the retrieval of HDEL proteins from the 
Golgi to the ER in an ERD2 dependent fashion and for normal 
mitochondrial morphology and inheritance 
YER083C GET2 
Subunit of the GET complex; involved in insertion of proteins into the 
ER membrane; required for the retrieval of HDEL proteins from the 
Golgi to the ER in an ERD2 dependent fashion and for meiotic nuclear 
division 
YDR508C GNP1 
High-affinity glutamine permease, also transports Leu, Ser, Thr, Cys, Met 
and Asn; expression is fully dependent on Grr1p and modulated by the 
Ssy1p-Ptr3p-Ssy5p (SPS) sensor of extracellular amino acids 
YGR032W GSC2 
Catalytic subunit of 1,3-beta-glucan synthase, involved in formation of 
the inner layer of the spore wall; activity positively regulated by Rho1p 
and negatively by Smk1p; has similarity to an alternate catalytic subunit, 
Fks1p (Gsc1p) 
   
 
 
YJL101C 
 
 
GSH1 
Gamma glutamylcysteine synthetase catalyzes the first step in glutathione 
(GSH) biosynthesis; expression induced by oxidants, cadmium, and 
mercury 
YOL049W GSH2 
Glutathione synthetase, catalyzes the ATP-dependent synthesis of 
glutathione (GSH) from gamma-glutamylcysteine and glycine; induced 
by oxidative stress and heat shock 
YGL084C GUP1 
Plasma membrane protein involved in remodeling GPI anchors; member 
of the MBOAT family of putative membrane-bound O-acyltransferases; 
proposed to be involved in glycerol transport 
YOL095C HMI1 
Mitochondrial inner membrane localized ATP-dependent DNA helicase, 
required for the maintenance of the mitochondrial genome; not required 
for mitochondrial transcription; has homology to E. coli helicase uvrD 
YDR174W HMO1 
Chromatin associated high mobility group (HMG) family member 
involved in genome maintenance; rDNA-binding component of the Pol I 
transcription system; associates with a 5'-3' DNA helicase and Fpr1p, a 
prolyl isomerase 
YOR025W HST3 
Member of the Sir2 family of NAD(+)-dependent protein deacetylases; 
involved along with Hst4p in telomeric silencing, cell cycle progression, 
radiation resistance, genomic stability and short-chain fatty acid 
metabolism 
YJR118C ILM1 
Protein of unknown function; may be involved in mitochondrial DNA 
maintenance; required for slowed DNA synthesis-induced filamentous 
growth 
YIL002C INP51 
Phosphatidylinositol 4,5-bisphosphate 5-phosphatase, synaptojanin-like 
protein with an N-terminal Sac1 domain, plays a role in 
phosphatidylinositol 4,5-bisphosphate homeostasis and in endocytosis; 
null mutation confers cold-tolerant growth 
YOL081W IRA2 
GTPase-activating protein that negatively regulates RAS by converting it 
from the GTP- to the GDP-bound inactive form, required for reducing 
cAMP levels under nutrient limiting conditions, has similarity to Ira1p 
and human neurofibromin 
YER019W ISC1 
Mitochondrial membrane localized inositol phosphosphingolipid 
phospholipase C, hydrolyzes complex sphingolipids to produce ceramide; 
activated by phosphatidylserine, cardiolipin, and phosphatidylglycerol; 
mediates Na+ and Li+ halotolerance 
YKL032C IXR1 
Protein that binds DNA containing intrastrand cross-links formed by 
cisplatin, contains two HMG (high mobility group box) domains, which 
confer the ability to bend cisplatin-modified DNA; mediates aerobic 
transcriptional repression of COX5b 
YDR483W KRE2 
Alpha1,2-mannosyltransferase of the Golgi involved in protein 
mannosylation 
YJL062W LAS21 
Integral plasma membrane protein involved in the synthesis of the 
glycosylphosphatidylinositol (GPI) core structure; mutations affect cell 
wall integrity 
YPL055C LGE1 
Protein of unknown function; null mutant forms abnormally large cells, 
and homozygous diploid null mutant displays delayed premeiotic DNA 
synthesis and reduced efficiency of meiotic nuclear division 
YNL147W LSM7 
Lsm (Like Sm) protein; part of heteroheptameric complexes (Lsm2p-7p 
and either Lsm1p or 8p): cytoplasmic Lsm1p complex involved in 
mRNA decay; nuclear Lsm8p complex part of U6 snRNP and possibly 
involved in processing tRNA, snoRNA, and rRNA 
 
 
 
 
 
 
 
 
YCR020C-A 
 
 
MAK31 
Non-catalytic subunit of N-terminal acetyltransferase of the NatC type; 
required for replication of dsRNA virus; member of the Sm protein 
family 
YNL307C MCK1 
Protein serine/threonine/tyrosine (dual-specificity) kinase involved in 
control of chromosome segregation and in regulating entry into meiosis; 
related to mammalian glycogen synthase kinases of the GSK-3 family 
YPR070W MED1 
Subunit of the RNA polymerase II mediator complex; associates with 
core polymerase subunits to form the RNA polymerase II holoenzyme; 
essential for transcriptional regulation 
YIL128W MET18 
DNA repair and TFIIH regulator, required for both nucleotide excision 
repair (NER) and RNA polymerase II (RNAP II) transcription; involved 
in telomere maintenance 
YNL076W MKS1 
Pleiotropic negative transcriptional regulator involved in Ras-CAMP and 
lysine biosynthetic pathways and nitrogen regulation; involved in 
retrograde (RTG) mitochondria-to-nucleus signaling 
YGL124C MON1 
Protein required for fusion of cvt-vesicles and autophagosomes with the 
vacuole; associates, as a complex with Ccz1p, with a perivacuolar 
compartment; potential Cdc28p substrate 
YMR224C MRE11 
Subunit of a complex with Rad50p and Xrs2p (MRX complex) that 
functions in repair of DNA double-strand breaks and in telomere stability, 
exhibits nuclease activity that appears to be required for MRX function; 
widely conserved 
YLR338W OPI9 
Dubious open reading frame unlikely to encode a protein, based on 
available experimental and comparative sequence data; partially overlaps 
the verified ORF VRP1/YLR337C 
YDL232W OST4 
Subunit of the oligosaccharyltransferase complex of the ER lumen, which 
catalyzes protein asparagine-linked glycosylation; type I membrane 
protein required for incorporation of Ost3p or Ost6p into the OST 
complex 
YOR360C PDE2 
High-affinity cyclic AMP phosphodiesterase, component of the cAMP-
dependent protein kinase signaling system, protects the cell from 
extracellular cAMP, contains readthrough motif surrounding termination 
codon 
YGL013C PDR1 
Zinc cluster protein that is a master regulator involved in recruiting other 
zinc cluster proteins to pleiotropic drug response elements (PDREs) to 
fine tune the regulation of multidrug resistance genes 
YER149C PEA2 
Coiled-coil polarisome protein required for polarized morphogenesis, cell 
fusion, and low affinity Ca2+ influx; forms polarisome complex with 
Bni1p, Bud6p, and Spa2p; localizes to sites of polarized growth 
YER153C PET122 
Mitochondrial translational activator specific for the COX3 mRNA, acts 
together with Pet54p and Pet494p; located in the mitochondrial inner 
membrane 
YNL003C PET8 
S-adenosylmethionine transporter of the mitochondrial inner membrane, 
member of the mitochondrial carrier family; required for biotin 
biosynthesis and respiratory growth 
YDR265W PEX10 
Peroxisomal membrane E3 ubiquitin ligase required for for Ubc4p-
dependent Pex5p ubiquitination and peroxisomal matrix protein import; 
contains zinc-binding RING domain; mutations in human homolog cause 
various peroxisomal disorders 
YDR244W PEX5 
Peroxisomal membrane signal receptor for the C-terminal tripeptide 
signal sequence (PTS1) of peroxisomal matrix proteins, required for 
peroxisomal matrix protein import; also proposed to have PTS1-receptor 
independent functions 
YMR205C PFK2 
Beta subunit of heterooctameric phosphofructokinase involved in 
glycolysis, indispensable for anaerobic growth, activated by fructose-2,6-
bisphosphate and AMP, mutation inhibits glucose induction of cell cycle-
related genes 
YDR276C PMP3 
Small plasma membrane protein related to a family of plant polypeptides 
that are overexpressed under high salt concentration or low temperature, 
not essential for viability, deletion causes hyperpolarization of the plasma 
membrane potential 
YAL023C PMT2 
Protein O-mannosyltransferase, transfers mannose residues from dolichyl 
phosphate-D-mannose to protein serine/threonine residues; acts in a 
complex with Pmt1p, can instead interact with Pmt5p in some conditions; 
target for new antifungals 
YPR191W QCR2 
Subunit 2 of the ubiquinol cytochrome-c reductase complex, which is a 
component of the mitochondrial inner membrane electron transport chain; 
phosphorylated; transcription is regulated by Hap1p, Hap2p/Hap3p, and 
heme 
YMR075W RCO1 
Essential subunit of the histone deacetylase Rpd3S complex; interacts 
with Eaf3p 
YHL027W RIM101 
Transcriptional repressor involved in response to pH and in cell wall 
construction; required for alkaline pH-stimulated haploid invasive growth 
and sporulation; activated by proteolytic processing; similar to A. 
nidulans PacC 
YMR154C RIM13 
Calpain-like cysteine protease involved in proteolytic activation of 
Rim101p in response to alkaline pH; has similarity to A. nidulans palB 
YFL033C RIM15 
Glucose-repressible protein kinase involved in signal transduction during 
cell proliferation in response to nutrients, specifically the establishment of 
stationary phase; identified as a regulator of IME2; substrate of Pho80p-
Pho85p kinase 
YGL045W RIM8 
Protein involved in proteolytic activation of Rim101p in response to 
alkaline pH; similar to A. nidulans PalF; essential for anaerobic growth; 
member of the arrestin-related trafficking adaptor family 
YMR063W RIM9 
Protein of unknown function, involved in the proteolytic activation of 
Rim101p in response to alkaline pH; has similarity to A. nidulans PalI; 
putative membrane protein 
YPL089C RLM1 
MADS-box transcription factor, component of the protein kinase C-
mediated MAP kinase pathway involved in the maintenance of cell 
integrity; phosphorylated and activated by the MAP-kinase Slt2p 
YHR021C RPS27B 
Protein component of the small (40S) ribosomal subunit; nearly identical 
to Rps27Ap and has similarity to rat S27 ribosomal protein 
YGL244W RTF1 
Subunit of the RNA polymerase II-associated Paf1 complex; directly or 
indirectly regulates DNA-binding properties of Spt15p and relative 
activities of different TATA elements; involved in telomere maintenance 
YOR216C RUD3 
Golgi matrix protein involved in the structural organization of the cis-
Golgi; interacts genetically with COG3 and USO1 
YCR009C RVS161 
Amphiphysin-like lipid raft protein; interacts with Rvs167p and regulates 
polarization of the actin cytoskeleton, endocytosis, cell polarity, cell 
fusion and viability following starvation or osmotic stress 
YDR388W RVS167 
Actin-associated protein, interacts with Rvs161p to regulate actin 
cytoskeleton, endocytosis, and viability following starvation or osmotic 
stress; homolog of mammalian amphiphysin 
 
 
 
 
 
 
 
 
 
 
 
 
YDR469W 
 
 
 
SDC1 
Subunit of the COMPASS (Set1C) complex, which methylates lysine 4 of 
histone H3 and is required in chromatin silencing at telomeres; contains a 
Dpy-30 domain that mediates interaction with Bre2p; similar to C. 
elegans and human DPY-30 
YBR171W SEC66 
Non-essential subunit of Sec63 complex (Sec63p, Sec62p, Sec66p and 
Sec72p); with Sec61 complex, Kar2p/BiP and Lhs1p forms a channel 
competent for SRP-dependent and post-translational SRP-independent 
protein targeting and import into the ER 
YCL010C SGF29 Probable subunit of SAGA histone acetyltransferase complex 
YGL066W SGF73 
Subunit of SAGA histone acetyltransferase complex; involved in 
formation of the preinitiation complex assembly at promoters; null 
mutant displays defects in premeiotic DNA synthesis 
YLR079W SIC1 
Inhibitor of Cdc28-Clb kinase complexes that controls G1/S phase 
transition, preventing premature S phase and ensuring genomic integrity; 
phosphorylation targets Sic1p for SCF(CDC4)-dependent turnover; 
functional homolog of mammalian Kip1 
YBL061C SKT5 
Activator of Chs3p (chitin synthase III), recruits Chs3p to the bud neck 
via interaction with Bni4p; has similarity to Shc1p, which activates 
Chs3p during sporulation 
YBL007C SLA1 
Cytoskeletal protein binding protein required for assembly of the cortical 
actin cytoskeleton; interacts with proteins regulating actin dynamics and 
proteins required for endocytosis; found in the nucleus and cell cortex; 
has 3 SH3 domains 
YBR077C SLM4 
Component of the EGO complex, which is involved in the regulation of 
microautophagy, and of the GSE complex, which is required for proper 
sorting of amino acid permease Gap1p; gene exhibits synthetic genetic 
interaction with MSS4 
YDR477W SNF1 
AMP-activated serine/threonine protein kinase found in a complex 
containing Snf4p and members of the Sip1p/Sip2p/Gal83p family; 
required for transcription of glucose-repressed genes, thermotolerance, 
sporulation, and peroxisome biogenesis 
YGL115W SNF4 
Activating gamma subunit of the AMP-activated Snf1p kinase complex 
(contains Snf1p and a Sip1p/Sip2p/Gal83p family member); activates 
glucose-repressed genes, represses glucose-induced genes; role in 
sporulation, and peroxisome biogenesis 
YCR033W SNT1 
Subunit of the Set3C deacetylase complex that interacts directly with the 
Set3C subunit, Sif2p; putative DNA-binding protein 
YPL057C SUR1 
Probable catalytic subunit of a mannosylinositol phosphorylceramide 
(MIPC) synthase, forms a complex with probable regulatory subunit 
Csg2p; function in sphingolipid biosynthesis is overlapping with that of 
Csh1p 
YBR175W SWD3 
Essential subunit of the COMPASS (Set1C) complex, which methylates 
histone H3 on lysine 4 and is required in transcriptional silencing near 
telomeres; WD40 beta propeller superfamily member and ortholog of 
mammalian WDR5 
YNL081C SWS2 
Putative mitochondrial ribosomal protein of the small subunit, has 
similarity to E. coli S13 ribosomal protein; participates in controlling 
sporulation efficiency 
YPR140W TAZ1 
Lyso-phosphatidylcholine acyltransferase, required for normal 
phospholipid content of mitochondrial membranes; may remodel acyl 
groups of cardiolipin in the inner membrane; human ortholog tafazzin is 
implicated in Barth syndrome 
   
 
 
 
YOL018C 
 
 
 
TLG2 
Syntaxin-like t-SNARE that forms a complex with Tlg1p and Vti1p and 
mediates fusion of endosome-derived vesicles with the late Golgi; binds 
Vps45p, which prevents Tlg2p degradation and also facilitates t-SNARE 
complex formation 
YDR074W TPS2 
Phosphatase subunit of the trehalose-6-phosphate synthase/phosphatase 
complex, which synthesizes the storage carbohydrate trehalose; 
expression is induced by stress conditions and repressed by the Ras-
cAMP pathway 
YER090W TRP2 
Anthranilate synthase, catalyzes the initial step of tryptophan 
biosynthesis, forms multifunctional hetero-oligomeric anthranilate 
synthase:indole-3-glycerol phosphate synthase enzyme complex with 
Trp3p 
YML028W TSA1 
Thioredoxin peroxidase, acts as both a ribosome-associated and free 
cytoplasmic antioxidant; self-associates to form a high-molecular weight 
chaperone complex under oxidative stress; deletion results in mutator 
phenotype 
YOR006C TSR3 
Putative protein of unknown function; green fluorescent protein (GFP)-
fusion protein localizes to both the cytoplasm and the nucleus 
YBR082C UBC4 
Ubiquitin-conjugating enzyme (E2), mediates degradation of abnormal or 
excess proteins, including calmodulin and histone H3; interacts with 
many SCF ubiquitin protein ligases; component of the cellular stress 
response 
YLL039C UBI4 
Ubiquitin, becomes conjugated to proteins, marking them for selective 
degradation via the ubiquitin-26S proteasome system; essential for the 
cellular stress response; encoded as a polyubiquitin precursor comprised 
of 5 head-to-tail repeats 
YER151C UBP3 
Ubiquitin-specific protease that interacts with Bre5p to co-regulate 
anterograde and retrograde transport between endoplasmic reticulum and 
Golgi compartments; inhibitor of gene silencing; cleaves ubiquitin 
fusions but not polyubiquitin 
YFR010W UBP6 
Ubiquitin-specific protease situated in the base subcomplex of the 26S 
proteasome, releases free ubiquitin from branched polyubiquitin chains; 
works in opposition to polyubiquitin elongation activity of Hul5p 
YLR386W VAC14 
Protein involved in regulated synthesis of PtdIns(3,5)P(2), in control of 
trafficking of some proteins to the vacuole lumen via the MVB, and in 
maintenance of vacuole size and acidity; interacts with Fig4p; activator of 
Fab1p 
YOR106W VAM3 
Syntaxin-related protein required for vacuolar assembly; functions with 
Vam7p in vacuolar protein trafficking; member of the syntaxin family of 
proteins 
YDL077C VAM6 
Vacuolar protein that plays a critical role in the tethering steps of 
vacuolar membrane fusion by facilitating guanine nucleotide exchange on 
small guanosine triphosphatase Ypt7p 
YGL212W VAM7 
Component of the vacuole SNARE complex involved in vacuolar 
morphogenesis; SNAP-25 homolog; functions with a syntaxin homolog 
Vam3p in vacuolar protein trafficking 
YLR373C VID22 
Glycosylated integral membrane protein localized to the plasma 
membrane; plays a role in fructose-1,6-bisphosphatase (FBPase) 
degradation; involved in FBPase transport from the cytosol to Vid 
(vacuole import and degradation) vesicles 
 
 
 
 
 
 
 
 
 
 
 
 
YOR089C 
 
 
 
VPS21 
GTPase required for transport during endocytosis and for correct sorting 
of vacuolar hydrolases; localized in endocytic intermediates; detected in 
mitochondria; geranylgeranylation required for membrane association; 
mammalian Rab5 homolog 
YKL041W VPS24 
One of four subunits of the endosomal sorting complex required for 
transport III (ESCRT-III); forms an ESCRT-III subcomplex with Did4p; 
involved in the sorting of transmembrane proteins into the multivesicular 
body (MVB) pathway 
YNR006W VPS27 
Endosomal protein that forms a complex with Hse1p; required for 
recycling Golgi proteins, forming lumenal membranes and sorting 
ubiquitinated proteins destined for degradation; has Ubiquitin Interaction 
Motifs which bind ubiquitin (Ubi4p) 
YPR173C VPS4 
AAA-ATPase involved in multivesicular body (MVB) protein sorting, 
ATP-bound Vps4p localizes to endosomes and catalyzes ESCRT-III 
disassembly and membrane release; ATPase activity is activated by 
Vta1p; regulates cellular sterol metabolism 
YDR080W VPS41 
Vacuolar membrane protein that is a subunit of the homotypic vacuole 
fusion and vacuole protein sorting (HOPS) complex; essential for 
membrane docking and fusion at the Golgi-to-endosome and endosome-
to-vacuole stages of protein transport 
YKR020W VPS51 
Component of the GARP (Golgi-associated retrograde protein) complex, 
Vps51p-Vps52p-Vps53p-Vps54p, which is required for the recycling of 
proteins from endosomes to the late Golgi; links the (VFT/GARP) 
complex to the SNARE Tlg1p 
YJL029C VPS53 
Component of the GARP (Golgi-associated retrograde protein) complex, 
Vps51p-Vps52p-Vps53p-Vps54p, which is required for the recycling of 
proteins from endosomes to the late Golgi; required for vacuolar protein 
sorting 
YDR372C VPS74 
Protein required for Golgi localization of glycosyltransferases; binds the 
cytosolic domains of Golgi glycosyltransferases; functions as a 
heterotetramer 
YML097C VPS9 
A guanine nucleotide exchange factor involved in vesicle-mediated 
vacuolar protein transport; specifically stimulates the intrinsic guanine 
nucleotide exchange activity of Vps21p/Rab5: similar to mammalian ras 
inhibitors; binds ubiquitin 
YLR337C VRP1 
Proline-rich actin-associated protein involved in cytoskeletal organization 
and cytokinesis; related to mammalian Wiskott-Aldrich syndrome protein 
(WASP)-interacting protein (WIP) 
YOR043W WHI2 
Protein required, with binding partner Psr1p, for full activation of the 
general stress response, possibly through Msn2p dephosphorylation; 
regulates growth during the diauxic shift; negative regulator of G1 cyclin 
expression 
YGR281W YOR1 
Plasma membrane ATP-binding cassette (ABC) transporter, multidrug 
transporter mediates export of many different organic anions including 
oligomycin; similar to human cystic fibrosis transmembrane receptor 
(CFTR) 
YBR111C YSA1 
Nudix hydrolase family member with ADP-ribose pyrophosphatase 
activity; shown to metabolize O-acetyl-ADP-ribose to AMP and 
acetylated ribose 5'-phosphate 
YGR270W YTA7 
Protein that localizes to chromatin and has a role in regulation of histone 
gene expression; has a bromodomain-like region that interacts with the N-
terminal tail of histone H3, and an ATPase domain; potentially 
phosphorylated by Cdc28p 
YMR294W-A   
Dubious open reading frame unlikely to encode a functional protein, 
substantially overlaps YMR295C; deletion causes sensitivity to unfolded 
protein response-inducing agents 
YOR062C   
Protein of unknown function; similar to YKR075Cp and Reg1p; 
expression regulated by glucose and Rgt1p; GFP-fusion protein is 
induced in response to the DNA-damaging agent MMS 
YHR078W   High osmolarity-regulated gene of unknown function 
YNL296W   
Dubious open reading frame unlikely to encode a functional protein; 
deletion adversely affects sporulation; deletion mutant exhibits synthetic 
phenotype under expression of mutant huntingtin fragment, but gene does 
not have human ortholog 
YPL041C   
Protein of unknown function involved in maintenance of proper telomere 
length 
YOR024W   
Dubious open reading frame unlikely to encode a protein, based on 
available experimental and comparative sequence data 
YGL081W   
Putative protein of unknown function; non-essential gene; interacts 
genetically with CHS5, a gene involved in chitin biosynthesis 
YJL175W   
Dubious open reading frame unlikely to encode a functional protein; 
deletion confers resistance to cisplatin, hypersensitivity to 5-fluorouracil, 
and growth defect at high pH with high calcium; overlaps gene for SWI3 
transcription factor 
YMR295C   
Protein of unknown function that associates with ribosomes; green 
fluorescent protein (GFP)-fusion protein localizes to the cell periphery 
and bud; YMR295C is not an essential gene 
YGR122W   
Probable ortholog of A. nidulans PalC, which is involved in pH 
regulation and binds to the ESCRT-III complex; null mutant does not 
properly process Rim101p and has decreased resistance to rapamycin; 
GFP-fusion protein is cytoplasmic 
YDR186C   
Putative protein of unknown function; may interact with ribosomes, 
based on co-purification experiments; green fluorescent protein (GFP)-
fusion protein localizes to the cytoplasm 
YLR255C   
Dubious ORF unlikely to encode a functional protein, based on available 
experimental and comparative sequence data 
YDR199W   
Dubious open reading frame unlikely to encode a protein, based on 
available experimental and comparative sequence data; partially overlaps 
the verified gene VPS64; computationally predicted to have thiol-
disulfide oxidoreductase activity 
YER119C-A   
Dubious open reading frame, not conserved in closely related 
Saccharomyces species; deletion mutation blocks replication of Brome 
mosaic virus in S. cerevisiae, but this is likely due to effects on the 
overlapping gene SCS2 
YNR071C   Putative protein of unknown function 
YBL062W   
Dubious open reading frame unlikely to encode a protein, based on 
available experimental and comparative sequence data 
YCL042W   
Putative protein of unknown function; epitope-tagged protein localizes to 
the cytoplasm 
YOL013W-A   Putative protein of unknown function; identified by SAGE 
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YDL243C AAD4 
Putative aryl-alcohol dehydrogenase with similarity to P. chrysosporium 
aryl-alcohol dehydrogenase, involved in the oxidative stress response; 
expression induced in cells treated with the mycotoxin patulin 
YGL256W ADH4 
Alcohol dehydrogenase isoenzyme type IV, dimeric enzyme demonstrated 
to be zinc-dependent despite sequence similarity to iron-activated alcohol 
dehydrogenases; transcription is induced in response to zinc deficiency 
YCL025C AGP1 
Low-affinity amino acid permease with broad substrate range, involved in 
uptake of asparagine, glutamine, and other amino acids; expression is 
regulated by the SPS plasma membrane amino acid sensor system (Ssy1p-
Ptr3p-Ssy5p) 
YMR003W AIM34 
Protein of unknown function; GFP-fusion protein localizes to the 
mitochondria; null mutant is viable and displays reduced frequency of 
mitochondrial genome loss 
YHR126C ANS1 Putative protein of unknown function; transcription dependent upon Azf1p 
YLR370C ARC18 
Subunit of the ARP2/3 complex, which is required for the motility and 
integrity of cortical actin patches 
YHL040C ARN1 
Transporter, member of the ARN family of transporters that specifically 
recognize siderophore-iron chelates; responsible for uptake of iron bound to 
ferrirubin, ferrirhodin, and related siderophores 
YDL074C BRE1 
E3 ubiquitin ligase, forms heterodimer with Rad6p to monoubiquinate 
histone H2B-K123, which is required for the subsequent methylation of 
histone H3-K4 and H3-K79; required for DSBR, transcription, silencing, 
and checkpoint control 
YNR051C BRE5 
Ubiquitin protease cofactor, forms deubiquitination complex with Ubp3p 
that coregulates anterograde and retrograde transport between the 
endoplasmic reticulum and Golgi compartments; null is sensitive to 
brefeldin A 
YBR131W CCZ1 
Protein involved in vacuolar assembly, essential for autophagy and the 
cytoplasm-to-vacuole pathway 
YER164W CHD1 
Nucleosome remodeling factor that functions in regulation of transcription 
elongation; contains a chromo domain, a helicase domain and a DNA-
binding domain; component of both the SAGA and SLIK complexes 
YDL155W CLB3 
B-type cyclin involved in cell cycle progression; activates Cdc28p to 
promote the G2/M transition; may be involved in DNA replication and 
spindle assembly; accumulates during S phase and G2, then targeted for 
ubiquitin-mediated degradation 
YPL256C CLN2 
G1 cyclin involved in regulation of the cell cycle; activates Cdc28p kinase 
to promote the G1 to S phase transition; late G1 specific expression depends 
on transcription factor complexes, MBF (Swi6p-Mbp1p) and SBF (Swi6p-
Swi4p) 
YML071C COG8 
Component of the conserved oligomeric Golgi complex (Cog1p through 
Cog8p), a cytosolic tethering complex that functions in protein trafficking 
to mediate fusion of transport vesicles to Golgi compartments 
YML129C COX14 
Mitochondrial membrane protein, involved in translational regulation of 
Cox1p and assembly of cytochrome c oxidase (complex IV); associates 
with complex IV assembly intermediates and complex III/complex IV 
supercomplexes 
YIR023W DAL81 
Positive regulator of genes in multiple nitrogen degradation pathways; 
contains DNA binding domain but does not appear to bind the 
dodecanucleotide sequence present in the promoter region of many genes 
involved in allantoin catabolism 
YKR024C DBP7 
Putative ATP-dependent RNA helicase of the DEAD-box family involved 
in ribosomal biogenesis; essential for growth under anaerobic conditions 
YOR030W DFG16 
Probable multiple transmembrane protein, involved in diploid invasive and 
pseudohyphal growth upon nitrogen starvation; required for accumulation 
of processed Rim101p 
YOR245C DGA1 
Diacylglycerol acyltransferase, catalyzes the terminal step of triacylglycerol 
(TAG) formation, acylates diacylglycerol using acyl-CoA as an acyl donor, 
localized to lipid particles 
YKL213C DOA1 
WD repeat protein required for ubiquitin-mediated protein degradation, 
forms complex with Cdc48p, plays a role in controlling cellular ubiquitin 
concentration; also promotes efficient NHEJ in postdiauxic/stationary phase 
YDR440W DOT1 
Nucleosomal histone H3-Lys79 methylase; methylation is required for 
telomeric silencing, meiotic checkpoint control, and DNA damage response 
YKL191W DPH2 
Protein required, along with Dph1p, Kti11p, Jjj3p, and Dph5p, for synthesis 
of diphthamide, which is a modified histidine residue of translation 
elongation factor 2 (Eft1p or Eft2p); may act in a complex with Dph1p and 
Kti11p 
YBR078W ECM33 
GPI-anchored protein of unknown function, has a possible role in apical 
bud growth; GPI-anchoring on the plasma membrane crucial to function; 
phosphorylated in mitochondria; similar to Sps2p and Pst1p 
YBL047C EDE1 
Key endocytic protein involved in a network of interactions with other 
endocytic proteins, binds membranes in a ubiquitin-dependent manner, may 
also bind ubiquitinated membrane-associated proteins 
YMR202W ERG2 
C-8 sterol isomerase, catalyzes the isomerization of the delta-8 double bond 
to the delta-7 position at an intermediate step in ergosterol biosynthesis 
YLR056W ERG3 
C-5 sterol desaturase, catalyzes the introduction of a C-5(6) double bond 
into episterol, a precursor in ergosterol biosynthesis; mutants are viable, but 
cannot grow on non-fermentable carbon sources 
YML008C ERG6 
Delta(24)-sterol C-methyltransferase, converts zymosterol to fecosterol in 
the ergosterol biosynthetic pathway by methylating position C-24; localized 
to both lipid particles and mitochondrial outer membrane 
YBR041W FAT1 
Fatty acid transporter and very long-chain fatty acyl-CoA synthetase, may 
form a complex with Faa1p or Faa4p that imports and activates exogenous 
fatty acids 
YBR019C GAL10 
UDP-glucose-4-epimerase, catalyzes the interconversion of UDP-galactose 
and UDP-D-glucose in galactose metabolism; also catalyzes the conversion 
of alpha-D-glucose or alpha-D-galactose to their beta-anomers 
YMR307W GAS1 
Beta-1,3-glucanosyltransferase, required for cell wall assembly and also has 
a role in transcriptional silencing; localizes to the cell surface via a 
glycosylphosphatidylinositol (GPI) anchor; also found at the nuclear 
periphery 
YGL020C GET1 
Subunit of the GET complex; involved in insertion of proteins into the ER 
membrane; required for the retrieval of HDEL proteins from the Golgi to 
the ER in an ERD2 dependent fashion and for normal mitochondrial 
morphology and inheritance 
YER083C GET2 
Subunit of the GET complex; involved in insertion of proteins into the ER 
membrane; required for the retrieval of HDEL proteins from the Golgi to 
the ER in an ERD2 dependent fashion and for meiotic nuclear division 
YDR508C GNP1 
High-affinity glutamine permease, also transports Leu, Ser, Thr, Cys, Met 
and Asn; expression is fully dependent on Grr1p and modulated by the 
Ssy1p-Ptr3p-Ssy5p (SPS) sensor of extracellular amino acids 
YER020W GPA2 
Nucleotide binding alpha subunit of the heterotrimeric G protein that 
interacts with the receptor Gpr1p, has signaling role in response to 
nutrients; green fluorescent protein (GFP)-fusion protein localizes to the 
cell periphery 
YJL101C GSH1 
Gamma glutamylcysteine synthetase catalyzes the first step in glutathione 
(GSH) biosynthesis; expression induced by oxidants, cadmium, and 
mercury 
YOL049W GSH2 
Glutathione synthetase, catalyzes the ATP-dependent synthesis of 
glutathione (GSH) from gamma-glutamylcysteine and glycine; induced by 
oxidative stress and heat shock 
YGL084C GUP1 
Plasma membrane protein involved in remodeling GPI anchors; member of 
the MBOAT family of putative membrane-bound O-acyltransferases; 
proposed to be involved in glycerol transport 
YGR223C HSV2 
Phosphatidylinositol 3,5-bisphosphate-binding protein, plays a role in 
micronucleophagy; predicted to fold as a seven-bladed beta-propeller; 
displays punctate cytoplasmic localization 
YJR118C ILM1 
Protein of unknown function; may be involved in mitochondrial DNA 
maintenance; required for slowed DNA synthesis-induced filamentous 
growth 
YOL081W IRA2 
GTPase-activating protein that negatively regulates RAS by converting it 
from the GTP- to the GDP-bound inactive form, required for reducing 
cAMP levels under nutrient limiting conditions, has similarity to Ira1p and 
human neurofibromin 
 
YER019W 
 
ISC1 
 
Mitochondrial membrane localized inositol phosphosphingolipid 
phospholipase C, hydrolyzes complex sphingolipids to produce ceramide; 
activated by phosphatidylserine, cardiolipin, and phosphatidylglycerol; 
mediates Na+ and Li+ halotolerance 
YKL032C IXR1 
Protein that binds DNA containing intrastrand cross-links formed by 
cisplatin, contains two HMG (high mobility group box) domains, which 
confer the ability to bend cisplatin-modified DNA; mediates aerobic 
transcriptional repression of COX5b 
YJL062W LAS21 
Integral plasma membrane protein involved in the synthesis of the 
glycosylphosphatidylinositol (GPI) core structure; mutations affect cell wall 
integrity 
YHR121W LSM12 
Protein of unknown function that may function in RNA processing; 
interacts with Pbp1p and Pbp4p and associates with ribosomes; contains an 
RNA-binding LSM domain and an AD domain; GFP-fusion protein is 
induced by the DNA-damaging agent MMS 
YPR070W MED1 
Subunit of the RNA polymerase II mediator complex; associates with core 
polymerase subunits to form the RNA polymerase II holoenzyme; essential 
for transcriptional regulation 
 
 
 
 
 
 
 
 
YNL076W 
 
 
MKS1 
Pleiotropic negative transcriptional regulator involved in Ras-CAMP and 
lysine biosynthetic pathways and nitrogen regulation; involved in retrograde 
(RTG) mitochondria-to-nucleus signaling 
YGL124C MON1 
Protein required for fusion of cvt-vesicles and autophagosomes with the 
vacuole; associates, as a complex with Ccz1p, with a perivacuolar 
compartment; potential Cdc28p substrate 
YNL297C MON2 
Peripheral membrane protein with a role in endocytosis and vacuole 
integrity, interacts with Arl1p and localizes to the endosome; member of the 
Sec7p family of proteins 
YMR224C MRE11 
Subunit of a complex with Rad50p and Xrs2p (MRX complex) that 
functions in repair of DNA double-strand breaks and in telomere stability, 
exhibits nuclease activity that appears to be required for MRX function; 
widely conserved 
YKL009W MRT4 
Protein involved in mRNA turnover and ribosome assembly, localizes to the 
nucleolus 
YHR004C NEM1 
Probable catalytic subunit of Nem1p-Spo7p phosphatase holoenzyme; 
regulates nuclear growth by controlling phospholipid biosynthesis, required 
for normal nuclear envelope morphology and sporulation; homolog of the 
human protein Dullard 
YGL151W NUT1 
Component of the RNA polymerase II mediator complex, which is required 
for transcriptional activation and also has a role in basal transcription 
YLR338W OPI9 
Dubious open reading frame unlikely to encode a protein, based on 
available experimental and comparative sequence data; partially overlaps 
the verified ORF VRP1/YLR337C 
YDL232W OST4 
Subunit of the oligosaccharyltransferase complex of the ER lumen, which 
catalyzes protein asparagine-linked glycosylation; type I membrane protein 
required for incorporation of Ost3p or Ost6p into the OST complex 
YOR360C PDE2 
High-affinity cyclic AMP phosphodiesterase, component of the cAMP-
dependent protein kinase signaling system, protects the cell from 
extracellular cAMP, contains readthrough motif surrounding termination 
codon 
YOR153W PDR5 
Plasma membrane ATP-binding cassette (ABC) transporter, multidrug 
transporter actively regulated by Pdr1p; also involved in steroid transport, 
cation resistance, and cellular detoxification during exponential growth 
YER149C PEA2 
Coiled-coil polarisome protein required for polarized morphogenesis, cell 
fusion, and low affinity Ca2+ influx; forms polarisome complex with 
Bni1p, Bud6p, and Spa2p; localizes to sites of polarized growth 
YNL003C PET8 
S-adenosylmethionine transporter of the mitochondrial inner membrane, 
member of the mitochondrial carrier family; required for biotin biosynthesis 
and respiratory growth 
YDR244W PEX5 
Peroxisomal membrane signal receptor for the C-terminal tripeptide signal 
sequence (PTS1) of peroxisomal matrix proteins, required for peroxisomal 
matrix protein import; also proposed to have PTS1-receptor independent 
functions 
YMR205C PFK2 
Beta subunit of heterooctameric phosphofructokinase involved in 
glycolysis, indispensable for anaerobic growth, activated by fructose-2,6-
bisphosphate and AMP, mutation inhibits glucose induction of cell cycle-
related genes 
   
 
 
 
YDR276C 
 
 
 
PMP3 
Small plasma membrane protein related to a family of plant polypeptides 
that are overexpressed under high salt concentration or low temperature, not 
essential for viability, deletion causes hyperpolarization of the plasma 
membrane potential 
YAL023C PMT2 
Protein O-mannosyltransferase, transfers mannose residues from dolichyl 
phosphate-D-mannose to protein serine/threonine residues; acts in a 
complex with Pmt1p, can instead interact with Pmt5p in some conditions; 
target for new antifungals 
YDR314C RAD34 Protein involved in nucleotide excision repair (NER); homologous to RAD4 
YMR274C RCE1 
Type II CAAX prenyl protease involved in the proteolysis and maturation 
of Ras and the a-factor mating pheromone 
YMR154C RIM13 
Calpain-like cysteine protease involved in proteolytic activation of 
Rim101p in response to alkaline pH; has similarity to A. nidulans palB 
YFL033C RIM15 
Glucose-repressible protein kinase involved in signal transduction during 
cell proliferation in response to nutrients, specifically the establishment of 
stationary phase; identified as a regulator of IME2; substrate of Pho80p-
Pho85p kinase 
YOR275C RIM20 
Protein involved in proteolytic activation of Rim101p in response to 
alkaline pH; PalA/AIP1/Alix family member; interaction with the ESCRT-
III subunit Snf7p suggests a relationship between pH response and 
multivesicular body formation 
YNL294C RIM21 
Component of the RIM101 pathway, has a role in cell wall construction and 
alkaline pH response; has similarity to A. nidulans PalH 
YMR063W RIM9 
Protein of unknown function, involved in the proteolytic activation of 
Rim101p in response to alkaline pH; has similarity to A. nidulans PalI; 
putative membrane protein 
YBR246W RRT2 
Putative protein of unknown function; non-essential gene identified in a 
screen for mutants with increased levels of rDNA transcription; null 
mutants display a weak carboxypeptidase Y missorting/secretion phenotype 
 
 
YGL244W 
 
 
RTF1 
 
 
Subunit of the RNA polymerase II-associated Paf1 complex; directly or 
indirectly regulates DNA-binding properties of Spt15p and relative 
activities of different TATA elements; involved in telomere maintenance 
YOR216C RUD3 
Golgi matrix protein involved in the structural organization of the cis-Golgi; 
interacts genetically with COG3 and USO1 
YCR009C RVS161 
Amphiphysin-like lipid raft protein; interacts with Rvs167p and regulates 
polarization of the actin cytoskeleton, endocytosis, cell polarity, cell fusion 
and viability following starvation or osmotic stress 
YDR388W RVS167 
Actin-associated protein, interacts with Rvs161p to regulate actin 
cytoskeleton, endocytosis, and viability following starvation or osmotic 
stress; homolog of mammalian amphiphysin 
YDR469W SDC1 
Subunit of the COMPASS (Set1C) complex, which methylates lysine 4 of 
histone H3 and is required in chromatin silencing at telomeres; contains a 
Dpy-30 domain that mediates interaction with Bre2p; similar to C. elegans 
and human DPY-30 
 
 
 
 
 
 
 
 
 
 
 
 
YBR171W 
 
 
 
SEC66 
Non-essential subunit of Sec63 complex (Sec63p, Sec62p, Sec66p and 
Sec72p); with Sec61 complex, Kar2p/BiP and Lhs1p forms a channel 
competent for SRP-dependent and post-translational SRP-independent 
protein targeting and import into the ER 
YOR140W SFL1 
Transcriptional repressor and activator; involved in repression of 
flocculation-related genes, and activation of stress responsive genes; 
negatively regulated by cAMP-dependent protein kinase A subunit Tpk2p 
YCL010C SGF29 Probable subunit of SAGA histone acetyltransferase complex 
YBR077C SLM4 
Component of the EGO complex, which is involved in the regulation of 
microautophagy, and of the GSE complex, which is required for proper 
sorting of amino acid permease Gap1p; gene exhibits synthetic genetic 
interaction with MSS4 
YDR477W SNF1 
AMP-activated serine/threonine protein kinase found in a complex 
containing Snf4p and members of the Sip1p/Sip2p/Gal83p family; required 
for transcription of glucose-repressed genes, thermotolerance, sporulation, 
and peroxisome biogenesis 
YGL115W SNF4 
Activating gamma subunit of the AMP-activated Snf1p kinase complex 
(contains Snf1p and a Sip1p/Sip2p/Gal83p family member); activates 
glucose-repressed genes, represses glucose-induced genes; role in 
sporulation, and peroxisome biogenesis 
YCR033W SNT1 
Subunit of the Set3C deacetylase complex that interacts directly with the 
Set3C subunit, Sif2p; putative DNA-binding protein 
YCL037C SRO9 
Cytoplasmic RNA-binding protein that associates with translating 
ribosomes; involved in heme regulation of Hap1p as a component of the 
HMC complex, also involved in the organization of actin filaments; 
contains a La motif 
YDR310C SUM1 
Transcriptional repressor required for mitotic repression of middle 
sporulation-specific genes; also acts as general replication initiation factor; 
involved in telomere maintenance, chromatin silencing; regulated by 
pachytene checkpoint 
YPL057C SUR1 
Probable catalytic subunit of a mannosylinositol phosphorylceramide 
(MIPC) synthase, forms a complex with probable regulatory subunit Csg2p; 
function in sphingolipid biosynthesis is overlapping with that of Csh1p 
YDR297W SUR2 
Sphinganine C4-hydroxylase, catalyses the conversion of sphinganine to 
phytosphingosine in sphingolipid biosyntheis 
YAR042W SWH1 
Protein similar to mammalian oxysterol-binding protein; contains ankyrin 
repeats; localizes to the Golgi and the nucleus-vacuole junction 
YLR182W SWI6 
Transcription cofactor, forms complexes with DNA-binding proteins Swi4p 
and Mbp1p to regulate transcription at the G1/S transition; involved in 
meiotic gene expression; localization regulated by phosphorylation; 
potential Cdc28p substrate 
YNL081C SWS2 
Putative mitochondrial ribosomal protein of the small subunit, has similarity 
to E. coli S13 ribosomal protein; participates in controlling sporulation 
efficiency 
YOL018C TLG2 
Syntaxin-like t-SNARE that forms a complex with Tlg1p and Vti1p and 
mediates fusion of endosome-derived vesicles with the late Golgi; binds 
Vps45p, which prevents Tlg2p degradation and also facilitates t-SNARE 
complex formation 
   
 
 
 
YNL079C 
 
 
 
TPM1 
Major isoform of tropomyosin; binds to and stabilizes actin cables and 
filaments, which direct polarized cell growth and the distribution of several 
organelles; acetylated by the NatB complex and acetylated form binds actin 
most efficiently 
YML028W TSA1 
Thioredoxin peroxidase, acts as both a ribosome-associated and free 
cytoplasmic antioxidant; self-associates to form a high-molecular weight 
chaperone complex under oxidative stress; deletion results in mutator 
phenotype 
YOR006C TSR3 
Putative protein of unknown function; green fluorescent protein (GFP)-
fusion protein localizes to both the cytoplasm and the nucleus 
YLL039C UBI4 
Ubiquitin, becomes conjugated to proteins, marking them for selective 
degradation via the ubiquitin-26S proteasome system; essential for the 
cellular stress response; encoded as a polyubiquitin precursor comprised of 
5 head-to-tail repeats 
YER151C UBP3 
Ubiquitin-specific protease that interacts with Bre5p to co-regulate 
anterograde and retrograde transport between endoplasmic reticulum and 
Golgi compartments; inhibitor of gene silencing; cleaves ubiquitin fusions 
but not polyubiquitin 
YFR010W UBP6 
Ubiquitin-specific protease situated in the base subcomplex of the 26S 
proteasome, releases free ubiquitin from branched polyubiquitin chains; 
works in opposition to polyubiquitin elongation activity of Hul5p 
YNL229C URE2 
Nitrogen catabolite repression transcriptional regulator that acts by 
inhibition of GLN3 transcription in good nitrogen source; has glutathione 
peroxidase activity and can mutate to acquire GST activity; altered form 
creates [URE3] prion 
YOR106W VAM3 
Syntaxin-related protein required for vacuolar assembly; functions with 
Vam7p in vacuolar protein trafficking; member of the syntaxin family of 
proteins 
YDL077C VAM6 
Vacuolar protein that plays a critical role in the tethering steps of vacuolar 
membrane fusion by facilitating guanine nucleotide exchange on small 
guanosine triphosphatase Ypt7p 
YHL035C VMR1 
Protein of unknown function that may interact with ribosomes, based on co-
purification experiments; member of the ATP-binding cassette (ABC) 
family; potential Cdc28p substrate; detected in purified mitochondria in 
high-throughput studies 
YKR001C VPS1 
Dynamin-like GTPase required for vacuolar sorting; also involved in actin 
cytoskeleton organization, late Golgi-retention of some proteins, regulating 
peroxisome biogenesis 
YOR089C VPS21 
GTPase required for transport during endocytosis and for correct sorting of 
vacuolar hydrolases; localized in endocytic intermediates; detected in 
mitochondria; geranylgeranylation required for membrane association; 
mammalian Rab5 homolog 
YKL041W VPS24 
One of four subunits of the endosomal sorting complex required for 
transport III (ESCRT-III); forms an ESCRT-III subcomplex with Did4p; 
involved in the sorting of transmembrane proteins into the multivesicular 
body (MVB) pathway 
YNR006W VPS27 
Endosomal protein that forms a complex with Hse1p; required for recycling 
Golgi proteins, forming lumenal membranes and sorting ubiquitinated 
proteins destined for degradation; has Ubiquitin Interaction Motifs which 
bind ubiquitin (Ubi4p) 
YPR173C VPS4 
AAA-ATPase involved in multivesicular body (MVB) protein sorting, 
ATP-bound Vps4p localizes to endosomes and catalyzes ESCRT-III 
disassembly and membrane release; ATPase activity is activated by Vta1p; 
regulates cellular sterol metabolism 
YDR080W VPS41 
Vacuolar membrane protein that is a subunit of the homotypic vacuole 
fusion and vacuole protein sorting (HOPS) complex; essential for 
membrane docking and fusion at the Golgi-to-endosome and endosome-to-
vacuole stages of protein transport 
YKR020W VPS51 
Component of the GARP (Golgi-associated retrograde protein) complex, 
Vps51p-Vps52p-Vps53p-Vps54p, which is required for the recycling of 
proteins from endosomes to the late Golgi; links the (VFT/GARP) complex 
to the SNARE Tlg1p 
YJL029C VPS53 
Component of the GARP (Golgi-associated retrograde protein) complex, 
Vps51p-Vps52p-Vps53p-Vps54p, which is required for the recycling of 
proteins from endosomes to the late Golgi; required for vacuolar protein 
sorting 
YAL002W VPS8 
Membrane-associated protein that interacts with Vps21p to facilitate soluble 
vacuolar protein localization; component of the CORVET complex; 
required for localization and trafficking of the CPY sorting receptor; 
contains RING finger motif 
YOR043W WHI2 
Protein required, with binding partner Psr1p, for full activation of the 
general stress response, possibly through Msn2p dephosphorylation; 
regulates growth during the diauxic shift; negative regulator of G1 cyclin 
expression 
YML001W YPT7 
GTPase; GTP-binding protein of the rab family; required for homotypic 
fusion event in vacuole inheritance, for endosome-endosome fusion, similar 
to mammalian Rab7 
YMR294W-
A   
Dubious open reading frame unlikely to encode a functional protein, 
substantially overlaps YMR295C; deletion causes sensitivity to unfolded 
protein response-inducing agents 
YOR062C   
Protein of unknown function; similar to YKR075Cp and Reg1p; expression 
regulated by glucose and Rgt1p; GFP-fusion protein is induced in response 
to the DNA-damaging agent MMS 
 
 
YNL296W   
 
 
Dubious open reading frame unlikely to encode a functional protein; 
deletion adversely affects sporulation; deletion mutant exhibits synthetic 
phenotype under expression of mutant huntingtin fragment, but gene does 
not have human ortholog 
YGR250C   
Putative RNA binding protein; localizes to stress granules induced by 
glucose deprivation; interacts with Rbg1p in a two-hybrid 
YLR374C   
Dubious open reading frame unlikely to encode a protein, based on 
available experimental and comparative sequence data; partially overlaps 
the uncharacterized ORF STP3/YLR375W 
YMR295C   
Protein of unknown function that associates with ribosomes; green 
fluorescent protein (GFP)-fusion protein localizes to the cell periphery and 
bud; YMR295C is not an essential gene 
YDR186C   
Putative protein of unknown function; may interact with ribosomes, based 
on co-purification experiments; green fluorescent protein (GFP)-fusion 
protein localizes to the cytoplasm 
YDR199W   
Dubious open reading frame unlikely to encode a protein, based on 
available experimental and comparative sequence data; partially overlaps 
the verified gene VPS64; computationally predicted to have thiol-disulfide 
oxidoreductase activity 
YNR071C   Putative protein of unknown function 
YOR059C   Hypothetical protein 
YCL042W   
Putative protein of unknown function; epitope-tagged protein localizes to 
the cytoplasm 
YOL013W-
A   Putative protein of unknown function; identified by SAGE 
YML012C-
A   
Dubious open reading frame unlikely to encode a protein, based on 
available experimental and comparative sequence data; partially overlaps 
the verified gene SEL1 
 
 
Table B.6: Lovastatin + Δhmg2 Δxxx PE interactions 
YDL243C AAD4 
Putative aryl-alcohol dehydrogenase with similarity to P. chrysosporium 
aryl-alcohol dehydrogenase, involved in the oxidative stress response; 
expression induced in cells treated with the mycotoxin patulin 
YMR282C AEP2 
Mitochondrial protein, likely involved in translation of the mitochondrial 
OLI1 mRNA; exhibits genetic interaction with the OLI1 mRNA 5'-
untranslated leader 
YCL025C AGP1 
Low-affinity amino acid permease with broad substrate range, involved in 
uptake of asparagine, glutamine, and other amino acids; expression is 
regulated by the SPS plasma membrane amino acid sensor system (Ssy1p-
Ptr3p-Ssy5p) 
YMR003W AIM34 
Protein of unknown function; GFP-fusion protein localizes to the 
mitochondria; null mutant is viable and displays reduced frequency of 
mitochondrial genome loss 
YHR126C ANS1 Putative protein of unknown function; transcription dependent upon Azf1p 
YDL074C BRE1 
E3 ubiquitin ligase, forms heterodimer with Rad6p to monoubiquinate 
histone H2B-K123, which is required for the subsequent methylation of 
histone H3-K4 and H3-K79; required for DSBR, transcription, silencing, 
and checkpoint control 
YBR131W CCZ1 
Protein involved in vacuolar assembly, essential for autophagy and the 
cytoplasm-to-vacuole pathway 
 
YER164W 
 
CHD1 
 
Nucleosome remodeling factor that functions in regulation of transcription 
elongation; contains a chromo domain, a helicase domain and a DNA-
binding domain; component of both the SAGA and SLIK complexes 
YBR023C CHS3 
Chitin synthase III, catalyzes the transfer of N-acetylglucosamine (GlcNAc) 
to chitin; required for synthesis of the majority of cell wall chitin, the chitin 
ring during bud emergence, and spore wall chitosan 
YDL155W CLB3 
B-type cyclin involved in cell cycle progression; activates Cdc28p to 
promote the G2/M transition; may be involved in DNA replication and 
spindle assembly; accumulates during S phase and G2, then targeted for 
ubiquitin-mediated degradation 
YLR087C CSF1 
Protein required for fermentation at low temperature; the authentic, non-
tagged protein is detected in highly purified mitochondria in high-
throughput studies 
YCR017C CWH43 
Putative sensor/transporter protein involved in cell wall biogenesis; contains 
14-16 transmembrane segments and several putative glycosylation and 
phosphorylation sites; null mutation is synthetically lethal with pkc1 
deletion 
YIR023W DAL81 
Positive regulator of genes in multiple nitrogen degradation pathways; 
contains DNA binding domain but does not appear to bind the 
dodecanucleotide sequence present in the promoter region of many genes 
involved in allantoin catabolism 
YKR024C DBP7 
Putative ATP-dependent RNA helicase of the DEAD-box family involved 
in ribosomal biogenesis; essential for growth under anaerobic conditions 
YAL013W DEP1 
Transcriptional modulator involved in regulation of structural phospholipid 
biosynthesis genes and metabolically unrelated genes, as well as 
maintenance of telomeres, mating efficiency, and sporulation 
YOR245C DGA1 
Diacylglycerol acyltransferase, catalyzes the terminal step of triacylglycerol 
(TAG) formation, acylates diacylglycerol using acyl-CoA as an acyl donor, 
localized to lipid particles 
YKL213C DOA1 
WD repeat protein required for ubiquitin-mediated protein degradation, 
forms complex with Cdc48p, plays a role in controlling cellular ubiquitin 
concentration; also promotes efficient NHEJ in postdiauxic/stationary phase 
YBR078W ECM33 
GPI-anchored protein of unknown function, has a possible role in apical bud 
growth; GPI-anchoring on the plasma membrane crucial to function; 
phosphorylated in mitochondria; similar to Sps2p and Pst1p 
YDR414C ERD1 
Predicted membrane protein required for the retention of lumenal 
endoplasmic reticulum proteins; mutants secrete the endogenous ER 
protein, BiP (Kar2p) 
YMR202W ERG2 
C-8 sterol isomerase, catalyzes the isomerization of the delta-8 double bond 
to the delta-7 position at an intermediate step in ergosterol biosynthesis 
YLR056W ERG3 
C-5 sterol desaturase, catalyzes the introduction of a C-5(6) double bond 
into episterol, a precursor in ergosterol biosynthesis; mutants are viable, but 
cannot grow on non-fermentable carbon sources 
YML008C ERG6 
Delta(24)-sterol C-methyltransferase, converts zymosterol to fecosterol in 
the ergosterol biosynthetic pathway by methylating position C-24; localized 
to both lipid particles and mitochondrial outer membrane 
 
 
YBR041W 
 
 
FAT1 
Fatty acid transporter and very long-chain fatty acyl-CoA synthetase, may 
form a complex with Faa1p or Faa4p that imports and activates exogenous 
fatty acids 
YBR019C GAL10 
UDP-glucose-4-epimerase, catalyzes the interconversion of UDP-galactose 
and UDP-D-glucose in galactose metabolism; also catalyzes the conversion 
of alpha-D-glucose or alpha-D-galactose to their beta-anomers 
YMR307W GAS1 
Beta-1,3-glucanosyltransferase, required for cell wall assembly and also has 
a role in transcriptional silencing; localizes to the cell surface via a 
glycosylphosphatidylinositol (GPI) anchor; also found at the nuclear 
periphery 
YGL020C GET1 
Subunit of the GET complex; involved in insertion of proteins into the ER 
membrane; required for the retrieval of HDEL proteins from the Golgi to 
the ER in an ERD2 dependent fashion and for normal mitochondrial 
morphology and inheritance 
YER083C GET2 
Subunit of the GET complex; involved in insertion of proteins into the ER 
membrane; required for the retrieval of HDEL proteins from the Golgi to 
the ER in an ERD2 dependent fashion and for meiotic nuclear division 
YDR508C GNP1 
High-affinity glutamine permease, also transports Leu, Ser, Thr, Cys, Met 
and Asn; expression is fully dependent on Grr1p and modulated by the 
Ssy1p-Ptr3p-Ssy5p (SPS) sensor of extracellular amino acids 
YJL101C GSH1 
Gamma glutamylcysteine synthetase catalyzes the first step in glutathione 
(GSH) biosynthesis; expression induced by oxidants, cadmium, and 
mercury 
YOL049W GSH2 
Glutathione synthetase, catalyzes the ATP-dependent synthesis of 
glutathione (GSH) from gamma-glutamylcysteine and glycine; induced by 
oxidative stress and heat shock 
YGL084C GUP1 
Plasma membrane protein involved in remodeling GPI anchors; member of 
the MBOAT family of putative membrane-bound O-acyltransferases; 
proposed to be involved in glycerol transport 
YOR038C HIR2 
Subunit of the HIR complex, a nucleosome assembly complex involved in 
regulation of histone gene transcription; recruits Swi-Snf complexes to 
histone gene promoters; promotes heterochromatic gene silencing with 
Asf1p 
YJR118C ILM1 
Protein of unknown function; may be involved in mitochondrial DNA 
maintenance; required for slowed DNA synthesis-induced filamentous 
growth 
YMR035W IMP2 
Catalytic subunit of the mitochondrial inner membrane peptidase complex, 
required for maturation of mitochondrial proteins of the intermembrane 
space; complex contains Imp1p and Imp2p (both catalytic subunits), and 
Som1p 
YIL002C INP51 
Phosphatidylinositol 4,5-bisphosphate 5-phosphatase, synaptojanin-like 
protein with an N-terminal Sac1 domain, plays a role in 
phosphatidylinositol 4,5-bisphosphate homeostasis and in endocytosis; null 
mutation confers cold-tolerant growth 
YOL081W IRA2 
GTPase-activating protein that negatively regulates RAS by converting it 
from the GTP- to the GDP-bound inactive form, required for reducing 
cAMP levels under nutrient limiting conditions, has similarity to Ira1p and 
human neurofibromin 
 
 
 
YER019W 
 
 
 
ISC1 
 
 
 
Mitochondrial membrane localized inositol phosphosphingolipid 
phospholipase C, hydrolyzes complex sphingolipids to produce ceramide; 
activated by phosphatidylserine, cardiolipin, and phosphatidylglycerol; 
mediates Na+ and Li+ halotolerance 
YKL032C IXR1 
Protein that binds DNA containing intrastrand cross-links formed by 
cisplatin, contains two HMG (high mobility group box) domains, which 
confer the ability to bend cisplatin-modified DNA; mediates aerobic 
transcriptional repression of COX5b 
YJL062W LAS21 
Integral plasma membrane protein involved in the synthesis of the 
glycosylphosphatidylinositol (GPI) core structure; mutations affect cell wall 
integrity 
YOL009C MDM12 
Mitochondrial outer membrane protein, required for transmission of 
mitochondria to daughter cells; component of the ERMES complex that 
links the ER to mitochondria; may influence import and assembly of outer 
membrane beta-barrel proteins 
YKL009W MRT4 
Protein involved in mRNA turnover and ribosome assembly, localizes to the 
nucleolus 
YOL112W MSB4 
GTPase-activating protein of the Ras superfamily that acts primarily on 
Sec4p, localizes to the bud site and bud tip, has similarity to Msb3p; msb3 
msb4 double mutation causes defects in secretion and actin organization 
YDR277C MTH1 
Negative regulator of the glucose-sensing signal transduction pathway, 
required for repression of transcription by Rgt1p; interacts with Rgt1p and 
the Snf3p and Rgt2p glucose sensors; phosphorylated by Yck1p, triggering 
Mth1p degradation 
YLR338W OPI9 
Dubious open reading frame unlikely to encode a protein, based on 
available experimental and comparative sequence data; partially overlaps 
the verified ORF VRP1/YLR337C 
YDL232W OST4 
Subunit of the oligosaccharyltransferase complex of the ER lumen, which 
catalyzes protein asparagine-linked glycosylation; type I membrane protein 
required for incorporation of Ost3p or Ost6p into the OST complex 
YHL013C OTU2 
Protein of unknown function that may interact with ribosomes, based on co-
purification experiments; member of the ovarian tumor-like (OTU) 
superfamily of predicted cysteine proteases; shows cytoplasmic localization 
YDR071C PAA1 
Polyamine acetyltransferase; acetylates polyamines (e.g. putrescine, 
spermidine, spermine) and also aralkylamines (e.g. tryptamine, 
phenylethylamine); may be involved in transcription and/or DNA 
replication 
YOR360C PDE2 
High-affinity cyclic AMP phosphodiesterase, component of the cAMP-
dependent protein kinase signaling system, protects the cell from 
extracellular cAMP, contains readthrough motif surrounding termination 
codon 
YGL013C PDR1 
Zinc cluster protein that is a master regulator involved in recruiting other 
zinc cluster proteins to pleiotropic drug response elements (PDREs) to fine 
tune the regulation of multidrug resistance genes 
YOR153W PDR5 
Plasma membrane ATP-binding cassette (ABC) transporter, multidrug 
transporter actively regulated by Pdr1p; also involved in steroid transport, 
cation resistance, and cellular detoxification during exponential growth 
 
 
YER149C 
 
 
PEA2 
 
 
Coiled-coil polarisome protein required for polarized morphogenesis, cell 
fusion, and low affinity Ca2+ influx; forms polarisome complex with 
Bni1p, Bud6p, and Spa2p; localizes to sites of polarized growth 
YNL003C PET8 
S-adenosylmethionine transporter of the mitochondrial inner membrane, 
member of the mitochondrial carrier family; required for biotin biosynthesis 
and respiratory growth 
YAL023C PMT2 
Protein O-mannosyltransferase, transfers mannose residues from dolichyl 
phosphate-D-mannose to protein serine/threonine residues; acts in a 
complex with Pmt1p, can instead interact with Pmt5p in some conditions; 
target for new antifungals 
YDR314C RAD34 Protein involved in nucleotide excision repair (NER); homologous to RAD4 
YHL027W RIM101 
Transcriptional repressor involved in response to pH and in cell wall 
construction; required for alkaline pH-stimulated haploid invasive growth 
and sporulation; activated by proteolytic processing; similar to A. nidulans 
PacC 
YMR154C RIM13 
Calpain-like cysteine protease involved in proteolytic activation of Rim101p 
in response to alkaline pH; has similarity to A. nidulans palB 
YFL033C RIM15 
Glucose-repressible protein kinase involved in signal transduction during 
cell proliferation in response to nutrients, specifically the establishment of 
stationary phase; identified as a regulator of IME2; substrate of Pho80p-
Pho85p kinase 
YMR063W RIM9 
Protein of unknown function, involved in the proteolytic activation of 
Rim101p in response to alkaline pH; has similarity to A. nidulans PalI; 
putative membrane protein 
YPL089C RLM1 
MADS-box transcription factor, component of the protein kinase C-
mediated MAP kinase pathway involved in the maintenance of cell 
integrity; phosphorylated and activated by the MAP-kinase Slt2p 
YOR312C RPL20B 
Protein component of the large (60S) ribosomal subunit, nearly identical to 
Rpl20Ap and has similarity to rat L18a ribosomal protein 
YJL136C RPS21B 
Protein component of the small (40S) ribosomal subunit; nearly identical to 
Rps21Ap and has similarity to rat S21 ribosomal protein 
YHR021C RPS27B 
Protein component of the small (40S) ribosomal subunit; nearly identical to 
Rps27Ap and has similarity to rat S27 ribosomal protein 
YGL244W RTF1 
Subunit of the RNA polymerase II-associated Paf1 complex; directly or 
indirectly regulates DNA-binding properties of Spt15p and relative 
activities of different TATA elements; involved in telomere maintenance 
YOR216C RUD3 
Golgi matrix protein involved in the structural organization of the cis-Golgi; 
interacts genetically with COG3 and USO1 
YCR009C RVS161 
Amphiphysin-like lipid raft protein; interacts with Rvs167p and regulates 
polarization of the actin cytoskeleton, endocytosis, cell polarity, cell fusion 
and viability following starvation or osmotic stress 
YDR388W RVS167 
Actin-associated protein, interacts with Rvs161p to regulate actin 
cytoskeleton, endocytosis, and viability following starvation or osmotic 
stress; homolog of mammalian amphiphysin 
YDR469W SDC1 
Subunit of the COMPASS (Set1C) complex, which methylates lysine 4 of 
histone H3 and is required in chromatin silencing at telomeres; contains a 
Dpy-30 domain that mediates interaction with Bre2p; similar to C. elegans 
and human DPY-30 
YBR171W SEC66 
Non-essential subunit of Sec63 complex (Sec63p, Sec62p, Sec66p and 
Sec72p); with Sec61 complex, Kar2p/BiP and Lhs1p forms a channel 
competent for SRP-dependent and post-translational SRP-independent 
protein targeting and import into the ER 
YCL010C SGF29 Probable subunit of SAGA histone acetyltransferase complex 
YLR079W SIC1 
Inhibitor of Cdc28-Clb kinase complexes that controls G1/S phase 
transition, preventing premature S phase and ensuring genomic integrity; 
phosphorylation targets Sic1p for SCF(CDC4)-dependent turnover; 
functional homolog of mammalian Kip1 
YBR077C SLM4 
Component of the EGO complex, which is involved in the regulation of 
microautophagy, and of the GSE complex, which is required for proper 
sorting of amino acid permease Gap1p; gene exhibits synthetic genetic 
interaction with MSS4 
YDR477W SNF1 
AMP-activated serine/threonine protein kinase found in a complex 
containing Snf4p and members of the Sip1p/Sip2p/Gal83p family; required 
for transcription of glucose-repressed genes, thermotolerance, sporulation, 
and peroxisome biogenesis 
YGL115W SNF4 
Activating gamma subunit of the AMP-activated Snf1p kinase complex 
(contains Snf1p and a Sip1p/Sip2p/Gal83p family member); activates 
glucose-repressed genes, represses glucose-induced genes; role in 
sporulation, and peroxisome biogenesis 
YCR033W SNT1 
Subunit of the Set3C deacetylase complex that interacts directly with the 
Set3C subunit, Sif2p; putative DNA-binding protein 
YDR297W SUR2 
Sphinganine C4-hydroxylase, catalyses the conversion of sphinganine to 
phytosphingosine in sphingolipid biosyntheis 
YHR181W SVP26 
Integral membrane protein of the early Golgi apparatus and endoplasmic 
reticulum, involved in COP II vesicle transport; may also function to 
promote retention of proteins in the early Golgi compartment 
YLR182W SWI6 
Transcription cofactor, forms complexes with DNA-binding proteins Swi4p 
and Mbp1p to regulate transcription at the G1/S transition; involved in 
meiotic gene expression; localization regulated by phosphorylation; 
potential Cdc28p substrate 
YOL018C TLG2 
Syntaxin-like t-SNARE that forms a complex with Tlg1p and Vti1p and 
mediates fusion of endosome-derived vesicles with the late Golgi; binds 
Vps45p, which prevents Tlg2p degradation and also facilitates t-SNARE 
complex formation 
YER090W TRP2 
Anthranilate synthase, catalyzes the initial step of tryptophan biosynthesis, 
forms multifunctional hetero-oligomeric anthranilate synthase:indole-3-
glycerol phosphate synthase enzyme complex with Trp3p 
YKL211C TRP3 
Bifunctional enzyme exhibiting both indole-3-glycerol-phosphate synthase 
and anthranilate synthase activities, forms multifunctional hetero-oligomeric 
anthranilate synthase:indole-3-glycerol phosphate synthase enzyme 
complex with Trp2p 
YML028W TSA1 
Thioredoxin peroxidase, acts as both a ribosome-associated and free 
cytoplasmic antioxidant; self-associates to form a high-molecular weight 
chaperone complex under oxidative stress; deletion results in mutator 
phenotype 
 
YOR006C 
 
TSR3 
 
Putative protein of unknown function; green fluorescent protein (GFP)-
fusion protein localizes to both the cytoplasm and the nucleus 
YLL039C UBI4 
Ubiquitin, becomes conjugated to proteins, marking them for selective 
degradation via the ubiquitin-26S proteasome system; essential for the 
cellular stress response; encoded as a polyubiquitin precursor comprised of 
5 head-to-tail repeats 
YER151C UBP3 
Ubiquitin-specific protease that interacts with Bre5p to co-regulate 
anterograde and retrograde transport between endoplasmic reticulum and 
Golgi compartments; inhibitor of gene silencing; cleaves ubiquitin fusions 
but not polyubiquitin 
YFR010W UBP6 
Ubiquitin-specific protease situated in the base subcomplex of the 26S 
proteasome, releases free ubiquitin from branched polyubiquitin chains; 
works in opposition to polyubiquitin elongation activity of Hul5p 
YOR106W VAM3 
Syntaxin-related protein required for vacuolar assembly; functions with 
Vam7p in vacuolar protein trafficking; member of the syntaxin family of 
proteins 
YDL077C VAM6 
Vacuolar protein that plays a critical role in the tethering steps of vacuolar 
membrane fusion by facilitating guanine nucleotide exchange on small 
guanosine triphosphatase Ypt7p 
YGL212W VAM7 
Component of the vacuole SNARE complex involved in vacuolar 
morphogenesis; SNAP-25 homolog; functions with a syntaxin homolog 
Vam3p in vacuolar protein trafficking 
YLR373C VID22 
Glycosylated integral membrane protein localized to the plasma membrane; 
plays a role in fructose-1,6-bisphosphatase (FBPase) degradation; involved 
in FBPase transport from the cytosol to Vid (vacuole import and 
degradation) vesicles 
YKR001C VPS1 
Dynamin-like GTPase required for vacuolar sorting; also involved in actin 
cytoskeleton organization, late Golgi-retention of some proteins, regulating 
peroxisome biogenesis 
YKL041W VPS24 
One of four subunits of the endosomal sorting complex required for 
transport III (ESCRT-III); forms an ESCRT-III subcomplex with Did4p; 
involved in the sorting of transmembrane proteins into the multivesicular 
body (MVB) pathway 
YNR006W VPS27 
Endosomal protein that forms a complex with Hse1p; required for recycling 
Golgi proteins, forming lumenal membranes and sorting ubiquitinated 
proteins destined for degradation; has Ubiquitin Interaction Motifs which 
bind ubiquitin (Ubi4p) 
YPR173C VPS4 
AAA-ATPase involved in multivesicular body (MVB) protein sorting, 
ATP-bound Vps4p localizes to endosomes and catalyzes ESCRT-III 
disassembly and membrane release; ATPase activity is activated by Vta1p; 
regulates cellular sterol metabolism 
YDR080W VPS41 
Vacuolar membrane protein that is a subunit of the homotypic vacuole 
fusion and vacuole protein sorting (HOPS) complex; essential for 
membrane docking and fusion at the Golgi-to-endosome and endosome-to-
vacuole stages of protein transport 
 
 
 
YKR020W 
 
 
 
VPS51 
 
 
 
Component of the GARP (Golgi-associated retrograde protein) complex, 
Vps51p-Vps52p-Vps53p-Vps54p, which is required for the recycling of 
proteins from endosomes to the late Golgi; links the (VFT/GARP) complex 
to the SNARE Tlg1p 
YJL029C VPS53 
Component of the GARP (Golgi-associated retrograde protein) complex, 
Vps51p-Vps52p-Vps53p-Vps54p, which is required for the recycling of 
proteins from endosomes to the late Golgi; required for vacuolar protein 
sorting 
YML097C VPS9 
A guanine nucleotide exchange factor involved in vesicle-mediated vacuolar 
protein transport; specifically stimulates the intrinsic guanine nucleotide 
exchange activity of Vps21p/Rab5: similar to mammalian ras inhibitors; 
binds ubiquitin 
YLR337C VRP1 
Proline-rich actin-associated protein involved in cytoskeletal organization 
and cytokinesis; related to mammalian Wiskott-Aldrich syndrome protein 
(WASP)-interacting protein (WIP) 
YOR043W WHI2 
Protein required, with binding partner Psr1p, for full activation of the 
general stress response, possibly through Msn2p dephosphorylation; 
regulates growth during the diauxic shift; negative regulator of G1 cyclin 
expression 
YML001W YPT7 
GTPase; GTP-binding protein of the rab family; required for homotypic 
fusion event in vacuole inheritance, for endosome-endosome fusion, similar 
to mammalian Rab7 
YBR111C YSA1 
Nudix hydrolase family member with ADP-ribose pyrophosphatase activity; 
shown to metabolize O-acetyl-ADP-ribose to AMP and acetylated ribose 5'-
phosphate 
YJL211C   
Dubious open reading frame unlikely to encode a protein, based on 
available experimental and comparative sequence data; partially overlaps 
the verified gene YJL210W/PEX2 
YHR210C   
Putative protein of unknown function; non-essential gene; highly expressed 
under anaeorbic conditions; sequence similarity to aldose 1-epimerases such 
as GAL10 
YOR062C   
Protein of unknown function; similar to YKR075Cp and Reg1p; expression 
regulated by glucose and Rgt1p; GFP-fusion protein is induced in response 
to the DNA-damaging agent MMS 
YPL041C   
Protein of unknown function involved in maintenance of proper telomere 
length 
YBR174C   
Dubious open reading frame unlikely to encode a protein, based on 
available experimental and comparative sequence data; partially overlaps 
the verified ORF YBR175W; null mutant is viable and sporulation defective 
YGR250C   
Putative RNA binding protein; localizes to stress granules induced by 
glucose deprivation; interacts with Rbg1p in a two-hybrid 
YMR295C   
Protein of unknown function that associates with ribosomes; green 
fluorescent protein (GFP)-fusion protein localizes to the cell periphery and 
bud; YMR295C is not an essential gene 
YNL170W   
Dubious open reading frame unlikely to encode a functional protein, based 
on available experimental and comparative sequence data 
YGR122W   
Probable ortholog of A. nidulans PalC, which is involved in pH regulation 
and binds to the ESCRT-III complex; null mutant does not properly process 
Rim101p and has decreased resistance to rapamycin; GFP-fusion protein is 
cytoplasmic 
YER119C-
A   
Dubious open reading frame, not conserved in closely related 
Saccharomyces species; deletion mutation blocks replication of Brome 
mosaic virus in S. cerevisiae, but this is likely due to effects on the 
overlapping gene SCS2 
YHL012W   
Putative protein of unknown function, has some homology to Ugp1p, which 
encodes UDP-glucose pyrophosphorylase 
YCL042W   
Putative protein of unknown function; epitope-tagged protein localizes to 
the cytoplasm 
 
 
